10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-18-160231.txt : 20180511 0001193125-18-160231.hdr.sgml : 20180511 20180511092148 ACCESSION NUMBER: 0001193125-18-160231 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulmatrix, Inc. CENTRAL INDEX KEY: 0001574235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461821392 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36199 FILM NUMBER: 18825140 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: SUITE 390 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-2333 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: SUITE 390 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Ruthigen, Inc. DATE OF NAME CHANGE: 20130411 10-Q 1 d418236d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36199

PULMATRIX, INC.

(Exact name of registrant as specified in its charter)


Delaware		46-1821392
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

99 Hayden Avenue, Suite 390 Lexington, MA		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (781) 357-2333

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 9, 2018, the registrant had 41,927,221 shares of common stock outstanding.

PULMATRIX, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2017

TABLE OF CONTENTS


PART I — FINANCIAL INFORMATION

Item 1. Financial Statements			3

Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017			3

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2018 and 2017 (unaudited)			4

Condensed Consolidated Statements of Cash Flows for the Three months Ended March 31, 2018 and 2017 (unaudited)			5

Notes to Condensed Consolidated Financial Statements (unaudited)			6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			13

Item 3. Quantitative and Qualitative Disclosures About Market Risk			18

Item 4. Controls and Procedures			18

PART II — OTHER INFORMATION

Item 1. Legal Proceedings			19

Item 1A. Risk Factors			19

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			19

Item 3. Defaults Upon Senior Securities			19

Item 4. Mine Safety Disclosures			19

Item 5. Other Information			19

Item 6. Exhibits			19

SIGNATURES			20

PART I — FINANCIAL INFORMATION

Item 1.

Financial Statements.

PULMATRIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)


	At March 31, 2018			At December 31, 2017
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	1,553		$	3,550
Accounts Receivable		153			—
Prepaid expenses and other current assets		346			696

Total current assets		2,052			4,246
Property and equipment, net		554			614
Long-term restricted cash		204			204
Goodwill		10,914			10,914

Total assets	$	13,724		$	15,978

Liabilities and stockholders’ equity
Current liabilities:
Loan payable, net of debt discount and issuance costs	$	2,524		$	3,221
Accounts payable		1,192			457
Accrued expenses		2,479			2,162
Derivative liability		1			1

Total current liabilities		6,196			5,841

Commitments (Note 13)
Stockholders’ equity:
Preferred stock, $0.0001 par value—500,000 authorized and 0 issued and outstanding at March 31, 2018 and December 31, 2017		—			—
Common stock, $0.0001 par value—100,000,000 shares authorized; 22,280,160 and 21,047,498 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively.		2			2
Additional paid-in capital		186,749			184,137
Accumulated deficit		(179,223	)		(174,002	)

Total stockholders’ equity		7,528			10,137

Total liabilities and stockholders’ equity	$	13,724		$	15,978

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

PULMATRIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except share and per share data)


	For the Three Months Ended March 31,
	2018			2017
Revenues	$	153		$	—

Operating expenses
Research and development		3,221			1,672
General and administrative		2,046			1,640

Total operating expenses		5,267			3,312

Loss from operations		(5,114	)		(3,312	)
Interest expense		(106	)		(187	)
Other income (expense), net		(1	)		16

Net loss	$	(5,221	)	$	(3,483	)

Net loss per share, basic and diluted	$	(0.24	)	$	(0.21	)

Weighted average shares used to compute basic and diluted net loss per share		21,876,985			16,791,362

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

PULMATRIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)


	For the Three Months Ended March 31,
	2018			2017
Cash flows from operating activities:
Net loss	$	(5,221	)	$	(3,483	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		60			64
Stock-based compensation		765			622
Non-cash rent expense		—			5
Non-cash interest expense		31			48
Non-cash debt issuance expense		2			4
Changes in operating assets and liabilities:
Accounts Receivable		(153	)		—
Prepaid expenses and other current assets		350			164
Accounts payable		735			(512	)
Accrued expenses		306			96

Net cash used in operating activities		(3,125	)		(2,992	)

Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		1,847			9,702
Proceeds from the exercise of stock options		—			300
Term loan principal payments		(719	)		(651	)

Net cash provided by financing activities		1,128			9,351

Net (decrease) increase in cash and cash equivalents		(1,997	)		6,359
Cash and cash equivalents — beginning of period		3,550			4,182

Cash and cash equivalents — end of period	$	1,553		$	10,541

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

PULMATRIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2017

(unaudited)

(in thousands, except share and per share data)

1. Organization

Pulmatrix, Inc. and its subsidiaries (the “Company”) is a clinical stage biotechnology company focused on the discovery and development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted), is engineered to deliver small, dense particles with highly efficient dispersibility and delivery to the airways, which can be used with an array of dry powder inhaler technologies and can be formulated with a variety of drug substances. The Company is developing a pipeline of iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory diseases and infections with significant unmet medical needs.

Liquidity

At March 31, 2018, the Company had unrestricted cash and cash equivalents of $1,553, an accumulated deficit of $179,223 and a deficit in working capital of $4,144. The Company will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels.

The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. If unable to raise additional capital when required or on acceptable terms, the Company may have to (i) delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize on unfavorable terms.

During the three months ended March 31, 2018, the Company sold 1,232,662 shares of its common stock for aggregate net proceeds of $1,847. (See Note 7). In April 2018, we closed on an underwritten public offering that brought in gross proceeds of approximately $15,900 (see Note 13).

The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing and, ultimately, to generate revenue. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s condensed consolidated financial statements as of March 31, 2018 do not include any adjustments that might become necessary should the Company be unable to continue as a going concern.

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2018, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 13, 2018.

3. Summary of Significant Accounting Policies

In the three months ended March 31, 2018, there were no changes to the Company’s significant accounting policies identified in the Company’s most recent annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s current report on Form 10-K.

Recent Accounting Pronouncements

In March 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118”, (“ASU 2018-05”) to add various SEC paragraphs pursuant to the issuance of SEC Staff Accounting Bulletin No. 118 (“SAB 118”), to ASC 740 “Income Taxes”. SAB 118 was issued by the SEC in December 2017 to provide immediate guidance for accounting implications of U.S. tax reform under the “Tax Cuts and Jobs Act” (the “Tax Act”), which became effective for the Company on January 1, 2018. The Company has adopted ASU 2018-05 and adoption of this ASU has no significant impact on its condensed consolidated financial statements.

In February 2018, the FASB issued Accounting Standards Update No. 2018-02, “Income Statement — Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (“ASU 2018-02”), which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act and requires certain disclosures about stranded tax effects. ASU 2018-02 is effective for us beginning December 1, 2019 (with early adoption permitted) and shall be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the potential impact of adopting this guidance on its condensed consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of control of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. Since the Company is an emerging growth company and elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act, this ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its consolidated financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing revenue recognition accounting policies to determine the effect the guidance will have on its condensed consolidated financial statements and what changes to systems and controls may be warranted.

Use of Estimates

In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.

Revenue Recognition

The Company’s principal sources of revenue during the reporting period were reimbursement of clinical study costs. In all instances, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, and collectability of the resulting receivable is reasonably assured.

Goodwill

Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired, and liabilities assumed under the acquisition method of accounting for push-down accounting. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event

occurs or circumstances change that would more likely than not reduce the fair value of the Company’s reporting unit below its carrying amount. When performing the impairment assessment, the accounting standard for testing goodwill for impairment permits a company to first assess the qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the goodwill is impaired. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of goodwill is impaired, the Company must perform a quantitative impairment test. The Company completed a qualitative assessment and determined that there was no impairment of goodwill as of March 31, 2018.

4. Prepaid Expenses and Other Current Assets

Prepaid expenses consisted of the following:


	At March 31, 2018		At December 31, 2017
Prepaid Insurance	$	120	$	204
Prepaid Clinical Trials		16		421
Prepaid Other		112		44
Deferred Operating Costs		98		27

Total prepaid and other current assets	$	346	$	696

5. Debt

Loan and Security Agreement and Warrant Agreement

On June 11, 2015, Pulmatrix Operating entered into a Loan and Security Agreement (“LSA”) with Hercules Technology Growth Capital, Inc. (“Hercules”), for a term loan in a principal amount of $7,000 (“Term Loan”). The term loan is secured by substantially all of the Company’s assets, excluding intellectual property. As of March 31, 2018, the outstanding principal balance of the term loan was $2,540.

The term loan bears interest at a floating annual rate equal to the greater of (i) 9.50% and (ii) the sum of (a) the prime rate as reported by The Wall Street Journal minus 3.25% plus (b) 8.50%. The Company is required to make interest payments in cash on the first business day of each month, beginning on July 1, 2015. Since August 1, 2016, the Company has been required to make monthly payments on the first business day of each month consisting of principal and interest based upon a 30-month amortization schedule, and any unpaid principal and interest is due on the maturity date of July 1, 2018. Upon repayment of the term loan, the Company is also required to pay an end of term charge to the Lenders equal to $245. As of March 31, 2018, the company has accrued $236 of the total $245 end of term charge, of which $11 and $21 accrued during the three months ended March 31, 2018 and 2017, respectively.

The Company may elect to prepay all, but not less than all, of the outstanding principal balance of the term loan, subject to a prepayment fee of 1% – 3%, depending on the date of repayment. Contingent on the occurrence of several events, including that the Company’s closing stock price exceed $11.73 per share for the seven days preceding a payment date, the Company may elect to pay, in whole or in part, any regularly scheduled installment of principal up to an aggregate maximum amount of $1,000 by converting a portion of the principal into shares of the Company’s common stock at a price of $11.73 per share. Hercules may elect to receive payments in the Company common stock by requiring the Company to affect a conversion option whereby Hercules can elect to receive a principal installment payment in shares of the Company common stock based on a price of $11.73 per share, subject to an aggregate maximum principal amount of $1,000.

The Company determined that the Company’s provisions allowing conversion of all or a portion of the LSA contained a beneficial conversion feature (“BCF”). The BCF is contingent upon the occurrence of certain events and as such, the Company will not record the BCF until the contingency is resolved. Through March 31, 2018 the contingency was not resolved.

The credit facility includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and undergoing a change in control, in each case subject to certain exceptions. In general, the Term Loan prohibits the Company from (i) repurchasing or redeeming any class of capital stock, including common stock or (ii) declaring or paying any cash dividend or making cash distribution on any class of capital stock, including common stock.

The LSA includes provisions requiring the embedded interest rate reset upon an event of default and the put option upon an event of default or qualified change of control each represent an embedded derivative instrument requiring bifurcation from the loan. The embedded derivatives were bundled and valued as one compound derivative in accordance with the applicable accounting guidance

for derivatives and hedging. The fair value of the compound derivative at issuance of $11 was recorded as a derivative liability and as a discount to the debt. The derivative liability is remeasured at fair value at each reporting date, with changes in fair value being recorded as other income (expense) in the statements of operations (Note 10). At March 31, 2018 and December 31, 2017, the fair value of the derivative liability was valued at $1. The net debt discounts resulting from the embedded compound derivative and lender fees are being amortized as interest expense from the date of issuance through the maturity date using the effective interest method. The Company incurred interest expense of $106 and $187 during the three months ended March 31, 2018 and 2017, respectively. Of the total interest expense, $75 and $139 was payable in cash during the three months ended March 31, 2018 and 2017, respectively.

The carrying amounts of the Company’s Term Loan as of March 31, 2018 and December 31, 2017 were as follows:


	Hercules Term Loan			Debt Discount			Issuance Costs			Total
Balance — January 1, 2018	$	3,259		$	(35	)	$	(3	)	$	3,221
Accretion of debt discount					20						20
Accretion of issuance costs								2			2
Principal payments		(719	)								(719	)

Balance — March 31, 2018	$	2,540		$	(15	)	$	(1	)	$	2,524

6. Accrued Expenses and Other Current Liabilities

Accrued expenses consisted of the following:


	At March 31, 2018		At December 31, 2017
Accrued vacation	$	96	$	57
Accrued wages and incentive		1,124		1,113
Accrued clinical & consulting		774		568
Accrued legal & patent		117		61
Accrued end of term fee		236		225
Deferred Rent		67		68
Accrued other expenses		65		70

Total accrued expenses	$	2,479	$	2,162

7. Common Stock

At-the-Market Offering

On March 17, 2017, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”) to act as the Company’s sales agent with respect to the issuance and sale of up to $11,000,000 of the Company’s shares of common stock, from time to time in an at-the-market public offering (the “Offering”). Sales of common stock under the Sales Agreement are made pursuant to an effective shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission on July 15, 2016, and subsequently declared effective on August 3, 2016 (File No. 333-212546), and a related prospectus. BTIG acts as the Company’s sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The NASDAQ Global Market. If expressly authorized by the Company, BTIG may also sell the Company’s common stock in privately negotiated transactions. There is no specific date on which the Offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account.

BTIG is entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of the Company’s common stock pursuant to the Sales Agreement.

During the three month period ended March 31, 2018, the Company sold 1,232,662 shares of its common stock under the Sales Agreement at an average selling price of approximately $1.54 per share which resulted in gross proceeds of approximately $1,904 and net proceeds of approximately $1,847 after payment of 3% commission to BTIG and other issuance costs.

8. Warrants

There were 3,284,440 common stock warrants outstanding at March 31, 2018. The warrants had a weighted-average exercise price of $7.79 with no intrinsic value and a remaining contractual life of 2.20 years. No warrants were issued, exercised, cancelled or forfeited during the period ending March 31, 2018.

9. Stock-Based Compensation

The Company sponsors the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan). As of March 31, 2018, the 2013 Plan provides for the grant of up to 5,096,675 shares of Company Common Stock, of which 1,359,051 shares remained available for future grant.

In addition, the Company has two legacy plans: The Pulmatrix Operating’s 2013 Employee, Director and Consultant Equity Incentive Plan (the “Original 2013 Plan”) and Pulmatrix Operating’s 2003 Employee, Director, and Consultant Stock Plan (the “2003 Plan”). As of March 31, 2018, a total of 498,882 shares of Company Common Stock may be delivered under options outstanding under the Original 2013 Plan and the 2003 Plan, however no additional awards may be granted under the Original 2013 Plan or the 2003 Plan.

Options

During the three months ended March 31, 2018, the Company granted no options to employees, directors or consultants.

During the three months ended March 31, 2017, the Company granted options to purchase 343,555 shares of Company Common Stock to employees and options to purchase 22,000 shares of Company Common Stock to directors. At the date of grant the fair value of those options aggregated to $659 and $42 respectively. The stock options granted vest over 48 months (the “Time Based Options”). Subject to the grantees’ continuous service with the Company, Time Based Options vest 25% on the first anniversary of the option grant date and the remainder in 36 equal monthly installments beginning in the month after the vesting start date. Stock options generally expire ten years after the date of grant.

The following table summarizes stock option activity for the three months ended March 31, 2018:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term ( Years)		Aggregate Intrinsic Value
Outstanding — January 1, 2018		3,695,634		$	5.69		7.77	$	—
Granted		—		$	—
Exercised		—		$	—
Forfeited or expired		(2,286	)	$	3.95

Outstanding — March 31, 2018		3,693,348		$	5.69		7.53	$	—

Exercisable — March 31, 2018		2,024,694		$	7.07		6.66	$	—

Vested and expected to vest — March 31, 2018		3,653,330		$	5.70		7.52	$	—

The estimated fair values of employee stock options granted during the three months ended March 31, 2018 and 2017, were determined on the date of grant using the Black-Scholes option-pricing model with the following assumptions:


	Three Months Ended March 31,
	2018		2017
Expected option life (years)		—	5.80 - 6.71
Risk-free interest rate		—	2.10% - 2.23%
Expected volatility		—	76.6% - 79.9%
Expected dividend yield		—	0%

The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was based upon the historical volatility for industry peers and used an average of those volatilities. The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity. The dividend yield considers that the Company has not historically paid dividends and does not expect to pay dividends in the foreseeable future. As of March 31, 2018, there was $3,703 of unrecognized stock-based compensation expense related to unvested stock options granted under the Company’s stock award plans. This expense is expected to be recognized over a weighted-average period of approximately 1.9 years.

The following table presents total stock-based compensation expense for the three months ended March 31, 2018:


	Three Months Ended March 31,
	2018		2017
Research and development	$	210	$	153
General and administrative		555		462

Total stock based compensation expense	$	765	$	615

Restricted Stock Units (RSU)

In August 2015, the Company granted 10,374 RSUs to other employees that vest over a two year period. The Company recorded stock-based compensation expense of $7 for the RSUs during the three months ended March 31, 2017. At March 31, 2018, no RSUs were outstanding.

10. Fair Value Measurements

Information about the liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017, and the input categories associated with those liabilities, is as follows:


	March 31, 2018
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Liabilities:
Embedded compound derivative	$	—	$	—	$	1	$	1


	December 31, 2017
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Liabilities:
Embedded compound derivative	$	—	$	—	$	1	$	1

Embedded Compound Derivatives — LSA with Hercules

As described in Note 5, the LSA contains an interest rate reset upon an event of default and a put option upon an event of default or qualified change of control. Each of these features represents an embedded derivative instrument requiring bifurcation from the Term Loan. The embedded derivatives were bundled and valued as one compound derivative in accordance with the applicable accounting guidance for derivatives and hedging. The proceeds from the issuance of the Term Loan were allocated first to the warrant and compound derivative at their respective fair values, with the residual going to the carrying amount of the loan resulting in a discount to the face value of the debt. The fair value of the compound derivative upon issuance of $11 was recognized as a derivative liability and will be adjusted to fair value at each reporting date. At March 31, 2018, the fair value of the derivative liability was remeasured and valued at $1. The fair value of the derivative instruments is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company used an income approach to estimate the fair value of the derivative liability and estimated the probability of an event of default occurring at various dates and then estimates the present value of the amount the holders would receive upon an event of default.

The significant assumption used in the model is the probability of the following scenarios occurring:


	At Issuance Date	At March 31, 2018
Probability of an event of default	10%	5%
Prepayment penalties	1.0% - 3.0%	1.0%
End of term payment	$245,000	245,000
Risk-free interest rate	1.01%	1.53%

A roll-forward of the preferred stock warrant liability and derivative liability categorized with Level 3 inputs is as follows:


	Derivative Instruments
Balance — January 1, 2018	$	1
Change in fair value		—

Balance — March 31, 2018	$	1

Gains and/or losses arising from changes in the estimated fair value of the warrants and embedded compound derivatives were recorded within other income, net, on the condensed consolidated statement of operations.

11. Net Loss Per Share

The Company computes basic and diluted net loss per share using a methodology that gives effect to the impact of outstanding participating securities (the “two-class method”). As the three months ended March 31, 2018 and 2017 resulted in net losses attributable to common shareholders, there is no income allocation required under the two-class method or dilution attributed to weighted average shares outstanding in the calculation of diluted net loss per share.

The following potentially dilutive securities outstanding prior to the use of the treasury stock method have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive.


	As of March 31,
	2018		2017
Options to purchase common stock		3,693,348		3,003,785
Warrants to purchase common stock		3,284,440		3,284,440
Settlement of term loan		85,251		85,251

12. Commitments

Future minimum lease payments under the non-cancelable operating lease for office and lab space is as follows:


	Amount
2018	$	491
2019		676
2020		698

Total	$	1,865

13. Subsequent Events

On April 3, 2018, the Company closed its previously announced firm commitment underwritten public offering in which, pursuant to the underwriting agreement (the “Underwriting Agreement”) entered into between the Company and Oppenheimer & Co. Inc., as representative of the underwriters (the “Underwriters”), dated March 28, 2018, the Company issued and sold (i) 15,660,000 common units (“Common Units”), with each Common Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), one Series A warrant (collectively, the “Series A Warrants”) to purchase one share of Common Stock and one Series B warrant (collectively, the “Series B Warrants”) to purchase one share of Common Stock, and (ii) 7,840,000 pre-funded units (the “Pre-Funded Units” and, together with the Common Units, the “Units”), with each Pre-Funded Unit being comprised of one pre-funded warrant to purchase one share of Common Stock, one Series A Warrant and one Series B Warrant. The public offering price was $0.65 per Common Unit and $0.64 per Pre-Funded Unit.

In addition, on April 4, 2018, the Company closed on the sale of 1,150,000 additional Common Units pursuant to the Underwriters’ option to purchase up to an additional 1,150,000 Units, which was exercised in full. After giving effect to the exercise of the Underwriters’ overallotment option, the total gross proceeds from the offering were approximately $15.9 million, prior to deducting underwriting discounts and commissions and other estimated offering expenses.

The Company is currently evaluating the requirements for classification of the Series A, Series B, and Pre-funded warrants which were issued in this financing.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The information set forth below should be read in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q as well as the audited financial statements and the notes thereto contained in our current report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2018. Unless stated otherwise, references in this Quarterly Report on Form 10-Q to “us,” “we,” “our,” or our “Company” and similar terms refer to Pulmatrix, Inc., a Delaware corporation.

Forward-Looking Statements

This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control that could cause our actual results, performance and achievements to differ materially from those expressed or implied in these forward-looking statements. Factors which may affect our results include, but are not limited to:

•

our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;

•

our inability to carry out research, development and commercialization plans;

•

our inability to manufacture our product candidates on a commercial scale on our own, or in collaborations with third parties;

•

our inability to complete preclinical testing and clinical trials as anticipated;

•

our ability to adequately protect and enforce rights to intellectual property;

•

difficulties in obtaining financing on commercially reasonable terms;

•

intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;

•

entry of new competitors and products and potential technological obsolescence of our products;

•

adverse market and economic conditions;

•

loss of one or more key executives or scientists; and

•

difficulties in securing regulatory approval to market our product candidates.

For a more detailed discussion of these and other factors that may affect our business and that could cause the actual results to differ materially from those projected in these forward-looking statements, see the risk factors and uncertainties set forth in Part II, Item 1A of this Quarterly Report. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

Overview

Recent Developments

Business

Pulmatrix, Inc. and its subsidiary (the Company) is a clinical stage biotechnology company focused on the discovery and development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted), is engineered to deliver small, dense particles with highly efficient dispersibility and delivery to the airways, which can be used with an array of dry powder inhaler technologies and can be formulated with a variety of drug substances. The Company is developing a pipeline of iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory diseases and infections with significant unmet medical needs. Since our inception in 2003, we have devoted substantially all of our efforts to product research and development. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date through proceeds from issuances of common and convertible preferred stock, issuances of convertible debt, collaborations with third parties and non-dilutive grants received from government agencies.

In April 2018, the Company issued and sold (i) 16,810,000 common units (“Common Units”), with each Common Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), one Series A warrant (collectively, the “Series A Warrants”) to purchase one share of Common Stock and one Series B warrant (collectively, the “Series B Warrants”) to purchase one share of Common Stock, and (ii) 7,840,000 pre-funded units (the “Pre-Funded Units” and, together with the Common Units, the “Units”), with each Pre-Funded Unit being comprised of one pre-funded warrant to purchase one share of Common Stock, one Series A Warrant and one Series B Warrant. Gross proceeds of the public offering before commissions and fees were approximately $15.9 million.

We expect to continue to incur significant expenses and increasing operating losses for at least the next several years based on our drug development plans. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities, as we:

•

initiate and expand clinical trials for Pulmazole for allergic bronchopulmonary aspergillosis (“ABPA”), and other indications for immunocompromised at-risk patients;

•

seek regulatory approval for our product candidates;

•

hire personnel to support our product development, commercialization and administrative efforts; and

•

advance the research and development related activities for inhaled therapeutic products in our pipeline.

We will not generate product sales unless and until we successfully complete clinical developments and obtain regulatory approvals for our product candidates. Additionally, we currently utilize third-party contract research organizations, or CROs, to carry out our clinical development activities, and we do not yet have a commercial organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. Accordingly, we anticipate that we will seek to fund our operations through public or private equity or debt financings or other sources, potentially including collaborative commercial arrangements. Likewise, we intend to seek to limit our commercialization costs by partnering with other companies with complementary capabilities or larger infrastructure including sales and marketing.

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

Financial Overview

Revenues

To date, we have not generated any product sales. Our 2018 revenue resulted from an award from Cystic Fibrosis Foundation Therapeutics (“CFFT”), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to support the development of Pulmazole for the treatment of ABPA in patients with asthma and cystic fibrosis.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for the research and development of our preclinical and clinical candidates, and include:

•

employee-related expenses, including salaries, benefits and stock-based compensation expense;

•

expenses incurred under agreements with CROs, contract manufacturing organizations, or CMOs, and consultants that conduct our clinical trials and preclinical activities;

•

the cost of acquiring, developing and manufacturing clinical trial materials and lab supplies;

•

facility, depreciation and other expenses, which include direct and allocated expenses for rent, maintenance of our facility, insurance and other supplies; and

•

costs associated with preclinical activities and regulatory operations.

We expense research and development costs to operations as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors.

Research and development activities are central to our business model. We utilize a combination of internal and external efforts to advance product development from early stage work to clinical trial manufacturing and clinical trial support. External efforts include work with consultants and substantial work at CROs and CMOs. We support an internal research and development team and facility for our pipeline programs. To move these programs forward along our development timelines, a large portion, approximately

(69% of staff) are research and development employees. In addition, we maintain a 12,000 square foot research and development facility which includes capital equipment for the manufacture and characterization of our iSPERSE™ powders for our pipeline programs. As we identify opportunities for iSPERSE™ in respiratory indications, we anticipate additional head count, capital, and development costs will be incurred to support these programs.

Because of the numerous risks and uncertainties associated with product development, however, we cannot determine with certainty the duration and completion costs of these or other current or future preclinical studies and clinical trials. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs such as stock-based compensation for personnel and consultants in executive, finance, business development, corporate communications and human resource functions, facility costs not otherwise included in research and development expenses, patent filing fees and professional legal fees. Other general and administrative expenses include travel expenses and professional fees for consulting, auditing and tax services.

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission requirements, director and officer liability insurance, investor relations costs and other costs associated with being a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in staffing and related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidates.

Interest Expense

We have been incurring and expect to continue to incur interest expense associated with a term loan executed in June 2015.

Other Expenses, Net

Other income, net is comprised primarily of gains and/or losses resulting from fair value adjustments for compound derivative instruments embedded within certain of our convertible notes.

Critical Accounting Policies

This management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in the notes to our condensed consolidated financial statements appearing elsewhere in this Form 10-Q and in our audited financial statements included in our current report on Form 10-K filed with the SEC on March 13, 2018, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.

Use of Estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.

Revenue Recognition

Our principal source of revenue during the reporting period was income for reimbursement of clinical study costs as part of a grant received from CFFT. In all instances, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exits, delivery has occurred or services have been rendered, and collectability of the resulting receivable is reasonably assured.

Goodwill

Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired under the acquisition method of accounting for push-down accounting. Goodwill is not amortized but is evaluated for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the related reporting unit below its carrying amount. When performing the impairment assessment, the accounting standard for testing goodwill for impairment permits a company to first assess the qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the goodwill is impaired. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of goodwill is impaired, we must perform the goodwill impairment test. We have determined that goodwill was not impaired as of March 31, 2018.

Results of Operations

Three Months Ended March 31, 2018 Compared with Three Months Ended March 31, 2017

The following table sets forth our results of operations for each of the periods set forth below (in thousands):


	Three months ended March 31,
	2018			2017			Change
Revenue	$	153		$	—		$	153
Operating expenses
Research and development		3,221			1,672			1,549
General and administrative		2,046			1,640			406

Total operating expenses		5,267			3,312			1,955

Loss from operations		(5,114	)		(3,312	)		(1,802	)
Interest expense		(106	)		(187	)		81
Other (expense) income, net		(1	)		16			(17	)

Net loss	$	(5,221	)	$	(3,483	)	$	(1,738	)

Revenue — For the three months ended March 31, 2018, revenue was $0.2 million compared to no revenue for the three months ended March 31, 2017. The increase in revenue was the result of clinical study costs reimbursed by CFFT.

Research and development expenses — For the three months ended March 31, 2018, research and development expense was $3.2 million compared to $1.7 million for the three months ended March 31, 2017, an increase of $1.5 million. The increase was primarily due to increased spend of $0.6 million on the Pulmazole project, $0.5 million on the PUR1800 project, $0.2 million in employment costs and $0.2 million in scientific consulting costs.

General and administrative expenses — For the three months ended March 31, 2018, general and administrative expense was $2.0 million compared to $1.6 million for the three months ended March 31, 2017, an increase of $0.4 million. The increase was primarily due to an increase of $0.3 in employments costs and $0.2 million in patent costs related to the in-licensed Respivert compounds, partially offset by a decrease of $0.1 million in legal and professional consulting costs.

Interest expense — For the three months ended March 31, 2018 interest expense was $0.1 million compared to $0.2 million for the three months ended March 31, 2017. During both periods, interest expense incurred related to the term loan agreement that we entered in June 2015.

Liquidity and Capital Resources

Through March 31, 2018, we have incurred an accumulated deficit of $179.2 million, primarily as a result of expenses incurred through a combination of research and development activities related to our various product candidates and general and administrative expenses supporting those activities. We have financed our operations since inception primarily through the sale of preferred and common stock and the issuance of convertible promissory notes and term loans. Our total cash and cash equivalents balance as of March 31, 2018 was $1.6 million. In April 2018, we closed on an underwritten public offering that brought in gross proceeds of approximately $15.9 million for the sale of 16.8 million shares of common stock which includes Series A, Series B and pre-funded common stock warrants. The Series A warrants have a six-month expiration, the Series B have a five-year expiration and the pre-funded warrants have no expiration date. To continue our operations, we will need to raise more capital by the end of 2018. We anticipate that we will continue to incur losses, and that such losses will increase over the next several years due to development costs associated with our iSPERSE™ pipeline programs. We expect that our research and development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, other third-party funding and other collaborations and strategic alliances. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing and, ultimately, to generate revenue. Those factors raise substantial doubt about the Company’s ability to continue as a going concern.

The following table sets forth the major sources and uses of cash for each of the periods set forth below (in thousands):


	Three months ended March 31,
	2018			2017
Net cash used in operating activities	$	(3,125	)	$	(2,992	)
Net cash provided by financing activities		1,128			9,351

Net increase (decrease) in cash and cash equivalents	$	(1,997	)	$	6,359

Cash Flows from Operating Activities

Net cash used in operating activities for the three months ended March 31, 2018 was $3.1 million, which was primarily the result of a net loss of $5.2 million, partially offset by $1.2 million in cash inflows associated with changes in operating assets and liabilities and $0.9 million of net non-cash adjustments. The net cash inflows associated with changes in operating assets and liabilities was primarily due to increases in accounts payable of $0.7 million, increases in accrued expenses of $0.3 million, decreases in prepaid expenses and other current assets of $0.4 million, partially offset by a decrease in accounts receivable of $0.2 million. Our non-cash adjustments were primarily comprised of $0.8 million of stock-based compensation expense and $0.1 million of depreciation and amortization.

Net cash used in operating activities for the three months ended March 31, 2017 was $3.0 million, which was primarily the result of a net loss of $3.5 million and $0.2 million in cash outflows associated with changes in operating assets and liabilities, partially offset by $0.7 million of net non-cash adjustments. The net cash outflows associated with changes in operating assets and liabilities was primarily due to a decrease in accounts payable of $0.5 million, partially offset by decrease in prepaid expenses and other current assets of $0.2 million and an increase in accrued expenses of $0.1 million. Our non-cash adjustments were primarily comprised of $0.6 million of stock-based compensation expense and $0.1 million of depreciation and amortization.

Cash Flows from Financing Activities

Net cash provided by financing activities for the three months ended March 31, 2018 was $1.1 million, as compared to $9.4 for the three months ended March 31, 2017. Net cash provided by financing activities for the three months ended March 31, 2018 resulted from the issuance of common stock of $1.8 million, partially offset by $0.7 million of term loan principal payments. Net cash provided by financing activities for the three months ended March 31, 2017 resulted from the issuance of common stock of $9.7 million and $0.3 million from the exercise of stock options, partially offset by $0.6 million of term loan principal payments.

Financings

On March 17, 2017, the Company entered into an At-The-Market Sales Agreement with respect to the issuance and sale of up to $11,000,000 of the Company’s common stock from time to time in an at-the-market public offering. During the period ending March 31, 2018, the sold 1,232,622 shares of its common stock pursuant to the At-The-Market Sales Agreement for aggregate net proceeds of $1,847.

On March 28, 2018, we entered into an underwriting agreement with Oppenheimer and Co., Inc. relating to a public offering. Subsequent to March 31, 2018, 16,810,000 Common Units were sold and 7,840,000 pre-funded warrants were issued. Each Common Stock Unit was comprised of a share of common stock and one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock. Gross proceeds of the public offering before commissions and fees were approximately $15,900.

Based on our planned use for our existing cash resources, we believe that our available funds will be sufficient to enable us to support clinical development of our Pulmazole program through completion of a Phase 1b trial and a toxicology study in support of PUR1800, the latter of which is expected to conclude during the fourth quarter, 2018. The funding will not be sufficient to complete additional clinical work for any of the pipeline programs. We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

•

the initiation, progress, timing, costs and results of clinical studies for existing and new pipeline programs based on iSPERSE™;

•

the outcome, timing and cost of regulatory approvals by the FDA and European regulatory authorities, including the potential for these agencies to require that we perform studies in addition to those that we currently have planned;

•

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

•

our need to expand our research and development activities;

•

our need and ability to hire additional personnel;

•

our need to implement additional infrastructure and internal systems;

•

the cost of establishing and maintaining a commercial-scale manufacturing line; and

•

the cost of establishing sales, marketing and distribution capabilities for any products for which we may receive regulatory approval.

If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.

Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during the quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.

Legal Proceedings.

From time to time, we may be involved in litigation that arises through the normal course of business. As of the date of this filing, we are not aware of any material legal proceedings to which we or any of our subsidiaries is a party or to which any of our property is subject, nor are we aware of any such threatened or pending litigation or any such proceedings known to be contemplated by governmental authorities.

We are not aware of any material proceedings in which any of our directors, officers or affiliates or any registered or beneficial stockholder of more than 5% of our common stock, or any associate of any of the foregoing, is a party adverse to or has a material interest adverse to, us or any of our subsidiaries.

Item 1A.

Risk Factors.

There have been no material changes to the risk factors disclosed under “Item 1A. Risk Factors” of our most recent Annual Report on Form 10-K. For more information concerning our risk factors, please refer to “Item 1A. Risk Factors” of our most recent Annual Report on Form 10-K.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Unregistered Sales of Equity Securities

None.

(b) Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the quarter ended March 31, 2018.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

See Index to Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	PULMATRIX, INC.

Date: May 11, 2018	By:	/s/ Robert W. Clarke
		Robert W. Clarke
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: May 11, 2018	By:	/s/ William Duke, Jr.
		William Duke, Jr.
		Chief Financial Officer
		(Principal Financial Officer)

EXHIBIT INDEX


Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation of Pulmatrix, Inc., as amended through June 15, 2015 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange commission on August 14, 2015).

3.2		Restated Bylaws of Pulmatrix, Inc., as amended through June 15, 2015 (incorporated by reference to Exhibit 3.2 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2015).

4.1		Form of Series A Warrant (incorporated by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-1, Amendment No. 4, filed with the SEC on March 28, 2018).

4.2		Form of Series B Warrant (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement on Form S-1, Amendment No. 4, filed with the SEC on March 28, 2018).

4.3		Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.7 to the Company’s Registration Statement on Form S-1, Amendment No. 4, filed with the SEC on March 28, 2018).

31.1*		Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017, (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited).

*	Filed herewith.

#	Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Pulmatrix, Inc. hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the Securities and Exchange Commission.

EX-31.1 2 d418236dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Robert W. Clarke, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Pulmatrix, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2018

/s/ Robert W. Clarke

Robert W. Clarke

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d418236dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, William Duke, Jr., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Pulmatrix, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2018

/s/ William Duke, Jr.

William Duke, Jr.

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 d418236dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Pulmatrix, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge and in the capacity of an officer, that:

The Quarterly Report for the quarter ended March 31, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Form 10-Q.


Dated: May 11, 2018		/s/ Robert W. Clarke
		Robert W. Clarke
		President and Chief Executive Officer
		(Principal Executive Officer)

Dated: May 11, 2018		/s/ William Duke, Jr.
		William Duke, Jr.
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 5 pulm-20180331.xml XBRL INSTANCE DOCUMENT 41927221

11000000

0.0001

0.65

0.64

7000000

245000000

10541000

139000

2479000

96000

2052000

153000

186749000

1192000

1124000

13724000

1553000

100000000

22280160

0.0001

22280160

2000

67000

2524000

15000

98000

1000

3703000

10914000

13724000

6196000

2524000

65000

698000

1865000

676000

112000

491000

0.0001

500000

346000

120000

554000

204000

-179223000

5.70

3653330

2024694

7.07

3693348

5.69

7528000

1000

16000 20000 236000 774000 4144000 117000

1000

1.54

1000000

75000

236000 0.03 0.01

0.0950

11000

245000000

1000

2540000

5096675

1359051

498882

3284440

7.79

4182000

2162000

57000

4246000

184137000

457000

1113000

15978000

3550000

100000000

21047498

0.0001

21047498

2000

68000

3221000

35000

27000

1000

10914000

15978000

5841000

3221000

70000

44000

0.0001

500000

696000

204000

614000

204000

-174002000

3695634

5.69

10137000

3000

421000 225000 568000 61000

1000

3259000

1 1 1 1 1

15660000

7840000

1150000

15900000

0.10

0.0101

0.030

0.010

0.05

0.010

0.0153

15900000

P2Y

10374

11000

P7Y9M7D

1000

6359000

4000

64000

-0.21

1640000

96000

-512000

-164000

187000

-2992000

3312000

9351000

-3483000

-3312000

16000

9702000

300000

-651000

1672000

622000

615000

16791362

5000 48000

3003785

P10Y

0.00

P6Y8M15D

0.0223

0.799

P5Y9M18D

0.0210

0.766

42000

22000

659000

343555

25% on the first anniversary of the option grant date and the remainder in 36 equal monthly installments beginning in the month after the vesting start date.

P48M

0.25

7000

187000

21000

462000

153000

85251

3284440

false

<div> 6. Accrued Expenses and Other Current Liabilities Accrued expenses consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued vacation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued wages and incentive </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,124</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,113</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued clinical & consulting </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">774</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">568</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued legal & patent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">117</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued end of term fee </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">236</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">225</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Deferred Rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">67</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued other expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,479</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,162</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2000

<div> 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2018, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 13, 2018. </div>

<div> 12. Commitments Future minimum lease payments under the non-cancelable operating lease for office and lab space is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amount</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">491</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">676</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2020 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">698</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,865</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-1997000

2000

719000

--12-31

60000

-0.24

<div> 11. Net Loss Per Share The Company computes basic and diluted net loss per share using a methodology that gives effect to the impact of outstanding participating securities (the “two-class method”). As the three months ended March 31, 2018 and 2017 resulted in net losses attributable to common shareholders, there is no income allocation required under the two-class method or dilution attributed to weighted average shares outstanding in the calculation of diluted net loss per share. The following potentially dilutive securities outstanding prior to the use of the treasury stock method have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> As of March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,693,348</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,003,785</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,284,440</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,284,440</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Settlement of term loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85,251</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85,251</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

P1Y10M24D

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 9. Stock-Based Compensation <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company sponsors the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan). As of March 31, 2018, the 2013 Plan provides for the grant of up to 5,096,675 shares of Company Common Stock, of which 1,359,051 shares remained available for future grant. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In addition, the Company has two legacy plans: The Pulmatrix Operating’s 2013 Employee, Director and Consultant Equity Incentive Plan (the “Original 2013 Plan”) and Pulmatrix Operating’s 2003 Employee, Director, and Consultant Stock Plan (the “2003 Plan”). As of March 31, 2018, a total of 498,882 shares of Company Common Stock may be delivered under options outstanding under the Original 2013 Plan and the 2003 Plan, however no additional awards may be granted under the Original 2013 Plan or the 2003 Plan. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Options <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During the three months ended March 31, 2018, the Company granted no options to employees, directors or consultants. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During the three months ended March 31, 2017, the Company granted options to purchase 343,555 shares of Company Common Stock to employees and options to purchase 22,000 shares of Company Common Stock to directors. At the date of grant the fair value of those options aggregated to $659 and $42 respectively. The stock options granted vest over 48 months (the “Time Based Options”). Subject to the grantees’ continuous service with the Company, Time Based Options vest 25% on the first anniversary of the option grant date and the remainder in 36 equal monthly installments beginning in the month after the vesting start date. Stock options generally expire ten years after the date of grant. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table summarizes stock option activity for the three months ended March 31, 2018: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term ( Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding — January 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,695,634</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.77</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Forfeited or expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,286</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.95</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding — March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,693,348</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.53</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Exercisable — March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,024,694</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.07</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.66</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested and expected to vest — March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,653,330</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.70</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.52</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The estimated fair values of employee stock options granted during the three months ended March 31, 2018 and 2017, were determined on the date of grant using the Black-Scholes option-pricing model with the following assumptions: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="5" align="center"> Three Months Ended March 31,</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2017</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected option life (years) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" align="center">5.80 - 6.71</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2.10% - 2.23%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" align="center">76.6% - 79.9%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was based upon the historical volatility for industry peers and used an average of those volatilities. The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity. The dividend yield considers that the Company has not historically paid dividends and does not expect to pay dividends in the foreseeable future. As of March 31, 2018, there was $3,703 of unrecognized stock-based compensation expense related to unvested stock options granted under the Company’s stock award plans. This expense is expected to be recognized over a weighted-average period of approximately 1.9 years. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table presents total stock-based compensation expense for the three months ended March 31, 2018: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">153</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">555</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">462</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">615</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 16pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Restricted Stock Units (RSU) <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In August 2015, the Company granted 10,374 RSUs to other employees that vest over a two year period. The Company recorded stock-based compensation expense of $7 for the RSUs during the three months ended March 31, 2017. At March 31, 2018, no RSUs were outstanding. </div>

Q1 2018 10-Q 2018-03-31 Pulmatrix, Inc.

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 16pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 10. Fair Value Measurements <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Information about the liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017, and the input categories associated with those liabilities, is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">March 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Fair Value Measurements Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Embedded compound derivative </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Fair Value Measurements Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Embedded compound derivative </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 16pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Embedded Compound Derivatives — LSA with Hercules <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> As described in Note 5, the LSA contains an interest rate reset upon an event of default and a put option upon an event of default or qualified change of control. Each of these features represents an embedded derivative instrument requiring bifurcation from the Term Loan. The embedded derivatives were bundled and valued as one compound derivative in accordance with the applicable accounting guidance for derivatives and hedging. The proceeds from the issuance of the Term Loan were allocated first to the warrant and compound derivative at their respective fair values, with the residual going to the carrying amount of the loan resulting in a discount to the face value of the debt. The fair value of the compound derivative upon issuance of $11 was recognized as a derivative liability and will be adjusted to fair value at each reporting date. At March 31, 2018, the fair value of the derivative liability was remeasured and valued at $1. The fair value of the derivative instruments is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company used an income approach to estimate the fair value of the derivative liability and estimated the probability of an event of default occurring at various dates and then estimates the present value of the amount the holders would receive upon an event of default. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The significant assumption used in the model is the probability of the following scenarios occurring: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="13%"></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">At Issuance Date</td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">At March 31, 2018</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Probability of an event of default </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">5%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Prepayment penalties </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.0% - 3.0%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.0%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> End of term payment </td> <td valign="bottom">  </td> <td valign="bottom" align="center">$245,000</td> <td valign="bottom"> </td> <td valign="bottom" align="center">245,000</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.01%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">1.53%</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was based upon the historical volatility for industry peers and used an average of those volatilities. The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity. The dividend yield considers that the Company has not historically paid dividends and does not expect to pay dividends in the foreseeable future. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> A roll-forward of the preferred stock warrant liability and derivative liability categorized with Level 3 inputs is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="23%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Derivative Instruments</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance — January 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Change in fair value </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance — March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Gains and/or losses arising from changes in the estimated fair value of the warrants and embedded compound derivatives were recorded within other income, net, on the condensed consolidated statement of operations. </div>

0001574235

<div> The significant assumption used in the model is the probability of the following scenarios occurring:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">At Issuance Date</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">At March 31, 2018</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Probability of an event of default </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">5%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Prepayment penalties </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.0% - 3.0%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.0%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> End of term payment </td> <td valign="bottom">  </td> <td valign="bottom" align="center">$245,000</td> <td valign="bottom">  </td> <td valign="bottom" align="center">245,000</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.01%</td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.53%</td> </tr> </table> </div>

<div> A roll-forward of the preferred stock warrant liability and derivative liability categorized with Level 3 inputs is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="23%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Instruments</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance — January 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Change in fair value </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance — March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

Smaller Reporting Company

2046000

153000

306000

735000

-350000

106000

-3125000

5267000

1128000

-5221000

-5114000

-1000

1847000

-719000

3221000

<div> The following potentially dilutive securities outstanding prior to the use of the treasury stock method have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> As of March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,693,348</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,003,785</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,284,440</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,284,440</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Settlement of term loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85,251</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85,251</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> Accrued expenses consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued vacation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued wages and incentive </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,124</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,113</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued clinical & consulting </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">774</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">568</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued legal & patent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">117</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued end of term fee </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">236</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">225</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Deferred Rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">67</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accrued other expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,479</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,162</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The carrying amounts of the Company’s Term Loan as of March 31, 2018 and December 31, 2017 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Hercules Term Loan</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Debt Discount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Issuance Costs</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance — January 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,259</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(35</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,221</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accretion of debt discount </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accretion of issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Principal payments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(719</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(719</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance — March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,540</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,524</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table presents total stock-based compensation expense for the three months ended March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">153</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">555</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">462</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">615</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

153000

<div> Future minimum lease payments under the non-cancelable operating lease for office and lab space is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amount</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">491</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">676</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2020 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">698</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,865</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

765000

2286

P7Y6M10D

P6Y7M28D

3.95

P7Y6M7D

<div> 8. Warrants There were 3,284,440 common stock warrants outstanding at March 31, 2018. The warrants had a weighted-average exercise price of $7.79 with no intrinsic value and a remaining contractual life of 2.20 years. No warrants were issued, exercised, cancelled or forfeited during the period ending March 31, 2018. </div>

<div> 13. Subsequent Events On April 3, 2018, the Company closed its previously announced firm commitment underwritten public offering in which, pursuant to the underwriting agreement (the “Underwriting Agreement”) entered into between the Company and Oppenheimer & Co. Inc., as representative of the underwriters (the “Underwriters”), dated March 28, 2018, the Company issued and sold (i) 15,660,000 common units (“Common Units”), with each Common Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), one Series A warrant (collectively, the “Series A Warrants”) to purchase one share of Common Stock and one Series B warrant (collectively, the “Series B Warrants”) to purchase one share of Common Stock, and (ii) 7,840,000 pre-funded units (the “Pre-Funded Units” and, together with the Common Units, the “Units”), with each Pre-Funded Unit being comprised of one pre-funded warrant to purchase one share of Common Stock, one Series A Warrant and one Series B Warrant. The public offering price was $0.65 per Common Unit and $0.64 per Pre-Funded Unit. In addition, on April 4, 2018, the Company closed on the sale of 1,150,000 additional Common Units pursuant to the Underwriters’ option to purchase up to an additional 1,150,000 Units, which was exercised in full. After giving effect to the exercise of the Underwriters’ overallotment option, the total gross proceeds from the offering were approximately $15.9 million, prior to deducting underwriting discounts and commissions and other estimated offering expenses. The Company is currently evaluating the requirements for classification of the Series A, Series B, and Pre-funded warrants which were issued in this financing. </div>

PULM

21876985

31000 1000 0 0 0 <div> 7. Common Stock At-the-Market Offering On March 17, 2017, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”) to act as the Company’s sales agent with respect to the issuance and sale of up to $11,000,000 of the Company’s shares of common stock, from time to time in an at-the-market public offering (the “Offering”). Sales of common stock under the Sales Agreement are made pursuant to an effective shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission on July 15, 2016, and subsequently declared effective on August 3, 2016 (File No. 333-212546), and a related prospectus. BTIG acts as the Company’s sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The NASDAQ Global Market. If expressly authorized by the Company, BTIG may also sell the Company’s common stock in privately negotiated transactions. There is no specific date on which the Offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account. BTIG is entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of the Company’s common stock pursuant to the Sales Agreement. During the three month period ended March 31, 2018, the Company sold 1,232,662 shares of its common stock under the Sales Agreement at an average selling price of approximately $1.54 per share which resulted in gross proceeds of approximately $1,904 and net proceeds of approximately $1,847 after payment of 3% commission to BTIG and other issuance costs. </div> <div> 4. Prepaid Expenses and Other Current Assets Prepaid expenses consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid Insurance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">204</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Prepaid Clinical Trials </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">421</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Deferred Operating Costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total prepaid and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">346</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Prepaid expenses consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> At December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid Insurance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">204</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Prepaid Clinical Trials </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">421</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Deferred Operating Costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total prepaid and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">346</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">696</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 0

3693348

1847000

1232662

1904000 0.03

30-month amortization schedule

245000

The Company is required to make interest payments in cash on the first business day of each month, beginning on July 1, 2015. Since August 1, 2016, the Company has been required to make monthly payments on the first business day of each month consisting of principal and interest based upon a 30-month amortization schedule

0.0850

11.73

The prime rate as reported by The Wall Street Journal minus 3.25% plus (b) 8.50%.

106000

11000

0.0325

555000

210000

719000

85251

P2Y2M12D

3284440

0001574235 pulm:WarrantsToPurchaseCommonStockMember 2018-01-01 2018-03-31 0001574235 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001574235 pulm:TermLoanMember 2018-01-01 2018-03-31 0001574235 us-gaap:SecuredDebtMember 2018-01-01 2018-03-31 0001574235 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001574235 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001574235 us-gaap:DerivativeMember 2018-01-01 2018-03-31 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMemberus-gaap:PrimeRateMember 2018-01-01 2018-03-31 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMember 2018-01-01 2018-03-31 0001574235 pulm:BtigLlcMemberpulm:AtTheMarketOfferingMember 2018-01-01 2018-03-31 0001574235 us-gaap:EmployeeStockOptionMemberpulm:ConsultantsMember 2018-01-01 2018-03-31 0001574235 us-gaap:EmployeeStockOptionMemberpulm:EmployeesMember 2018-01-01 2018-03-31 0001574235 us-gaap:EmployeeStockOptionMemberus-gaap:DirectorMember 2018-01-01 2018-03-31 0001574235 us-gaap:StockOptionMember 2018-01-01 2018-03-31 0001574235 2018-01-01 2018-03-31 0001574235 pulm:WarrantsToPurchaseCommonStockMember 2017-01-01 2017-03-31 0001574235 pulm:TermLoanMember 2017-01-01 2017-03-31 0001574235 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001574235 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMember 2017-01-01 2017-03-31 0001574235 us-gaap:RestrictedStockUnitsRSUMemberpulm:OtherEmployeesMember 2017-01-01 2017-03-31 0001574235 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-03-31 0001574235 us-gaap:EmployeeStockOptionMemberpulm:EmployeesMember 2017-01-01 2017-03-31 0001574235 us-gaap:EmployeeStockOptionMemberus-gaap:DirectorMember 2017-01-01 2017-03-31 0001574235 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2017-01-01 2017-03-31 0001574235 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2017-01-01 2017-03-31 0001574235 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001574235 us-gaap:StockOptionMember 2017-01-01 2017-03-31 0001574235 2017-01-01 2017-03-31 0001574235 2017-01-01 2017-12-31 0001574235 2015-01-01 2015-12-31 0001574235 us-gaap:RestrictedStockUnitsRSUMemberpulm:OtherEmployeesMember 2015-08-01 2015-08-31 0001574235 us-gaap:SubsequentEventMemberpulm:UnderwrittenPublicOfferingMember 2018-04-01 2018-04-30 0001574235 us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2018-03-31 2018-03-31 0001574235 us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MinimumMember 2015-06-11 2015-06-11 0001574235 us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MaximumMember 2015-06-11 2015-06-11 0001574235 us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-11 2015-06-11 0001574235 pulm:CommonUnitsMemberus-gaap:SubsequentEventMember 2018-04-04 2018-04-04 0001574235 pulm:CommonUnitsMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember 2018-04-04 2018-04-04 0001574235 pulm:PrefundedUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 pulm:CommonUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 pulm:CommonUnitsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 pulm:SeriesBWarrantMemberpulm:PrefundedUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 pulm:SeriesBWarrantMemberpulm:CommonUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 pulm:SeriesAWarrantMemberpulm:PrefundedUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 pulm:SeriesAWarrantMemberpulm:CommonUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 2018-04-03 0001574235 us-gaap:SecuredDebtMember 2017-12-31 0001574235 us-gaap:DerivativeMember 2017-12-31 0001574235 pulm:PreferredStockWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001574235 pulm:PreferredStockWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001574235 2017-12-31 0001574235 2016-12-31 0001574235 us-gaap:WarrantMember 2018-03-31 0001574235 pulm:LegacySharePlanMember 2018-03-31 0001574235 pulm:TwoThousandAndThirteenPlanMember 2018-03-31 0001574235 pulm:TermLoanMember 2018-03-31 0001574235 us-gaap:SecuredDebtMember 2018-03-31 0001574235 us-gaap:DerivativeMember 2018-03-31 0001574235 us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMemberus-gaap:MinimumMember 2018-03-31 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMember 2018-03-31 0001574235 pulm:BtigLlcMemberpulm:AtTheMarketOfferingMember 2018-03-31 0001574235 pulm:PreferredStockWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001574235 pulm:PreferredStockWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001574235 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0001574235 2018-03-31 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMember 2017-03-31 0001574235 2017-03-31 0001574235 us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-11 0001574235 pulm:HerculesLoanAndSecurityAgreementMemberpulm:TermLoanMember 2015-06-11 0001574235 pulm:PrefundedUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:CommonUnitsMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:CommonUnitsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:SeriesBWarrantMemberpulm:PrefundedUnitsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:SeriesBWarrantMemberpulm:CommonUnitsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:SeriesAWarrantMemberpulm:PrefundedUnitsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:SeriesAWarrantMemberpulm:CommonUnitsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpulm:UnderwritingAgreementMember 2018-04-03 0001574235 pulm:BtigLlcMemberus-gaap:MaximumMemberpulm:AtTheMarketOfferingMember 2017-03-17 0001574235 2018-05-09 shares iso4217:USD iso4217:USD shares pure pulm:Installment utr:D

EX-101.SCH 6 pulm-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Organization link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Accrued Expenses and Other Current Liabilities link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Common Stock link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Commitments link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Commitments (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Organization - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Debt - Loan and Security Agreement and Warrant Agreement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Debt - Summary of Carrying Amount of Company's Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Stock-Based Compensation - Estimated Fair Values of Employee Stock Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Fair Value Measurements - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Fair Value Measurements - Schedule of Significant Assumption Used in Model is Probability (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Fair Value Measurements - Schedule of Preferred Stock Warrant Liability and Derivative Liability Categorized with Level 3 (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Net Loss Per Share - Schedule of Computation of Diluted Weighted-Average Shares Outstanding Anti-Dilutive (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Commitments - Schedule of Future Minimum Lease Payments under the Non-Cancelable Operating Lease for Office and Lab Space (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 pulm-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 pulm-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 pulm-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses and Other Current Liabilities Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts Receivable Accrued clinical and consulting current. Accrued Clinical And Consulting Current Accrued clinical & consulting Accrued end of term fee. Accrued End Of Term Fee Accrued end of term fee Accrued legal and patent current. Accrued Legal And Patent Current Accrued legal & patent Accrued Liabilities, Current Accrued expenses Total accrued expenses Accrued Salaries, Current Accrued wages and incentive Accrued Vacation, Current Accrued vacation Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share-based Compensation Expense Stock-based compensation Amendment Flag Amendment Flag Amortization of Debt Discount (Premium) Accretion of issuance costs, debt discount Amortization of Debt Issuance Costs Accretion of issuance costs, issuance costs Amortization of Debt Issuance Costs and Discounts Accretion of issuance costs Amortization of Financing Costs, Term Loan Amortization of Financing Costs, Term Loan Accretion of issuance costs Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential dilutive securities excluded from computation of diluted net loss per common share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: At the Market Offering. At the Market Offering [Member] At the Market Offering [Member] Award Type [Axis] Award Type [Axis] Basis of Accounting [Text Block] Basis of Presentation BTIG LLC. BTIG LLC [Member] BTIG LLC [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and cash equivalents Unrestricted cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Class of Stock [Domain] Class of Stock [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of warrant or right cancelled. Class Of Warrant Or Right Cancelled Number of warrants cancelled Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Class of warrant or right exercised. Class Of Warrant Or Right Exercised Number of warrants exercised Class of warrant or right forfeited. Class Of Warrant Or Right Forfeited Number of warrants forfeited Class of warrant or right issued. Class Of Warrant Or Right Issued Number of warrants issued Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares called by each warrant Class of Warrant or Right [Table] Class of Warrant or Right [Table] Commitments and Contingencies Commitments (Note 13) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Subscriptions Aggregate offering on sale of common stock Common stock. Common Stock [Text Block] Common Stock Common Stock, Value, Issued Common stock, $0.0001 par value-100,000,000 shares authorized; 22,280,160 and 21,047,498 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively. Common units. Common Units [Member] Common Units [Member] Consultants. Consultants [Member] Consultants [Member] Counterparty Name [Axis] Counterparty Name [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Debt instrument accretion of debt discount. Debt Instrument Accretion Of Debt Discount Accretion of debt discount Accretion of debt discount Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Debt instrument basis spread Long-term Debt, Gross Ending balance Beginning balance Term loan principal outstanding Debt Instrument, Convertible, Carrying Amount of Equity Component Maximum principal amount available for conversion into common shares Debt Instrument, Convertible, Stock Price Trigger Debt instrument, convertible, stock price trigger Debt Instrument, Convertible, Threshold Trading Days Debt instrument, convertible, threshold trading days Debt Instrument, Description of Variable Rate Basis Basis of debt instrument interest rate Debt Instrument End Of Term Fee Debt Instrument End Of Term Fee End of term charge Debt Instrument, Face Amount Term loan principal amount Debt Instrument, Frequency of Periodic Payment Debt instrument periodic payment frequency Debt Instrument, Interest Rate, Stated Percentage Floating annual rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Payment Terms Debt instrument payment terms Debt Instrument, Periodic Payment Repayment charges Debt Instrument, Periodic Payment, Principal Principal payments Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Unamortized Discount Ending balance Beginning balance Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Non-cash debt issuance expense Deferred Costs, Current Deferred Operating Costs Deferred Rent Credit Deferred Rent Depreciation, Depletion and Amortization Depreciation and amortization Derivative Contract [Domain] Derivative Contract [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Liability, Current Derivative liability Derivative [Member] Derivative Instruments [Member] Director [Member] Director [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Disclosure of prepaid expenses and other current assets text block. Disclosure Of Prepaid Expenses And Other Current Assets Text Block Prepaid Expenses and Other Current Assets Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per share, basic and diluted Earnings Per Share [Text Block] Net Loss Per Share Embedded Derivative Financial Instruments [Member] Embedded Compound Derivative [Member] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized stock-based compensation expense, period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized stock-based compensation expenses Employees [Member] Employees [Member] Employees [Member] Employee Stock Option [Member] Employee Stock Option [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Assets Liabilities Quantitative Information [Line Items] Fair Value Assets Liabilities Quantitative Information [Line Items] Fair Value Assets Liabilities Quantitative Information [Line Items] Fair value assets liabilities quantitative information. Fair Value Assets Liabilities Quantitative Information [Table] Fair Value Assets Liabilities Quantitative Information [Table] Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Liability Class [Axis] Liability Class [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Concentration of Risk [Table Text Block] Schedule of Significant Assumption Used In Model Is Probability Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Fair Value Inputs, Prepayment Rate Prepayment penalties Fair Value Inputs, Probability of Default Probability of an event of default Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Liabilities Measured at Fair Value on a Recurring Basis Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Preferred Stock Warrant Liability and Derivative Liability Categorized with Level 3 Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Ending balance Beginning balance Fair value of warrant derivative liabilities at issuance recorded as debt discount. Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount Fair value of warrant derivative liabilities at issuance, recorded as debt discount Fixed rate of commission on sale of stock. Fixed Rate Of Commission On Sale Of Stock Fixed commission rate entitled to placement agent General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative [Member] Goodwill Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Goodwill, Impairment Loss Impairment of goodwill Hercules loan and security agreement. Hercules Loan And Security Agreement [Member] Hercules Loan and Security Agreement [Member] Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts Receivable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Interest Expense Interest expense Interest Expense, Debt Interest expense Interest Payable, Current Interest expense payable in cash Legacy share plan [Member] Legacy Share Plan [Member] Legacy Share Plan [Member] Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Financial and Nonfinancial Liabilities, Fair Value Disclosure Derivative liability Liabilities, Derivative liability Long-term Debt, Current Maturities Loan payable, net of debt discount and issuance costs Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Maximum [Member] Maximum [Member] Maximum percentage of prepayment fees. Maximum Percentage Of Pre Payment Fees Percentage of prepayment fee Minimum [Member] Minimum [Member] Minimum percentage of prepayment fees. Minimum Percentage Of Pre Payment Fees Percentage of prepayment fee Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Net Income (Loss) Attributable to Parent Net loss Net loss New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Noncash interest expenses. Non Cash Interest Expenses Non-cash interest expense Noncash rent expense. Noncash Rent Expense Non-cash rent expense Number of equal vesting installments. Number of Equal Vesting Installments Number of equal vesting installments Number of shares or warrants included in unit. Number Of Shares Or Warrants Included In Unit Number of shares Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses Operating Income (Loss) Loss from operations Operating Leases, Future Minimum Payments Due Total Operating Leases, Future Minimum Payments, Due in Three Years 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2019 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2018 Organization And Basis Of Presentation [Line Items] Organization And Basis Of Presentation [Line Items] Organization And Basis Of Presentation [Line Items] Organization And Basis Of Presentation [Table] Organization And Basis Of Presentation [Table] Organization And Basis Of Presentation [Table] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization Other Accrued Liabilities, Current Accrued other expenses Other employees. Other Employees [Member] Other Employees [Member] Other Nonoperating Income (Expense) Other income (expense), net Other Prepaid Expense, Current Prepaid Other EX-101.PRE 10 pulm-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 09, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	PULM
Entity Registrant Name	Pulmatrix, Inc.
Entity Central Index Key	0001574235
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		41,927,221

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,553	$ 3,550
Accounts Receivable	153
Prepaid expenses and other current assets	346	696
Total current assets	2,052	4,246
Property and equipment, net	554	614
Long-term restricted cash	204	204
Goodwill	10,914	10,914
Total assets	13,724	15,978
Current liabilities:
Loan payable, net of debt discount and issuance costs	2,524	3,221
Accounts payable	1,192	457
Accrued expenses	2,479	2,162
Derivative liability	1	1
Total current liabilities	6,196	5,841
Commitments (Note 13)
Stockholders' equity:
Preferred stock, $0.0001 par value-500,000 authorized and 0 issued and outstanding at March 31, 2018 and December 31, 2017
Common stock, $0.0001 par value-100,000,000 shares authorized; 22,280,160 and 21,047,498 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively.	2	2
Additional paid-in capital	186,749	184,137
Accumulated deficit	(179,223)	(174,002)
Total stockholders' equity	7,528	10,137
Total liabilities and stockholders' equity	$ 13,724	$ 15,978

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	22,280,160	21,047,498
Common stock, shares outstanding	22,280,160	21,047,498

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues	$ 153
Operating expenses
Research and development	3,221	$ 1,672
General and administrative	2,046	1,640
Total operating expenses	5,267	3,312
Loss from operations	(5,114)	(3,312)
Interest expense	(106)	(187)
Other income (expense), net	(1)	16
Net loss	$ (5,221)	$ (3,483)
Net loss per share, basic and diluted	$ (0.24)	$ (0.21)
Weighted average shares used to compute basic and diluted net loss per share	21,876,985	16,791,362

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (5,221)	$ (3,483)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	60	64
Stock-based compensation	765	622
Non-cash rent expense		5
Non-cash interest expense	31	48
Non-cash debt issuance expense	2	4
Changes in operating assets and liabilities:
Accounts Receivable	(153)
Prepaid expenses and other current assets	350	164
Accounts payable	735	(512)
Accrued expenses	306	96
Net cash used in operating activities	(3,125)	(2,992)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	1,847	9,702
Proceeds from the exercise of stock options		300
Term loan principal payments	(719)	(651)
Net cash provided by financing activities	1,128	9,351
Net (decrease) increase in cash and cash equivalents	(1,997)	6,359
Cash and cash equivalents - beginning of period	3,550	4,182
Cash and cash equivalents - end of period	$ 1,553	$ 10,541

XML 16 R6.htm IDEA: XBRL DOCUMENT

Organization	3 Months Ended
Organization	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Pulmatrix, Inc. and its subsidiaries (the “Company”) is a clinical stage biotechnology company focused on the discovery and development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted), is engineered to deliver small, dense particles with highly efficient dispersibility and delivery to the airways, which can be used with an array of dry powder inhaler technologies and can be formulated with a variety of drug substances. The Company is developing a pipeline of iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory diseases and infections with significant unmet medical needs. Liquidity At March 31, 2018, the Company had unrestricted cash and cash equivalents of $1,553, an accumulated deficit of $179,223 and a deficit in working capital of $4,144. The Company will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. If unable to raise additional capital when required or on acceptable terms, the Company may have to (i) delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize on unfavorable terms. During the three months ended March 31, 2018, the Company sold 1,232,662 shares of its common stock for aggregate net proceeds of $1,847. (See Note 7). In April 2018, we closed on an underwritten public offering that brought in gross proceeds of approximately $15,900 (see Note 13). The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing and, ultimately, to generate revenue. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s condensed consolidated financial statements as of March 31, 2018 do not include any adjustments that might become necessary should the Company be unable to continue as a going concern.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2018, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 13, 2018.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies In the three months ended March 31, 2018, there were no changes to the Company’s significant accounting policies identified in the Company’s most recent annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s current report on Form 10-K. Recent Accounting Pronouncements In March 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118”, (“ASU 2018-05”) to add various SEC paragraphs pursuant to the issuance of SEC Staff Accounting Bulletin No. 118 (“SAB 118”), to ASC 740 “Income Taxes”. SAB 118 was issued by the SEC in December 2017 to provide immediate guidance for accounting implications of U.S. tax reform under the “Tax Cuts and Jobs Act” (the “Tax Act”), which became effective for the Company on January 1, 2018. The Company has adopted ASU 2018-05 and adoption of this ASU has no significant impact on its condensed consolidated financial statements. In February 2018, the FASB issued Accounting Standards Update No. 2018-02, “Income Statement — Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (“ASU 2018-02”), which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act and requires certain disclosures about stranded tax effects. ASU 2018-02 is effective for us beginning December 1, 2019 (with early adoption permitted) and shall be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the potential impact of adopting this guidance on its condensed consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35,“Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of control of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. Since the Company is an emerging growth company and elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act, this ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its consolidated financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing revenue recognition accounting policies to determine the effect the guidance will have on its condensed consolidated financial statements and what changes to systems and controls may be warranted. Use of Estimates In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply. *Revenue Recognition* The Company’s principal sources of revenue during the reporting period were reimbursement of clinical study costs. In all instances, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, and collectability of the resulting receivable is reasonably assured. *Goodwill* Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired, and liabilities assumed under the acquisition method of accounting for push-down accounting. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the Company’s reporting unit below its carrying amount. When performing the impairment assessment, the accounting standard for testing goodwill for impairment permits a company to first assess the qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the goodwill is impaired. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of goodwill is impaired, the Company must perform a quantitative impairment test. The Company completed a qualitative assessment and determined that there was no impairment of goodwill as of March 31, 2018.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2018

Text Block [Abstract]

Prepaid Expenses and Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses consisted of the following:


	At March 31, 2018		At December 31, 2017
Prepaid Insurance	$	120	$	204
Prepaid Clinical Trials		16		421
Prepaid Other		112		44
Deferred Operating Costs		98		27

Total prepaid and other current assets	$	346	$	696

XML 20 R10.htm IDEA: XBRL DOCUMENT

Debt

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Debt

5. Debt

Loan and Security Agreement and Warrant Agreement

The carrying amounts of the Company’s Term Loan as of March 31, 2018 and December 31, 2017 were as follows:


	Hercules Term Loan			Debt Discount			Issuance Costs			Total
Balance — January 1, 2018	$	3,259		$	(35	)	$	(3	)	$	3,221
Accretion of debt discount					20						20
Accretion of issuance costs								2			2
Principal payments		(719	)								(719	)

Balance — March 31, 2018	$	2,540		$	(15	)	$	(1	)	$	2,524

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

6. Accrued Expenses and Other Current Liabilities

Accrued expenses consisted of the following:


	At March 31, 2018		At December 31, 2017
Accrued vacation	$	96	$	57
Accrued wages and incentive		1,124		1,113
Accrued clinical & consulting		774		568
Accrued legal & patent		117		61
Accrued end of term fee		236		225
Deferred Rent		67		68
Accrued other expenses		65		70

Total accrued expenses	$	2,479	$	2,162

XML 22 R12.htm IDEA: XBRL DOCUMENT

Common Stock	3 Months Ended
Common Stock	Mar. 31, 2018
Text Block [Abstract]
Common Stock	7. Common Stock At-the-Market Offering On March 17, 2017, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”) to act as the Company’s sales agent with respect to the issuance and sale of up to $11,000,000 of the Company’s shares of common stock, from time to time in an at-the-market public offering (the “Offering”). Sales of common stock under the Sales Agreement are made pursuant to an effective shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission on July 15, 2016, and subsequently declared effective on August 3, 2016 (File No. 333-212546), and a related prospectus. BTIG acts as the Company’s sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The NASDAQ Global Market. If expressly authorized by the Company, BTIG may also sell the Company’s common stock in privately negotiated transactions. There is no specific date on which the Offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account. BTIG is entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of the Company’s common stock pursuant to the Sales Agreement. During the three month period ended March 31, 2018, the Company sold 1,232,662 shares of its common stock under the Sales Agreement at an average selling price of approximately $1.54 per share which resulted in gross proceeds of approximately $1,904 and net proceeds of approximately $1,847 after payment of 3% commission to BTIG and other issuance costs.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Warrants	3 Months Ended
Warrants	Mar. 31, 2018
Equity [Abstract]
Warrants	8. Warrants There were 3,284,440 common stock warrants outstanding at March 31, 2018. The warrants had a weighted-average exercise price of $7.79 with no intrinsic value and a remaining contractual life of 2.20 years. No warrants were issued, exercised, cancelled or forfeited during the period ending March 31, 2018.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

Options

During the three months ended March 31, 2018, the Company granted no options to employees, directors or consultants.

The following table summarizes stock option activity for the three months ended March 31, 2018:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term ( Years)		Aggregate Intrinsic Value
Outstanding — January 1, 2018		3,695,634		$	5.69		7.77	$	—
Granted		—		$	—
Exercised		—		$	—
Forfeited or expired		(2,286	)	$	3.95

Outstanding — March 31, 2018		3,693,348		$	5.69		7.53	$	—

Exercisable — March 31, 2018		2,024,694		$	7.07		6.66	$	—

Vested and expected to vest — March 31, 2018		3,653,330		$	5.70		7.52	$	—


	Three Months Ended March 31,
	2018		2017
Expected option life (years)		—	5.80 - 6.71
Risk-free interest rate		—	2.10% - 2.23%
Expected volatility		—	76.6% - 79.9%
Expected dividend yield		—	0%

The following table presents total stock-based compensation expense for the three months ended March 31, 2018:


	Three Months Ended March 31,
	2018		2017
Research and development	$	210	$	153
General and administrative		555		462

Total stock based compensation expense	$	765	$	615

Restricted Stock Units (RSU)

XML 25 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

10. Fair Value Measurements

Information about the liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017, and the input categories associated with those liabilities, is as follows:


	March 31, 2018
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Liabilities:
Embedded compound derivative	$	—	$	—	$	1	$	1


	December 31, 2017
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Liabilities:
Embedded compound derivative	$	—	$	—	$	1	$	1

Embedded Compound Derivatives — LSA with Hercules

The significant assumption used in the model is the probability of the following scenarios occurring:


	At Issuance Date	At March 31, 2018
Probability of an event of default	10%	5%
Prepayment penalties	1.0% - 3.0%	1.0%
End of term payment	$245,000	245,000
Risk-free interest rate	1.01%	1.53%

A roll-forward of the preferred stock warrant liability and derivative liability categorized with Level 3 inputs is as follows:


	Derivative Instruments
Balance — January 1, 2018	$	1
Change in fair value		—

Balance — March 31, 2018	$	1

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Net Loss Per Share

11. Net Loss Per Share


	As of March 31,
	2018		2017
Options to purchase common stock		3,693,348		3,003,785
Warrants to purchase common stock		3,284,440		3,284,440
Settlement of term loan		85,251		85,251

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments

12. Commitments

Future minimum lease payments under the non-cancelable operating lease for office and lab space is as follows:


	Amount
2018	$	491
2019		676
2020		698

Total	$	1,865

XML 28 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On April 3, 2018, the Company closed its previously announced firm commitment underwritten public offering in which, pursuant to the underwriting agreement (the “Underwriting Agreement”) entered into between the Company and Oppenheimer & Co. Inc., as representative of the underwriters (the “Underwriters”), dated March 28, 2018, the Company issued and sold (i) 15,660,000 common units (“Common Units”), with each Common Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), one Series A warrant (collectively, the “Series A Warrants”) to purchase one share of Common Stock and one Series B warrant (collectively, the “Series B Warrants”) to purchase one share of Common Stock, and (ii) 7,840,000 pre-funded units (the “Pre-Funded Units” and, together with the Common Units, the “Units”), with each Pre-Funded Unit being comprised of one pre-funded warrant to purchase one share of Common Stock, one Series A Warrant and one Series B Warrant. The public offering price was $0.65 per Common Unit and $0.64 per Pre-Funded Unit. In addition, on April 4, 2018, the Company closed on the sale of 1,150,000 additional Common Units pursuant to the Underwriters’ option to purchase up to an additional 1,150,000 Units, which was exercised in full. After giving effect to the exercise of the Underwriters’ overallotment option, the total gross proceeds from the offering were approximately $15.9 million, prior to deducting underwriting discounts and commissions and other estimated offering expenses. The Company is currently evaluating the requirements for classification of the Series A, Series B, and Pre-funded warrants which were issued in this financing.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2018
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118”, (“ASU 2018-05”) to add various SEC paragraphs pursuant to the issuance of SEC Staff Accounting Bulletin No. 118 (“SAB 118”), to ASC 740 “Income Taxes”. SAB 118 was issued by the SEC in December 2017 to provide immediate guidance for accounting implications of U.S. tax reform under the “Tax Cuts and Jobs Act” (the “Tax Act”), which became effective for the Company on January 1, 2018. The Company has adopted ASU 2018-05 and adoption of this ASU has no significant impact on its condensed consolidated financial statements. In February 2018, the FASB issued Accounting Standards Update No. 2018-02, “Income Statement — Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (“ASU 2018-02”), which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act and requires certain disclosures about stranded tax effects. ASU 2018-02 is effective for us beginning December 1, 2019 (with early adoption permitted) and shall be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the potential impact of adopting this guidance on its condensed consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35,“Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of control of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. Since the Company is an emerging growth company and elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act, this ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its consolidated financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing revenue recognition accounting policies to determine the effect the guidance will have on its condensed consolidated financial statements and what changes to systems and controls may be warranted.
Use of Estimates	Use of Estimates In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.
Revenue Recognition	*Revenue Recognition* The Company’s principal sources of revenue during the reporting period were reimbursement of clinical study costs. In all instances, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, and collectability of the resulting receivable is reasonably assured.
Goodwill	*Goodwill* Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired, and liabilities assumed under the acquisition method of accounting for push-down accounting. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the Company’s reporting unit below its carrying amount. When performing the impairment assessment, the accounting standard for testing goodwill for impairment permits a company to first assess the qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the goodwill is impaired. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of goodwill is impaired, the Company must perform a quantitative impairment test. The Company completed a qualitative assessment and determined that there was no impairment of goodwill as of March 31, 2018.

XML 30 R20.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2018

Text Block [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses consisted of the following:


	At March 31, 2018		At December 31, 2017
Prepaid Insurance	$	120	$	204
Prepaid Clinical Trials		16		421
Prepaid Other		112		44
Deferred Operating Costs		98		27

Total prepaid and other current assets	$	346	$	696

XML 31 R21.htm IDEA: XBRL DOCUMENT

Debt (Tables)

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Summary of Carrying Amount of Company's Notes

The carrying amounts of the Company’s Term Loan as of March 31, 2018 and December 31, 2017 were as follows:


	Hercules Term Loan			Debt Discount			Issuance Costs			Total
Balance — January 1, 2018	$	3,259		$	(35	)	$	(3	)	$	3,221
Accretion of debt discount					20						20
Accretion of issuance costs								2			2
Principal payments		(719	)								(719	)

Balance — March 31, 2018	$	2,540		$	(15	)	$	(1	)	$	2,524

XML 32 R22.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following:


	At March 31, 2018		At December 31, 2017
Accrued vacation	$	96	$	57
Accrued wages and incentive		1,124		1,113
Accrued clinical & consulting		774		568
Accrued legal & patent		117		61
Accrued end of term fee		236		225
Deferred Rent		67		68
Accrued other expenses		65		70

Total accrued expenses	$	2,479	$	2,162

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity

The following table summarizes stock option activity for the three months ended March 31, 2018:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term ( Years)		Aggregate Intrinsic Value
Outstanding — January 1, 2018		3,695,634		$	5.69		7.77	$	—
Granted		—		$	—
Exercised		—		$	—
Forfeited or expired		(2,286	)	$	3.95

Outstanding — March 31, 2018		3,693,348		$	5.69		7.53	$	—

Exercisable — March 31, 2018		2,024,694		$	7.07		6.66	$	—

Vested and expected to vest — March 31, 2018		3,653,330		$	5.70		7.52	$	—

Calculation of Fair Value Assumptions Using Black Scholes Option Model


	Three Months Ended March 31,
	2018		2017
Expected option life (years)		—	5.80 - 6.71
Risk-free interest rate		—	2.10% - 2.23%
Expected volatility		—	76.6% - 79.9%
Expected dividend yield		—	0%

Stock-Based Compensation Expense

The following table presents total stock-based compensation expense for the three months ended March 31, 2018:


	Three Months Ended March 31,
	2018		2017
Research and development	$	210	$	153
General and administrative		555		462

Total stock based compensation expense	$	765	$	615

XML 34 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Schedule of Liabilities Measured at Fair Value on a Recurring Basis

Information about the liabilities measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017, and the input categories associated with those liabilities, is as follows:


	March 31, 2018
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Liabilities:
Embedded compound derivative	$	—	$	—	$	1	$	1


	December 31, 2017
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total
Liabilities:
Embedded compound derivative	$	—	$	—	$	1	$	1

Schedule of Significant Assumption Used In Model Is Probability

The significant assumption used in the model is the probability of the following scenarios occurring:


	At Issuance Date	At March 31, 2018
Probability of an event of default	10%	5%
Prepayment penalties	1.0% - 3.0%	1.0%
End of term payment	$245,000	245,000
Risk-free interest rate	1.01%	1.53%

Schedule of Preferred Stock Warrant Liability and Derivative Liability Categorized with Level 3

A roll-forward of the preferred stock warrant liability and derivative liability categorized with Level 3 inputs is as follows:


	Derivative Instruments
Balance — January 1, 2018	$	1
Change in fair value		—

Balance — March 31, 2018	$	1

- Definition

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Schedule of Computation of Diluted Weighted-Average Shares Outstanding Anti-Dilutive


	As of March 31,
	2018		2017
Options to purchase common stock		3,693,348		3,003,785
Warrants to purchase common stock		3,284,440		3,284,440
Settlement of term loan		85,251		85,251

XML 36 R26.htm IDEA: XBRL DOCUMENT

Commitments (Tables)

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments under the Non-Cancelable Operating Lease for Office and Lab Space

Future minimum lease payments under the non-cancelable operating lease for office and lab space is as follows:


	Amount
2018	$	491
2019		676
2020		698

Total	$	1,865

XML 37 R27.htm IDEA: XBRL DOCUMENT

Organization - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Organization And Basis Of Presentation [Line Items]
Accumulated deficit		$ (179,223)	$ (174,002)
Unrestricted cash and cash equivalents		1,553	$ 3,550	$ 10,541	$ 4,182
Working capital deficit		$ 4,144
Underwritten Public Offering [Member] \| Subsequent Event [Member]
Organization And Basis Of Presentation [Line Items]
Proceeds from sale of common stock	$ 15,900
BTIG LLC [Member] \| At the Market Offering [Member]
Organization And Basis Of Presentation [Line Items]
Sale of stock, number of shares sold in transaction		1,232,662
Proceeds from sale of common stock		$ 1,847

XML 38 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Impairment of goodwill	$ 0

XML 39 R29.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Insurance	$ 120	$ 204
Prepaid Clinical Trials	16	421
Prepaid Other	112	44
Deferred Operating Costs	98	27
Total prepaid and other current assets	$ 346	$ 696

XML 40 R30.htm IDEA: XBRL DOCUMENT

Debt - Loan and Security Agreement and Warrant Agreement - Additional Information (Detail) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018 USD ($) d $ / shares	Mar. 31, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2015 USD ($)	Jun. 11, 2015 USD ($)
Debt Instrument [Line Items]
Term loan principal outstanding	$ 2,524		$ 3,221
Accrued end of term fee	236		225
Fair value of warrant derivative liabilities at issuance, recorded as debt discount	1		$ 1	$ 11
Term Loan [Member]
Debt Instrument [Line Items]
Term loan principal outstanding	$ 2,540
Hercules Loan and Security Agreement [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Term loan principal amount					$ 7,000
Debt instrument basis spread	8.50%
Basis of debt instrument interest rate	The prime rate as reported by The Wall Street Journal minus 3.25% plus (b) 8.50%.
Debt instrument payment terms	The Company is required to make interest payments in cash on the first business day of each month, beginning on July 1, 2015. Since August 1, 2016, the Company has been required to make monthly payments on the first business day of each month consisting of principal and interest based upon a 30-month amortization schedule
Debt instrument periodic payment frequency	30-month amortization schedule
Repayment charges	$ 245
Accrued end of term fee	236
End of term charge	$ 11	$ 21
Percentage of prepayment fee	1.00%
Percentage of prepayment fee	3.00%
Maximum principal amount available for conversion into common shares	$ 1,000
Debt instrument, convertible, stock price trigger \| $ / shares	$ 11.73
Debt instrument, convertible, threshold trading days \| d	7
Interest expense	$ 106	187
Interest expense payable in cash	$ 75	$ 139
Hercules Loan and Security Agreement [Member] \| Term Loan [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Floating annual rate	9.50%
Hercules Loan and Security Agreement [Member] \| Term Loan [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument basis spread	3.25%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Debt - Summary of Carrying Amount of Company's Notes (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Short And Long Term Debt [Line Items]
Beginning balance	$ (35)
Accretion of debt discount	20
Accretion of issuance costs, debt discount	0
Ending balance	(15)
Beginning balance	(3)
Accretion of issuance costs, issuance costs	2
Ending balance	(1)
Beginning balance	3,221
Accretion of debt discount	20
Accretion of issuance costs	2
Principal payments	(719)
Ending balance	2,524
Hercules Term Loan [Member]
Short And Long Term Debt [Line Items]
Beginning balance	3,259
Accretion of issuance costs	0
Principal payments	(719)
Ending balance	$ 2,540

XML 42 R32.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued vacation	$ 96	$ 57
Accrued wages and incentive	1,124	1,113
Accrued clinical & consulting	774	568
Accrued legal & patent	117	61
Accrued end of term fee	236	225
Deferred Rent	67	68
Accrued other expenses	65	70
Total accrued expenses	$ 2,479	$ 2,162

XML 43 R33.htm IDEA: XBRL DOCUMENT

Common Stock - Additional Information (Detail) - At the Market Offering [Member] - BTIG LLC [Member] - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 17, 2017
Temporary Equity [Line Items]
Fixed commission rate entitled to placement agent	3.00%
Sale of stock, number of shares sold in transaction	1,232,662
Average selling price of common stock	$ 1.54
Gross proceeds from sale of shares	$ 1,904,000
Proceeds from sale of common stock	$ 1,847,000
Maximum [Member]
Temporary Equity [Line Items]
Aggregate offering on sale of common stock		$ 11,000,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Warrants - Additional Information (Detail)	3 Months Ended
Warrants - Additional Information (Detail)	Mar. 31, 2018 $ / shares shares
Class of Warrant or Right [Line Items]
Number of warrants issued	0
Number of warrants exercised	0
Number of warrants cancelled	0
Number of warrants forfeited	0
Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrants outstanding	3,284,440
Weighted-average exercise price of warrants \| $ / shares	$ 7.79
Weighted-average remaining contractual term of warrants	2 years 2 months 12 days

XML 45 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended
	Aug. 31, 2015 shares	Mar. 31, 2018 USD ($) shares	Mar. 31, 2017 USD ($) Installment shares	Dec. 31, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding		3,693,348		3,695,634
Number of options to purchase common stock, Granted		0
Unrecognized stock-based compensation expenses \| $		$ 3,703
Unrecognized stock-based compensation expense, period for recognition		1 year 10 months 24 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period			10 years
Employee Stock Option [Member] \| Time Based Options Vesting 48 Month [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			48 months
Award vesting percentage			25.00%
Number of equal vesting installments \| Installment			36
Award vesting term			25% on the first anniversary of the option grant date and the remainder in 36 equal monthly installments beginning in the month after the vesting start date.
Employee Stock Option [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase common stock, Granted		0	343,555
Aggregate weighted average amount of fair value of options \| $			$ 659
Employee Stock Option [Member] \| Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase common stock, Granted		0	22,000
Aggregate weighted average amount of fair value of options \| $			$ 42
Employee Stock Option [Member] \| Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase common stock, Granted		0
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of units, outstanding		0
Restricted Stock Units [Member] \| Other Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	2 years
Restricted stock units, granted	10,374
Stock-based compensation \| $			$ 7
2013 Employee, Director and Consultant Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate shares of Common Stock that may be delivered under options outstanding		5,096,675
Shares available for future grant		1,359,051
Legacy Share Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate shares of Common Stock that may be delivered under options outstanding		0
Shares outstanding		498,882

XML 46 R36.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of options, Outstanding beginning balance	3,695,634
Number of options, Granted	0
Number of options, Exercised	0
Number of options, Forfeited or expired	(2,286)
Number of options, Outstanding ending balance	3,693,348	3,695,634
Number of options, Exercisable	2,024,694
Number of options, Vested and expected to vest	3,653,330
Weighted average exercise price, Outstanding beginning balance	$ 5.69
Weighted average exercise price, Granted	0
Weighted average exercise price, Exercised	0
Weighted average exercise price, Forfeited or expired	3.95
Weighted average exercise price, Outstanding ending balance	5.69	$ 5.69
Weighted average exercise price, Exercisable	7.07
Weighted average exercise price, Vested and expected to vest	$ 5.70
Weighted average remaining contractual term, Outstanding ending balance	7 years 6 months 10 days	7 years 9 months 7 days
Weighted average remaining contractual term, Exercisable	6 years 7 months 28 days
Weighted average remaining contractual term, Vested and expected to vest	7 years 6 months 7 days
Aggregate intrinsic value, Outstanding	$ 0
Aggregate intrinsic value, Exercised	$ 0
Aggregate intrinsic value, Forfeited or expired	$ 0
Aggregate intrinsic value, Outstanding	$ 0
Aggregate intrinsic value, Exercisable	0
Aggregate intrinsic value, Vested and expected to vest	$ 0

XML 47 R37.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Estimated Fair Values of Employee Stock Options Granted (Detail) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life (years)	5 years 9 months 18 days
Risk-free interest rate	2.10%
Expected volatility	76.60%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life (years)	6 years 8 months 15 days
Risk-free interest rate	2.23%
Expected volatility	79.90%

XML 48 R38.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 765	$ 615
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	210	153
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 555	$ 462

XML 49 R39.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - Preferred Stock Warrants [Member] - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Derivative liability	$ 1	$ 1
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Derivative liability	$ 1	$ 1

XML 50 R40.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2015
Fair Value Assets Liabilities Quantitative Information [Line Items]
Fair value of warrant derivative liabilities at issuance, recorded as debt discount	$ 1	$ 1	$ 11
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Embedded Compound Derivative [Member]
Fair Value Assets Liabilities Quantitative Information [Line Items]
Derivative liability	$ 11

XML 51 R41.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Significant Assumption Used in Model is Probability (Detail) - Fair Value, Measurements, Recurring [Member] - Level 3 [Member] - Embedded Compound Derivative [Member] - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 11, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Probability of an event of default	5.00%	10.00%
Prepayment penalties	1.00%
End of term payment	$ 245,000	$ 245,000
Risk-free interest rate	1.53%	1.01%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Prepayment penalties		1.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Prepayment penalties		3.00%

XML 52 R42.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Preferred Stock Warrant Liability and Derivative Liability Categorized with Level 3 (Detail) - Derivative Instruments [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1
Change in fair value	0
Ending balance	$ 1

XML 53 R43.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Schedule of Computation of Diluted Weighted-Average Shares Outstanding Anti-Dilutive (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Term Loan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	85,251	85,251
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	3,284,440	3,284,440
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	3,693,348	3,003,785

XML 54 R44.htm IDEA: XBRL DOCUMENT

Commitments - Schedule of Future Minimum Lease Payments under the Non-Cancelable Operating Lease for Office and Lab Space (Detail) $ in Thousands	Mar. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 491
2019	676
2020	698
Total	$ 1,865

XML 55 R45.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Apr. 04, 2018	Apr. 03, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Common stock, par value			$ 0.0001		$ 0.0001
Proceeds from sale of common stock			$ 1,847	$ 9,702
Subsequent Event [Member] \| Common Units [Member]
Proceeds from sale of common stock	$ 15,900
Subsequent Event [Member] \| Over-Allotment Option [Member] \| Common Units [Member]
Number of shares issued and sold	1,150,000
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Common Units [Member]
Number of shares issued and sold		15,660,000
Price per unit		$ 0.65
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Common Units [Member] \| Series A Warrants [Member]
Number of shares		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Common Units [Member] \| Series B Warrants [Member]
Number of shares		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Common Units [Member] \| Common Stock [Member]
Number of shares		1
Common stock, par value		$ 0.0001
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Common Units [Member] \| Common Stock [Member] \| Series A Warrants [Member]
Number of shares called by each warrant		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Common Units [Member] \| Common Stock [Member] \| Series B Warrants [Member]
Number of shares called by each warrant		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Pre-funded Units [Member]
Number of shares issued and sold		7,840,000
Price per unit		$ 0.64
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Pre-funded Units [Member] \| Series A Warrants [Member]
Number of shares		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Pre-funded Units [Member] \| Series B Warrants [Member]
Number of shares		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Pre-funded Units [Member] \| Common Stock [Member] \| Series A Warrants [Member]
Number of shares called by each warrant		1
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Pre-funded Units [Member] \| Common Stock [Member] \| Series B Warrants [Member]
Number of shares called by each warrant		1

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 57 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 79 196 1 false 36 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://ruthigen.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://ruthigen.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://ruthigen.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://ruthigen.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://ruthigen.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Organization Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization Notes 6 false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation Notes 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock Prepaid Expenses and Other Current Assets Notes 9 false false R10.htm 111 - Disclosure - Debt Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Debt Notes 10 false false R11.htm 112 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses and Other Current Liabilities Notes 11 false false R12.htm 113 - Disclosure - Common Stock Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock Common Stock Notes 12 false false R13.htm 114 - Disclosure - Warrants Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Warrants Notes 13 false false R14.htm 115 - Disclosure - Stock-Based Compensation Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Notes 14 false false R15.htm 116 - Disclosure - Fair Value Measurements Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 15 false false R16.htm 117 - Disclosure - Net Loss Per Share Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Share Notes 16 false false R17.htm 118 - Disclosure - Commitments Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments Notes 17 false false R18.htm 119 - Disclosure - Subsequent Events Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 18 false false R19.htm 120 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 19 false false R20.htm 121 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlockTables Prepaid Expenses and Other Current Assets (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock 20 false false R21.htm 122 - Disclosure - Debt (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Debt (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Stock-Based Compensation (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 23 false false R24.htm 125 - Disclosure - Fair Value Measurements (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 24 false false R25.htm 126 - Disclosure - Net Loss Per Share (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Share (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 25 false false R26.htm 127 - Disclosure - Commitments (Tables) Sheet http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments (Tables) Tables http://ruthigen.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock 26 false false R27.htm 128 - Disclosure - Organization - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureOrganizationAdditionalInformation Organization - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Details 29 false false R30.htm 131 - Disclosure - Debt - Loan and Security Agreement and Warrant Agreement - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureDebtLoanAndSecurityAgreementAndWarrantAgreementAdditionalInformation Debt - Loan and Security Agreement and Warrant Agreement - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Debt - Summary of Carrying Amount of Company's Notes (Detail) Notes http://ruthigen.com/taxonomy/role/DisclosureDebtSummaryOfCarryingAmountOfCompanysNotes Debt - Summary of Carrying Amount of Company's Notes (Detail) Details 31 false false R32.htm 133 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpenses Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Detail) Details 32 false false R33.htm 134 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureCommonStockAdditionalInformation Common Stock - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Warrants - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureWarrantsAdditionalInformation Warrants - Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivity Stock-Based Compensation - Summary of Stock Option Activity (Detail) Details 36 false false R37.htm 138 - Disclosure - Stock-Based Compensation - Estimated Fair Values of Employee Stock Options Granted (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureStockBasedCompensationEstimatedFairValuesOfEmployeeStockOptionsGranted Stock-Based Compensation - Estimated Fair Values of Employee Stock Options Granted (Detail) Details 37 false false R38.htm 139 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Details 38 false false R39.htm 140 - Disclosure - Fair Value Measurements - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasis Fair Value Measurements - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 39 false false R40.htm 141 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Fair Value Measurements - Schedule of Significant Assumption Used in Model is Probability (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfSignificantAssumptionUsedInModelIsProbability Fair Value Measurements - Schedule of Significant Assumption Used in Model is Probability (Detail) Details 41 false false R42.htm 143 - Disclosure - Fair Value Measurements - Schedule of Preferred Stock Warrant Liability and Derivative Liability Categorized with Level 3 (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfPreferredStockWarrantLiabilityAndDerivativeLiabilityCategorizedWithLevel3 Fair Value Measurements - Schedule of Preferred Stock Warrant Liability and Derivative Liability Categorized with Level 3 (Detail) Details 42 false false R43.htm 144 - Disclosure - Net Loss Per Share - Schedule of Computation of Diluted Weighted-Average Shares Outstanding Anti-Dilutive (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingAntiDilutive Net Loss Per Share - Schedule of Computation of Diluted Weighted-Average Shares Outstanding Anti-Dilutive (Detail) Details 43 false false R44.htm 145 - Disclosure - Commitments - Schedule of Future Minimum Lease Payments under the Non-Cancelable Operating Lease for Office and Lab Space (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumLeasePaymentsUnderTheNonCancelableOperatingLeaseForOfficeAndLabSpace Commitments - Schedule of Future Minimum Lease Payments under the Non-Cancelable Operating Lease for Office and Lab Space (Detail) Details 44 false false R45.htm 146 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://ruthigen.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 45 false false All Reports Book All Reports pulm-20180331.xml pulm-20180331.xsd pulm-20180331_cal.xml pulm-20180331_def.xml pulm-20180331_lab.xml pulm-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 62 0001193125-18-160231-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-160231-xbrl.zip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

^$D.?_1O>-:H!^B (/;TL$WP7IOS+*+W)(5[30V MQ Y0E=53W!QG;^E*1[ _]/K"6O ='([R#1?R?[1#>L4=\])[I4 ^W7- MVR@3VL#KY#:)+.]%+3D^1 WY%/?(F9PP)&3F+1*/A1$Y/65,44_D;K(UHHI^ MBMODI#9%7FA*N#K% \-X+>?%2>I49W)>1-1YD_M(3F^/[$6('A^>IO12>V3R M?07OPP$HN,K^X79XROZE$?X[,\)OXJ8[&< .S]%'@?;1 O;2I]/+GD7J>F?1 M392Z@>!.^>L/?A9MZ&U06IIIG\8IM#&&LJ$TY\]F8D4%L>)%V6U CDW@[1:R MTSF!FA69M_O>T9"DZA<\U*P26+=9I-RR&,.B!"QM&$"KA[%0O;434[8*-31U MH],SS(XX,+$S9J]OB9:BRN*@IRJ:84JZTY&+4,-ZE/BJ^*Q.A8-BWE$T399E M0Y34GHD]0R2QH_2[XJ [T >J-.B8MKT!YG5LL31<\G7$^0=S^'85/-EQL">@ MXHB*WC-$S30DT>Y)MFAV'=M2>[9AF^I1!$\J;8%2 8VSES%),%&K"!DIXW4. M'"-Y& ,GBV*?;)AFFN$*1'>Q]^%D81)J2F)/;'-8P 6.1IF!5#&MP$OOAWYB/XMT_"%;G+ E;_$Y=G M!"RO+YTNK$=%^;D6_[M%UQ4?QB^$JRP@*[\..T&2V_4!'$HI M #%X:B'B3W!BP#LII02-3@<%+L@7Q \!U3$#&E$:15$*#Y,Z9D@@I F,@;P0 MD)249*DL6# *!B#@^9,% M.!: &@NC.!JSM8-1"O3@'0_D!."%V[$E%+6QBT%PQ7#&]#XF/)<;B4) JGC" M;)"G@%*^Q1DC+5;>IUGBGC^DO5,X%G2CLEDH3O;K]RM7B[ .#.5@LK^@"^%N#)S!^04IDQ?0P/&7(B%V:ILP2D08*1E0# V M14$.=!BO(\3^LR["1GZ H6.XEQ#QZWX7!H7)I[A"5CG=9S7=&=5T1L.8ZD<6 MC6'_4K)A!R_:9 .D^&>4SOZ?6<@F5C+2+9549/,KFCK?5FT-5G2;>QRK"E' MH9W(H)Y4:/2R2LD@2V$U!&R:-,[&0D";Q.5%R4%#\7@]B%49,(Q"<8BJ14!O M.#56+.46FX:)AF@T\H>LB 6$V!&!6R6!!4"EC.2O+:,$D:B MPS6\W\J_MU*;()DVO!=EVZ[72CNACO>'()(Y[0'=>9[%IRR2Q$O(#*@U^R_BQOW0ZVU0F7ZA/=91=+O;4511 MUK$-FM'IBG;?Z< _>EAIQ[([:A_6F79RQY[&HJR(JLS*)BT";G8)]VE1-@:. MI"I]K&(U& "[]K&1F^F(W;[>58Q.9V!WNWNP*%,Y^^\L2C],*27E#Q^$*?LK M>O?@2S@'Z'>?OOR*4WWG.LK-E?/E>O#UZC=\-"1\OC_[GW[])V@NL (?A.[7 MSU^OW@OQW>U;J07__3F'\N:OSY49OEY=_A/&>B\H,-NGWM<_V9_3-N\/PN?^ MS0T<204P^0 UG8E"B.9A\<&-?1?^#<>?BP;II'RC]OO0G51^$A_)[=]^*N)J MB\#ZT=]$I/9,/C3]'O9G7?[HQK<1=?$N9PF_8HRX4E#/C MCZ^A\*\L)!4'*G/YZBWA,@O&;AK[WX6B8[= K?K4]YM&@BOD3 4#S6&K6CS- MYVNG'DY#7;G_)/$PPRB=&S*\#P'"NR<8Z]H0?N^[$APMH2P -J5T?+7^O M-F2+1WS0/-8 0<,@(1AO4JA!+%@"0P)^-%MXO:B-BE5M*4ZU8=LTXJD8%+WP MB9 @NBP0)LENL9TI4A6#C,HXFOE^\2)&@WS/HUPPVB (" NHF,3H7TR?VH)# M@SH6ACTPYWM4-E.MX'GK!C0NBD-24N31380?E9:N2;,>\F9;G\VVKG&L< N: M9$B6@@V8T@Q+ I^X4%K+% #=6;6:8$%I, HL)-=;*0 7/36_[GD0;NM2S_1 M4^.M7_T>62W)QO1YM_X]VX5CPN:A07(\?@EV$$+[)VZ5L:U$ ZV/?.H*K\2I 9XT/BJ O$\'H &T@AXK:IW MJ;C-$C\D22)X+FU30=SA/8M":E4Z3="PDW]EP5-%:#*9V1:NL:*1X&1W69). M_VRTIL(=$QI=1@.3IB#.>UT4 0S/@@FCL-87O& E!714E7RTW!(G!*V0+&03 MBHI;-XBL$AVA2B*=C8J0/"ZB',:M!/G"!,GPGG@@K5LLN@UPS\*)ZWN+H(,U M]#+"<4;$<'OAT4*[A !6\XAOM87? 1_D*T:TJNR#07 CU!< 8S.")*I1']X% M6&H%$8;W;GP'PT0\_.LS!DO!=BKVRH^*IJ\BK 4>,@OCX-KGJ4L_*JI1P$J3 MFG# .2"T\#.+P_I1EM^P6,$?%;D8R:,&A)D NN7A91KW/U-;3*L 9":)(!-(<8-#HD-(P<]F';5#%* M5* %QHL 5IPO1/F<()I#0B=RGEL%]:N$9]7@?!42@@>?P78SA MTO!H3(/*X^"I(ER]:F.DNNC/)I3DL'QW<*+?(?W&[G>,D\/-7VK$,M6(X3R& M,P3(E7*849:74=/EL'@'0 !H9?6E.B\(/A!%G(14^V!TI)/F%,R':I>7@AI) MD(P8SEN9]PD MV?"^KMP]^@ ^RW")D82LLQQ.A*'> =?'2M,H'BNOBG',-VR;2W>'#0+04(J@JV+T@ M9('I>*6'<>(0#R@\*B8H". 2!)(CP/Z,Q?8JG'DLT0G5-O1Q8O$MEN\78'I2C/8_/^2I7JBO%"E$ MF.-#;E/BX5VX!;><._>.=X(<$[@OP1T-Y=<0B)705ZC>!\O_5I:E/)$#0)JV:W@;7,0)ZY5*$%O(&'"1ESNJ)F$@#\5,HRRRO345H5 M7;FFN]"TA[H%"/9.P%+C8'A.:CHRVEIRFE=(CM_#(%6:4V5H#6!RC:\1N6AHW)\4LF1$S0)EB02T\#_R:Y)&1FP5IT7QV I=> MWIIV^EED5/XT<#":?_R1C[G.;&\CJ[*]S78U[#:6=4K'X,6+_@0E)OPAT MJ&!QZX]@E[(<5)Y(2>@-FDI8=!SD*)8C)<(C( LW]M##JR B\X MGZEV!.Q& M;4]P+YB9?R:)&B>#T49# T:5K9"3[HF' M!RL[X&DZ->6M_$(PG[5??E#G+3[E6[]+49&J> MX#FR>-XS,"HS%>\QSUQ,QL1-J'/.3:O@PJ=\7_)\?6:&H6S/]C J*TB$\J5; MPO*32ZCS!&% &RXW/*/ZYS(;ME[@@.<*HIQZ^R6""[LLP:7'21?>+)B>M2P5 M-YV["@L(@C3/)4$*JY!K:2FE94'@A"='TZ1V+G.JDB9?X]H*8Z8C-8:C_2ZA MR<&,7-S^3^E%U1PNB3FQ2JF6&_0+3DG9S8NU\N9F?^0K?"Y+"AE/[3=,@/&A MQR2]C[PI7Q /K)L' F5)R6 V=-DREQO/E]P$%QC/A:]5BWX^/?7Z4@!:PH^F MSF=7;;I,$U8AIW!-+8#HS3/Y$TY_W6J1T,WCI_X[LMFRZO4#4!%I .5:*-G M^'NQ-&)JQ^Y2G,^)R\Y--=A-GOEJBSJ[?@O3T1]\RS88Z-.'EM>(4->T/"UD2+/\YDB!TW[>6VT*)-)7[CX MQ\92[? )_2N!NDV&;X<'ZY2W ^V#\"\WS-QX-L)NH[S/%\@$5EN*?M[%M=^J M&V(9J-2K2>?RJ(C>:C^X<72 MEGSTUI0WOD >^ )RDM+L%&$^5I8ZY_)D-0/DD94GW!=LAS]UCP7S8X:M695C MA*U9E6.$[<@4ZC,T CPQU=E>&_ G91FTJQ+LR[-NC3KLK4N/U,P_39F>;R_7#B324!$ MF@C#DCGO?C;$T'599O\9Z,=C9<$@;20<9[\N[,[2_34C\C56V MJ5) F26 +'=THV/+XJ"/E;/U#M:=[NFBJO=4U39E7=8-( !6D9?:BE82X!ET MEN.^^_K9CJGKBMEU1,F4^["0IB(Z7=L4.QU'ZFBFXQA:_S@Z,LIM>#X5/D=) M(@ ]!$H0NJ=N"_7P!;I%5RH?33+L(XPMG(E+MF;'VC9+!_]432Y,6%E:GUL][Q. M/\CRIMW]D#Y&(I5JE)Y%6T@&9?D@+6_C8+[>>A7YB@0^GI/)6JT"@=[\0$E$ MV_2R<@DT[08+1O"R#$BW^RCP:'D-S%.E'2C#B*>KP@!8[H?GEA=U#]?OCKF4 M I@<3Y>5U=/*864%%A$WJ8P,Y15#2EJ9%5JR16IM$,W&.;=LS$\:R&O[#2Y M: 6\*"5Y$6"&_@.ILMM4M3PL%)>7E,R2LEQ>3).7GWB)#4[1 MLA4U*QJ,_8K++%VVK6;(E)-:7$SJ%J;N83]P&.61-G"^Q;S>U!=S#+:@[$GV M+#6-+;.MEC0@793\H[YIV[:I2Y)F##F)4Q4#W0G*6&(1N7?LR?'U"&_ MI4.[6;6-TUP*D_O.%N/X$38/SGVON3'G5U82C):)9>6\2*TNUT8&AY<,C5%; MAJVV5&TOK3N/$5U)4ENF]6+-"E]-_TK>T^:LMHIB:2WM5!RE1XUN<\PLW3S7 M)$T#4G12R,NXG]R6L?26HN\EU^XUX;IV8]2%9MDIZ^UX$D1/A%R3^,$?DMS< M2SRT&9(PH5:-+Q&MODH\Y]&-O81FDE=_QWSZ+U'Z%TFOR#"Z"['T&.L<.8AB M_A4^)^_,)*R8CMRWNUVQ(VN&J-F*)CJR-!!-T^YJ5M_HJH:"'5(O/E[*?\G2 M;XK6JY#FH#A/>4D*-\K7476X*X+5=CU:F: $B+?=3'9O4]=MRW1L9R#V-6,@ M:H9MB98^&(C*0.U(DM8U5=5H>E*^GIZ4=ENX1HU,I'PG5%ESZG+9E+ [QSZ5 M53=1,H'K;12S:M9%%T+>!A [PPBY!&T)/3\FPY16HD:W21?>S +LQB=@\^GT M"5]"L_P#C!2X(7?Z5)PY=#S\Z6?>P^G-PEIXK/1F\0*K08S%B/.N+W>T@R9H M2[3C"@RDMR3;:!FF7FD%DF/99?>0:U;5NFCM)+=4W6Y)NLQ?>8.5B\>\V<*# MZP?4/(XSCC+:7X%.VE1W/./JCI_"HNK]; NY]#&BI?Z'3$$F!* NZGN&FHO MXMT[2[;'$I +-M+\;42A6+Z1OH(:ZF-9_F*#U%RA=-R5P)+F@=6:AHON&QAF MT:Z6YL#P;)$^>L3>5>C$K;0^<*E2F,]-14#5D8ODG1V?2ZF"-HW0.'/- MBG9OYN9BNM9-.^?SUJ)ZFW2 K)TI;WXHI E(G*AT-1 NDI.6X'&93'NG# N1 MG#3RI")/SJWZ[R:L92YBK6B."TO5U):N/ZJ;/S]3;IU$[$<;L\(F+=GPTQ.E'0[=997=-F2H*CZI9 MPM'(7\YI@M8> 7LI"9J5$W=&K\&](- K.NR M+,JPD3DU0F$ 4-[^@Y.J)92S%4Y'"B7V8ZYV)*:7KQ#5G\2-G_)0)MY%A1&1 MDC17<-B%QJ-M% 358*UTW_Q0M#VN-%1,*HV7><-'UN?8':57[)Z>YAH1'\J*YY7 MC1#''1BY4[K\F8?@3Y'#81'Y4]_VOY-XZ"?37U]B7_"&?R8SIM] MM:6=>G&6 .4-DN[474)X1++VY"7KK\P^>U!YN3W/'RW[-=OSX(+ZI9X[:I@; ME7-;P9A?5QO1>)1;OQ&-QR!F3A'F1D-<3Q .HGA$?!K7$'/_\F%EXBZN8V^5 MEF(9FV[;TZC?J;;MO23=GN(F/T687TF9U*90^ GS: /S\ WWCML#-O7N_'H,S4+N:JLXGK1 T,)^EXG7R:A8WD]. MX+-4LY26I&B@:IUW8(;9EDX@7&$7ZVFTC8WM@(V:U:A9C9K5J%D-S">F9IVA M?>L/6CZ-)IV2[YB$R])S:0;K62IB:LO0U9:JGDAQT(WM7>:)(+@#>Y=R_)@V MBEBCB!T[<(TBUL"\&T5LIO+MZTWG/[L2-U@4 FN)C&DEE[+D"ZT?DY>+0\SIN->WVUA$<28U$)CV"I;5KND9=8J5>C85W1\/M.X [_%J^']U% MRT0RD,1)[&,&/4SOD: LZE)6NW"3)!LS$OJ%$UUBJ8ZQ4ZK4VS=0,QNJF[L%;JMOYH"SP1T1X^U06KVARL8[-1C9_OZS2:E=O6U(Y MF5C^:;1-UNDE;[_[XEOMY#?6E9_\+8[P[D;[U*.C(.9U49H]=49[2FG+TD]S M-Y725M2?CFM7G?,!]A!A=^_ 3Y^:/79F>\PTVL;\/6;:;?O(]MCY["C/QY8T MH2<\^21H,O-/95=)/S6.A]?M>(CGZY["HYL(T6W*&D"-XF@L_-Z^;@LW(,62 M+'ZB#Z'U/R].[4XF@3^D!MX);0>8M*O-MTZGLVX3Z( M>S])HQCJ/TCG]T,N ,$\P&XEI/7X8(4MHX U(5UJMD56$QXKYQ#F3A<$L.(G*5TBB3\&[$<^?#DF,"/" L^Z6(8_"VAKKL ? MTU3]"D:>F^(3=V[L\8$6 9"7 F>@UV4M[80!GVG?,C>M#T-;-8516IDV )*Y M?BFQ62\#+R+L0487UD9LXCY5'N-E\('X)"&$M0.CK<">:V_$O%,QXZD?U98I MJ;1961@7'229=TMDJS^L-.&C\(0)HA2S5I$82Y7Q'I4+G&)EMZ-YU(2AV&NT MF1'K7H6$]9-\,L%/:J%;M]@ZH "5]DK CDV/>:W0G-T8XR-NL!OBZ#OUZ &] MY;;-BOZO4]K_>UV:%I_/19@J..\9"=,E?J_7>V2>XXDYW;]A@O*0=7O'#FXK M2+):0X>FG<,KYZG&87Z2#G-+6=]A;KR13R0G9T/\Y/U4GFG<'&O68F=M'.DN<;TQJ)J@M[K87?/@&V4SDW\EC4T_ ME5*46R*J&7M)8GLE25I-+:QHF<:AOB M9\A[P>^5'&9-QG&S+D>^+DW0S2(_L7%N[AY83A__OB(PAT]C#*[I,?P[/)@( M;Z^N?V?I%'XA6AO''[+"N7'"IU!PLKLL2='%J[>J 2M%*(LLM513$X GT+\L M1!A(4^2$8R@+C?FAM8587(J0/D8TV(1'H]2BL&@82^S5XVU@D'FJ'X:Q_&@6 MOFH* _&I(.X7KI/:-Y,;F"!.@&0X",, M+/S#(_[[7C3,\+N9ANC8?5N4!L:@VU4'G8[:^R9_TRX^_I?\CW=+85H$-G82?A&@U8N/.,H\ ML N89H&^>9J00T,J77S$4>N0(B"SX#&"]T.OAQ&1!X938105)554I]BA!E<) M=C],_?3IBMQ1ZV28?G''NX/:472[VU%44=9U1]2,3E>T^TX'_M&S-'-@V1VU MC\PKX8 7'R^S8.S"\?:]!6)NV&;PSP.0@9_OYH'KQW]@[8MR6Y=[=6>X=,U! M7]=M3>RHAB1JUJ GVI*JBQW)[O>=OJ;T595Q"LH<+G)>_?%[EIH8]47*4EM MSF,MQH7?:(@SH0<%/71N&T7LS!6Q$#N$']Y>(&FZF;:,F7CRR3M:6A97-B'XL/NP^U:]9NO;63GJLEA;IW M"0E5PBNQKU5MO/CV=\R]V^VR[CC9MA(5N?7,#0ON,S#U,\8]EF#(1\56A\=? M>>7XJZ\-?QH*X?<>>_E2SS4P-S WT>GK%N$9WQ+/ MXQ%\448S.6+_X?#QZ>?7DJ.ASXD$2,H-=DWP9Q-DV 1_'B-PS;H<)W#-NAPG M<#LYN=*ID^N>5NOZY4(V%I]:E6]-X M;XZ&!1OO3>.]:;PWC??FA$RRC?>F@?F5PMQX;QKOS5EZ)QKZG)9_X[RQ:[PW MK\WJV:Q+LR[-NC3KXXW?R.TRON.$E-]14^7SLL MM_6?)!YF 6$9V$TIG//.P':PL58RC'W@$VPT]25*B]"0,$L7"OS.7=_(: MWKLAZR&&L\=1T!;Z[O">]PI+B# BC(X 0]X#!L; D7-V+V_R #40CU;O@,?_ MG?DL7=P?9?&0)9[3'FNL>=<-B:NRV>%8M1SA%K920%N>T2,APS\3 M ;COS0_SS E(67>(%8#<<$CR%/):[S;\.0M3 Z&N,M\]B06 :I.CO/=$^\. M:_10$"=Q-"3$2ZI8^$F2T;<9P4JL&.QN$$1#FLH^\N,$.X[1IQ[=&$N#\(9N M\Y!@/<[\&)<>>W3A=V5.?M(J\'J#F?F)[\&*"G<1+5S$YAC"'$_XV1TCLCF M <+&.K;ACSY+[O?\A)(D?WGD DH/+/V?O>>1VY21H5H:(.\H-P\%RH)5^OPH MR[0[6J7-&/:/P^G+M_(\_R=*_T<_"+ SF>O]3Y;P1F65^8%*!+B5TF 2Q10C M#\B]O!93N@")N5 P@,O2"!4F3 &CDB0PP!3!YFR+! L7L$JD0)P$U!O8AD-D M!5H& ;<6]J>+;A,2/U!>Y0WIQF[\-TEAV>]]V)WE7H1=/^T;@C'&I4.:,DK> MU:Y$^MXG,=+GJ5XZB_<61,8.84T)Z_&& @$(#^*(-GN;3\ *PO!Z?1GS-UG% M!QCQ-O\5V\C-EU+#O-P$EOX"J1UE"5W;)*\<$1;#)GQ82I("J#<_L'W/V)\V M6HP"VD+P,;NCY;?8'E!"LTNPVD.@,DVY4":V)=M'=J7S^JP&]DW M-W:*SC*-/*_M_2ZV])RY]#E3-2$2ZW(4F;#"O<($%,D PZI>FH?P052T%#U=N [,5DXD5J=3F7(BC[%"^KL#^[7G\WPB^K2-Y0MK[/44[%^?7E^;2 M'Q5-;TG22DWR=L);"^=K9-Z:G1G]Y&]QA#76:_;NEV8HD!WRX0Y/N:VKSXJJ MQH-XWK:H>/Y.H.;GZ!;=0NA#0+_#[^WKMG 34POO$WT(K<9Y!X.*EX.U1DAJ M!M[2"VE_2&@3!-J:XR$* $!49F$HG)*9J*EEE!I._22-8A@WJ#Q*Y_1#+P/" M/,%L:%EE#@UN108I16+WCAN(L8AO\3+H-MSMDX,0^*.**7XNN,RUE5 /8(G M$*5*EN3M&A)_/.%^K3&!&1$6]#!P?P<.'_AC'Z>K8.2Y*3YQY\8>'V@1 "[Z M80!S!KH'?WL$CL,GGP08V4IES5W^LRHOA\+B)"P7G/2$0L,3:^ MWH-@]7- ^^D$UM@1XB@(1-C8CR"*(]L65%=>+Y>=O"AI_!;[\UL8UI85U3?P6R@;^"T:W\2+ M);F6X8(5?T49.K);)T5C"=O6>-%Q QK95(OL_)<;9F[\5%*>1QT=U*1!C6+K M6"..((WGK,UBZGJ MRSFW(+BV.>;.7[0T65Z-CV8% ^QY64U^Y8DYWKLH%H(H23 ./?:IZX&Z95@B M36&>+R/>Y^4&<",>L_F3);4QBH;114]K'L[/>F2S(/V6$&)J /?5#*/0P];6 MS".!QRR" 4,D*?PQYD%*T80P?)-5^D\O[5@[W9NW"U/$;O )P/C^G^3I19KS M*A;A0.Z8-(H:\C=%/OOD&OHCD=4^HXHMF1#5$; M*)IH6Z8N]KNRT^^86L>RI#TTZ)V2)[/[]F1"Y*F,65_(KV'EG*'50O/E4<79_W>YW^GU%AINV8?8Z<-T>F*+M]/MB3S,T659E2;;[A[YNSS*V]M,9 MAH.=VAV]B=5Y+3?Q\XG,>34J8A-VL]^PFU/1$IN8FB:FY@".[_(0.;* FKT M]M(BY1S/IB94YG5*C..+D]D/9.NM]3J6AQV:$::#% 9^0.(NNP^_3(B"=O'Q M>NP& (9P512OY/FBU8B%&J2;VUMV;U"19*77T;N*V!]T=%'KVK)H.5U)-/IF M5[%UIS-0C#T85$X\,NK:VT,51L(NJJV\."BS9!46+XS62I)HZ-.0+%X[%S/2 M*X#B& R [9\>V31;DIHEL31)D:5BUE2T-J\KZAE5]WW;59NH#3]TDG>ZR M)?DV05E[,6XW:]'C/&[MS]E\WI1X.P\]'@_I1 ]>LRW$"UZS+ M<0*WDY,KG3JY[@D>I[]B%Q@B[2Q_.W) (&A!!06J\-XWW MIO'>O$H6;+PWC?>F\=XTWIL3,LDVWIL&YE<*<^.]:;PW9^F=:.AS6OZ-\\:N M\=Z\-JMGLR[-NC3KTJS+L0.WWLDUDTM]&PO#P$V27RZMV+-%6E)[HV*;35S1)T7IFDXT\TZ?!.K>\SH";]O / M'__(^8WRNE^H;:7!KTGP/<>\]'S9A9A,L%,V=MM(:=?NT8C$!*NTW)+TD9"B M:P;MWDV'A-?3V T37FDQ3RFO)J^S:HPAH6T1"';R&/X[\^'I%B_ 6,V IYT3 ML%-Y"#.P-NWX=.+3K'G6JIQ6[1X.HRRDA2!&$38-F63)O>A%CV'EIW:)FL]Z MA;MCK!Z!11UOLQ2_) @D[_I!F[2/)P ZK?',VX>DBUK"HW,Q($@T7I$B [(* ME"38T#T,,S=@F?HMPVF?6TLT>"'##TXV$V3E(LB93P!CG +2YP890%'N.0P/^; '? MUR$R\QNL".%E0[)@Q\UEVBENO25!] @#^; MAVX$MONAC86^ M^TE*Q1=0A.XEUD6H3FP_]'RL?9$P>OM(5Q ,\RC.GL"A[RIRA2%"O+;P:<0) MP4F/Y/5A8A +DP-Q$^R(,W7IXI-G98NA2%]'HSZHE> POM^E9?KXRLKT?!W\4P'G+X-9K;QCF5K?,?JBU9% *Y=ZMFA)?4,<= W+U#6U:UDJT\JE67SK M@$\A1T(XK)$DC@?K GLBI@O7_S[!YE=[PU)49Y&4Y8YN=&Q9'/2QZI/>&8BV MVM-%5>^IJFW*NJQC(23UXJ,B:0;,7$%U.1IUG#^%PQBN8:1'V+\_A0Z330G< MR8A/:V =%'%[H)F#KF.(FM8U1)3$ !DG4F(LI<8JZ$V3B#4].&+)9X F-D" M-:CK*'TA:==-[B_CZ 'N9%[GZ?>$P-'WE?4L#.^<()2KK^+JRTI],VR'9YUFQ4N&'@AZ#IGB8O M6+ =9,5:A1561'.&9)]H8]"]ZGM;L $00-0519ZF0 GU MX^;K1T1$N6M?GL MO0BY+^31*:Z8L/XA_#ED0=],JV?_W'W]SI[>MS1-[HM]V[)%S38-T>D,NJ+3 MU2U-[FAVW]8;B_FYFVL*@SDJWG!_+7E1J#-C8S5_!5;S3R$S5U +!36RE(8+ M?A:Y095'KKE)+!$Z$?P+AGA;VN:Z'P;.=:?\W/OPX=&/W#F:X3X3++,:6K6G^$V T&E51[&1!0. O>!MAJ;FD_/K\LFQ5L2V? M;2VFRQJDX-C7"3J?$FF$9E //>>Q'V4)16U28CVI8$W-J;QO+1J_"BK $'/H M(-16!%"N8W;M=(0I.OS M!U_'Q^N$>[SW86O?DJ$[1C3):$2&S.X+)FA" MW8H1Y_,>&E_I\,PM1ZW,?H(SX=QH>ZVV*$<[[!#=5DO8U<5180"Z,$>.?-TSBL,)\BH.$!!B8;&V$791G=\-TM2V#IQ MDA\NAF3\/%\?W=4%!3&HB?[V G2VFF#^D$D&@@;V)DFX1(D9=7+I0&46E^ET M@Z(H@6N)D!-';Y6AOY0*G+QX&.<#U)1X*C91. VC)"V%!4BL(/.H7. S7&>W M*4ZR/LH E:C.O_$N8H4JM,NNJR+R"W9$'5(^OWF:$(K191QYE>^H+L'YJARO M72/$#9/8V.P8D/^O'Y2D?\8><,.B#P>$*4Z&F#C*,A# M/1)V=&$7*A]C;^#,&A9[A4=#^2$-GZ,Q2"S2!:Z! 54-FD (%)C OG.#SQVD\/.-CEH!6#M_9"PT&L8(J56@_1)LA%H M7SZJKWZE41 >ZR%U6\?$]2B=IJ*,Z@%>\PY$'(1>HFE4%@O'I((=]QVC-,A2 MGP9YX0-HR*2*5_J$L^7K36.GW.1>&#&M,?83=H&G,C!?2+;F[E;:V!(:ND$2 M41[DI*P3L4JYF-S!U80&HU7NO?^3>7>Y58HB1)F!LEWQ$VN-Q*-5*RS.\ 21 M@X]3_<9CMJWHEJJIP$&C+!C1>*:"#'NA C>OP,H^(C587&S"%JNB%C*5DJGT M3$%C,74\CI;&%I;$K&TAP I??MH']%Q51548%-2X$I3(E5<>AIQKE0DVJO-J M4.O*WS#H_509V5,2C6:VN+@]=4/ MA_4UP!9;H0![.+ZCX9-Q] @3YA&2R*,$!2/>@F"#)SDQ0(\B[&Z$DI@=OYRP M*/-H'!\-]*3PXU A*+7\4O'@HY9=2I$Y,9U);MWSJO9,Q( ,*T;QC/Q>\<'MH435_7ZM"KU-+K7;E[0V['(,( 4SIE:T>I[D%@+H("NJ>5>G.K83"+KL1SKT%TH#B!] V> MW,?1$GH;+_6"(;,)O?'S*VQQ<9U_2B,K9G@LSPC$9#H6%R4#'(2%C2".AA@D M3>.<:Z3%G9WO6R3H'9Q324H!HN'1^-P\=;VR[2?H5/>IMH9*2Q[>6[4ET)#H M7 NG^^_>?9B]O'/E;3D5D-D>4>W+3V:0; M%K-)@S,1PNO&$$R%5\1W+LAT*K.[!2KPP0F]2W9HT8]?1X4+L+!*)KU"5=E] MA()L=2Q%U6S1LO2NJ,FJ)-IF7Q8M394Z\J#?[_7D)D+A[*TC18B"W!:JO-I$ M)+R"B(3++("K3^Q_;Z'3H4TE*%\Z))GO'A M E'@"Y9\S;3A>S=@>@6$>Z3Q](,K 1QZE.1<@1?P *17]0H= M&':8?,57C*97L@.4#8'$X=X=-A"-6B I'RF[HYS#TJ2FS?OEPE*C@3#Q)P1S MYNF*,F*+MVXRM:XPL4?/?FHI=.,[EDZ4XH4/\[.HYH$6BIBX:7GL_^ MOT$KA:TUE='>K/LYGG].NBB!L)X#>>^BB1-3*F*?6D^H43.W;J+= +@&KE'T M.@)2YT>YI>MJBPK:BD?<(RC&4_:$:;<4165V0RH;V6_H>(WBOU%& D7\E-W4 M?]1:LJ;512JW6N1V+6Y8C%V0<1A01F]E\'8^2B4Y/03BT"LW-:>SD'>2FY@K MAR]%,!J/28S7$JX84B,]NY?GIVY%2O/SHC9N!)=4&"DJ$P>X>2L?AE(3+? P M"K((#! @&(W,/>>;1RU3V TQ31FX.0_@H'Z<"ALC"S$+9&ZK*TT]S/I )JRY M/%H;$EHE 4<( M@U46GE+'.A*Z8FNFF2Z>D2M$ZAM0OGQ4T&>DZ"!7IHJDAK MF4\E2>&J?A\%U/V"1@?D;M"4T-I1U3,\/\AR:ZX#@'CD-LV-'.$=J(VC$LT6 M'<@/'Z+@ 7<]$T9H24/M&5YA<;,T)9V9QQ;F]+M6@&95N#6X MP[^9=9E>#4KY-"V=WC'C]*R 0ILB+Y-!?0;38@IU^>KT"2%H60F T!'5%EDP M$G^1*<"%A$NIC=V- Q_U=WK/H8GV-.#I$:G%' ZW"&_"+@3<=X0W'J0*9V_, MU$'J[/X!,0/PJ_#'J$ICU9-[NA#%FWA=0'\E:L(X M*(^LKFKXK7E2O,0]*6L'\$6$(1A^Y324?/120Y='F%H6ND.SL, RYXU&O)^Q M>.^5!6S2^Y@0V(QA>H_78/0)K*1V)1%U-LHM155:AJ%@X%O,C/G,2CR&,9FL M93'B=W?HPDU9[2!JXB;4QPF#@$IF:69;>'L-H'R)X!GSYS;&!CF3V _XY(\@ M2X.(FR;]8(;FIV^MX3&LH8$W61H,$SNZ:%7]PG7-*4ER[AZ M/9I=^XNFO%%X9'^)PJB>.'O$Y0W,BX]B/9=Y.0YU?"^Y+![$T?@3SYSZ.NK2 M@^,ZW<:=ML\<=OWBHPR'50WK9S%9C/@5F;A/E#^^CGIXP3A&G'&=3=E>B/,T M$G5TKV!CX*:'3=(KKPA'S-98N&8Z27\I$G5\KX?WQ,L"X '9 Z[13Z0Z^)R MVO_.XEJ1GTNWW#D,6N92FB)@,I;+5KB[8N MR497,12SJ^W!KSRE[11A&@L+5>"I!<&3D).QE%HL"_6>X.3H5Z&= M'HDGPLLQ7BUSG;<$A-:&@T'*FQBF@@ 68H[!%AHEU;_6K[7,3"\K=52962E> M_!F4R,_.Y36\1"_BDX1<"$,28*\IU%Q^N9#8YPDJ.OPSU==^N3"-GZ9;40EP MD0?E'9^J@EGK3>!5WR],_<_U0^#OJ(M?V=7W+S;U1GT 9];UTOFU+W:N^LY_ M@LY^_:G7/][&?_\AT?^LU/7,>*[OI%-I*!F-RK]GU=*I((N7Z-[X6E9M>:\Z M/-!VNQC'C_#AV]>N6AJP9@,1 M]]UP;:TW9IL'J2W#5ENJ9JWT^HNW2-H>74E26Z:E[P/=?>^=D]HI?[+@W+/: M*HJEM31->BU;98_H-L?,TLUS3=(T('D@''K9A"!RPY/;,I;>4O03Z;YWO+@^ MT]%HUOJ\>[O2M)V..A@J><_[*L!H60-G8.@]T=;-@:C)756T'4L5%:G74P<# MP^K;2I/>\"H".^LMB^95"@B:[D6O*.ISH:^1ET1 EV($BB=)JKGL94.>-S_, MYA\_$IJ$YX]OLS@ISM]*-D3F/;%$3&BD)<,T=_%R2WA9J2DNVR90I-PD0BBIRS6A[>Y6 M2;Y[]L!8Z!>I5[[')A S;0!N\)?='SV2U%=L799%6S,547/TONC875OL&;V. MUK<^/EBUBX1]YO+@5?I1_!4-;W(\C:RSD2 M]C]W8Y->UT1;\R2D)0QSO ?%A]=BOEY$F]F">M/D:8S=A[1"Y$?,@SLLDXD/ M:7[X<;.;N&VR4@=_,WRL1- MYW5_/G;>D>6]J"7'AZAQ !]/<\(LV#4D] J/Z(BI,S@O6O23WD9S>'MF+$#T^/,T7"S*;?%_!^W M"JZR?[@=GK)_:83_SHSPF[CI3@:PPW/T4:!]M("]].GTLF>1NMY9=!.EK)YZ MS5]_\+-H0V^#TM),^S1.H8TQE VE.7\V$RLJB!4L(H$%C8Y+X.T6LM,Y@9H5 MF;?[UHN:7COJ;%'\&M8XV%-\FJ(/>KVN8HBJT[-$394TT=:MKFBK,KPUD#5+ M&[QTAO[0C6/:<80U&\I[&,V/V[Q!H][G",,<>;6G115@T"$[-UB$M2&F49QN MP@/@DM<6_F8K6Z;1R^N'O[U@]%LS]5ZF;D+^-L[*_B>)AR#]J8I_&POO'PJNB0UWZ:HD474PM>%2'HY7BW&#>F M\:7FB(X;T'9-I?*E?1#^Y8;8^;TD*U>U-KH?O, =7FTI^GE;*=ZJ&_L"?CX1 M!,\;/V!1Y21#1TY*NN%%G135V+!,HE?5+P[J_'NIYUXR[.-4BF,T:W,BTN?$ MM:V://*YUL]2B!N!=*XP;[M13T2&'B.:C3)4$3Z7126$O.KRX67.EDSRUI0W MOM<=^%YPDJ+J%&$^5I9Z#?[^)KZI68]F/9KU:-;CF ![::WXQ"_I_Q3]N<).6,/Q&=VOYN8_;ECY!> M<#6;-G#3"#>5<0]I,,Q[_-),-*_L\KN1QOH2EA?YO$V#LGZ294!/:@_\2D(2 M8V$#V *N-_9#/TFQ8<<)ELC5]5=29T=K"AUL:A]H'(G->AS?>C1ZV@JE=ZBU M1EALK3D5KVG4V-7;U;D.%=D"T_'COT7A>"1H3]V@^27"U&=]7S(LDB7\]\XESCR<=[UCM#N)OYZ=.>RA%IMJ;T M.VI75"Q3%C6CHXN.KJMBW]&5KFD;LJW)3:?6F4ZMTLI=.;6?3J0IY[3O+,G& M8P#I?V%UF"8648847,Z0=5<9#+)G9]G9,='J/'0:G5UWX[%<;5%GUV^A8W/1 MTBY8H=479,]4/53=,$-=WQ^KOYP_MIGZ>+S0*^W5VYBX?XM^F/@>.5XW9BG/ M=^#8^Y+52QQ&(_I3Z87FNAV%[[B]G3NERY\$C0;$$Z?(X3R0V+V;KJK5_T[B MH9],?WV)C;@;RBVCW!49NW",L)YMM3IE81J#_I:QVEW+B]R]%?XB;IS\_-I( M[=S=Q02TJVFB?@+:H10;3GW_AQMD.^;'SE(*Z9MZQ-46X:MMPSU1'H<;MHTMVV<2'VX;=?3;)LGT%EIWNRK+>W4B[,$ M*&^0=*?N$L(CDK4G+UE_C5TX,[V#RLOM>?YHV:_9G@<7U"_UW%'#W*B%+H-C MJ2BV"X^!VE*UO32V/QJEYC5Y#/:3+MG("OSU,14UN&KK94];QK9NEM\T00 MW(&]ZP1:[#6*6*.('3MPC2+6P+P;16RF,,AM+ P#-TE^N7 FDX" 6I424"?< M$Z((7D,_)!NJZ3RZL5<=[P\WR%AQDB3)QNR[ M/97=Z&J.VE?,OJA8?4G4+$T6'=4P15GN#51U8-O&0&K*;FQ1=N,T2B9@W0W0 MO_VQB]KXR/5CW(18WB8:"837T:F5WTB$.Y: (7A9[(=W,,AZY>KI!0 K#[>$ M1Q)CW0Z/P!8=P\;TA"BDHWD #D) IQ*RA!8%@>\[@3O\6X0M%04D@3<92.(D M]K%( 4SOD4!X]--[^G194,0M]U-3 *0I -(4 -EI 9!M&S*8YOH%0.R7*X6Q M]M1-:8NULN/U>=GQN7:'?Z_4=:'\>:V&"\U:[;"2P8DT5%@-Y^5X+NVCT-B. MMW?:W:BA!'TQ,2\]T^RI,]I32EN6?IJ[J92VHOYT M7+OJG ^PARB RU;@IT_-'CNS/68:;6/^'C/MMGUD>^Q\=I3G/P!>H2<\^21H MBA^Z=E_4>O@/Q3+%CF/;HC'H&G;7T 8=JW_H%KA& MZ0)F)!+&C$9"@*00)IQ(0A9ZA%7L7E6BAFB4=,,A"2@G5 4HW 0YP?DTHRA& MC\!HY $]3' .P):+T&U300WX>Z ;1P )]DNU["V;)>[Q-ZYR$3:]*S=M8UJ M=TT_G7&4\8Z3.S/+->VDEJHJ+Q*]N&$XGV;+^U G_O_VGK6W;23)[PO,?R!R M,T &$!V^']F9 !0ES7DW$_MBYQ;[*: DVN:M1&I)RH_]]5=5W22;>EFV)86R M"P5FG1[<@]/#2ZL?+7LOIU!:T?$(J6C*\9&*NY]:@+RN>YON^TE/!-OBN?C?>?;(MLW;KW^K%KP!PN'0M M8IIBJ30BK/M0#1&C:>)PO"E1/>Q5B+;J6J[2ETW#=F5#=TS9]6Q+5BV];_8] MTS5L&/1=6X.4G0"\#:4LS[L4EN012=ZN$FLIO7CCVYZ^.%C%W/]%1%U17-_F[BRX#F-,VQ M'J.X'2)A1\3+7R?TVBINMN$WV917UPAWU>#E--K.8KB::5N^IKNR/>@-9,-S M5<"R"DA7NXKEFD#11O>[CI,!$9_;_[3^5)7>#LCX^: _D=ZS1_:Z:%1=[NW" M.HK?Z:*EG0J7[R#_OR\SPZI-ZG?5OF=W9;WK>[*AJK;<'?0=N>][AMFW@$\4 ME[&"_N[3HY)W7\C9+5,(G5&VI(SGB_[G,P7@^]SZI_VGYNR0*9X!^HZ9@JZU M>!TV6([;'S('U\H_>).TEFP0:'-LO'U"#'TZ0L4X#;!54(W"9X%=/UWP_ M0KX97.G;.Q1ONT/(;EEL2=E1K*.\Z YS];OEI$>]BX&E#WJP+XYJ@\NEV(X, MWH8AZSW5Z'<]Q5?L06F;/47([0 1/U:Z[7%3MM=!VV_/$ZVRO2)KMQM75X=_ MI$F6-=!!W"U[K(!Y :E8X7.33,9AFO7_/8_RAR])'O:B;#1),MBVW5?B>)XS MT"Q;E77/T0 52E]VNY8JFS8,\+7^P/+U1RMQID%Z'<5RGLP^4NB-?V8!._85 M':K,HO^$']7J\U4PC28/'Q?"S$L'I9P3Z1]!2KA;R/>O+'\15F/M;C67-V$: MTE%?2>]HCM$Q# 5V83I-8GZP^(ZO44J$#MA!#L^N.4)\0N>6R\=N@K$4P!OX M#;4!XT$IY#(5YIF1299<23_;)[;+3@C'"9:\,S9EAYZK%V'Y4""EA1*$&4:5 M'F2'3V R[413)#J#W-L-2;P7EMI]D+,:Z?2!?S*4CC!Y0Z C%*%35*!3EN M(^C?'&U8KXPT3N,G-MWHX/A"#<<)JB)JB9-A!SZ<"NVR("ZNI<8"I;]F4B:0 M6E"1VHR3&LR"A?A5%(,R!)A@%E#Z.0L% MH5)DO3M 3<$HU*XE=RF1!D$^]^9-JX=[=B.[^[K?%=^?B5L!R+Y_E7QW88< M]]L5KJ^NBTRA=[\R@24JV32)X>\1$U:MJGT;JI9T:J5&*R$P*'282",7Z,$& MZ3B3N@G\#Z9X7^D>_Z\#[Z);?>Z)-S4REW'U7-]FV!-K<3+OXMN:N;957U^2 M$^$H,( H*V:GKLYJ Z.I*!+$[!W\8_H*G<2WXYJA@J:C^?E5U1&BKL9WU>'D"*CCT=82NQD2. M%E0PQA(K<"3G&8$VJZ">"5"C#8([BZX_V>\%%F"*%7B0:CL"(- M?NW@:[P+'R:T#:%S@OC<:3Q*IJ%T&=R'F?BP\"X^M7079#QZ(0T?-APL)+.H"E2_X<3$1@"9CM;\DP _SE L4(8$GO%^?!QW%X M'7%D.$K#F6?H2,,$M9<00O$UJ_53 M!=FNM)16EV-K\%BZQ73PE2+:"U 3>($ 7H+@87B^!ES$< @"/PT113 0'',, MC3./'<@T("<=Q7G(40<$/Y_0AN!;?F)]0KD8I@.Z:?CO>02CI!%'_+B,3<-B MA\D\KTU]*[RF? B9 M/(B2>89-37- ZJ\$;78#VP#S2<$,]"!B,")<\S %#_P#&1932'2@&1">)MF, MK0M> 'L0!J"S^/CWL$SV9_8K3L44&D[(@($).>99P*=X'8B'&4J(L-Q;5,3L M5751&4F!EX2T[6E]D,I(<8T,4X"FT4 $<#8&'2V.A MU4^M?EIVNT@U&2M4TS.YWY 5=ZW.665S?@UOPWA.X@ %95$,D[$,HC_/#C*L2M97>[SK2$%<[29W549Z 0:9CXC.+Q]FK"_%>9J,A>_(EN!T53";7L3D 5,=65A>EM-&(YAE')*PE8&RG11@#_4#,">B.Z@1,R')C+B1H M7$LF)7"*2K45ZH==(T3S@UY%;9-/*/"/IL(]5WC,DTNRL%Q:N;"3_:"PM&L8 M()55@_C)YMBA)$+S-8K1[RWA"V/J$Y*&P9CP=,6?7YG 6*40<1)RHJF(@C 5 MDV!'OF.8!ED:3:F\ @9@(),,KYP2B\5^XT^C(+N1KIC5F$89<^!)!A8;659$ MO, :VX##8)(E1(,_]O_GXNHA*$4 \W05D5_[4H5_ M'@[S&HDS.$'DX'"R;\8LMI4,R4S%VHWYY"H" M+3T MT+CQ"CY&AAU*N%69A6C_U59=K)EK'&'5BW8Q0;$??BXN%$"AQ!PEQ#FWKP6Z M"?+:Y07JPO&Y%@R@$'L9RJVOI.DWNX(4C_BO=ES8IKTN;9P4R MP(YBF5&2Q$S]^A0V;^OG:%W*F-4;O*>P.VY2EE,UN8"IS*:#+C6FPG>;7 M\$)64V;RF_D*HH)A21H!_N"U%8:)N(<8#PTI.4^<6RFIC1[A2B\0'PYN@X@Z M?''>!X_@.F)WD.Q#M<3C9V_UFBGG,_+XN0M;.JZKM322(NN3MB@0R2!9\*]1 M$98Q@C0!JX7=S5)'+7)VP;>(T&O04Z <$'A?931N%7F^HJJ#L;CY9TL8BP! M_RRM<.*_F^!VV7GGQMMF+""QW:'9)Q2B9 \9_%Q$^+E1F4G3 #FYJ*\$;=$Z M_F^@ZNU;1EJTSV\G:K/M;R3;#D;A+*!ZZ*U$*0Q"7R "'P8U*&8H,*_XA^>= M=T!RQ $[8,"\6+(ER8R:!O^J;K[*"D>@: A*%A;(IJ"2>TQ6HY5'CA0)8>XZ M4+/)*!AB5^B]Y&M71JZQB"+ M$1*ANGQ1X9Q(O3F%]:,8RP/QKBW!)XSBVV1R6\19 &/X8(DS6 8KAV=F%!/3 MX^@*0P)DVL +R58MGSB1SLCI3^+K!*<:!EF4=>H>/5-KZ*BAZBJ>Y$Z) M*+3#R! U:HI&$VP(N-_1+?,0A-T59^3F.QCRX$7"H%MFZ8Q#H'S8:C2#")8I M;M5_V&D%>?C!Q:K.T'C 80B:2OTA48H=E<'L9,8O-,RDLU.AT485+VGHUF"_X/B MMX.+R>8!E1.$U&R>E7)A +LZP\@\K:Q#3Z/D3*D:B 6\4W;FJPR)D^,T#$., M7V+(%H^*%6[/!*,]3'4\%%&5*IF.9?2@85 M$%!!EN J,?:%ZB]M_:,W)GC_ MX!J^E;9O2MH6VXXRD\71F3? 3' 24<,POPO#HN!#2*>A"WN<"R4<-)H'I3F 7T4F%6XB;7KG\VS&WF[?D0GL#&%$N4 MCN93;FL4!584.&#)*Z*02?0OJMN"7Y&8R<@9SWD*:)GC5A+M K4.0W#]BG@S M6""4Y6'._XGT#S1KP&"AJ(@0>>?\P5PXY@;RZ/MRZHI.1+EA%F>)P[E#RM!59486$1+S'? MOH[L*!YC3BUDU0J "41'MA+C; 3%K@6YP@#!U./I0J(=T1O!BUF@14@3+4%3 MQR45343YX\NH;[JPJ-*A1BDKAD6F\RPO]A16]&_,Q16+$'8$=VPQA4!IP)"B M0VO63M@5[F#GD/ #HZRD7'B)N.2 +/EU71JVZ5&PU4'S/,1B?S#)/X,3M>QTH^TRGU M"8GR*8M,@FUQEV)%+WJ5<9V1[]* MJMFQ+%#Z2MFI!?5.MEC%Z+/?ON%OBP=K6$GTZ$82!@&^6%Q_"A3"$H4 +*:2 M*0J[406*'6,Z>-:*2]"?E1-D:U9OS>=9PA5? [7Z6%@HOOT"B B(VRM2C @G M=\.IN*2S="JI?*+LKU,C$CP9-0?LX[U4"6FX$D!Q*81T80'=8@$K7K]0.ED^ ML=4"%E^/11P,D;B"]Q%LN=UQ#+;CVZ;$@6CEJSE=MBYFQ1FI\#W8D'I+\5N M02%;DM@"@7-J62(\>)S_Q$JQ%N4K"Y&A,0#\9IG$:R)C,Z&'OQGTVPMQB%D\ MF':G@:S-VE6K-!B&$<=CXOJS-B@SA*F"K)@$C+9IG94DW%5,25XER)Y M+AX5)4EHF%Z6&&ZJV4WJ.,)RMW9-8X&U_(YO6+PZY;DTG"E#5;:H=KX!R;&6)=6Y:Q&I9PG)4Y MPHK(*-8;S&#$/>7T**;YLVJ>N!7VIV!VTL:PDD+R(ZB:FGPC0=%C^I5E0XNP M*E@264:I0:)^$AE%^G!9RQ=3.=[>/HZOM[*%UAGUS/S?QQ&'R_3 "M]+QZFPV2RNU9^ MFNGZ74V75=/T9,/J^K+;][KPGYYCV /'[>IXJ:9!5V&\^W3^[?.?OWU86D[= M25EH"/EECD?'^/VD0MO5;I!%(R\>]Z+)/-]/)[55;335KFEU754>]!%@LSN0 M7;V'!R%ZNN[:JJF:%@"L K":ZMB6ZPA]@I\'61T[W[+P[*JL[-G91KI*?V"I M ULV3>P/U^UV9GWN]*9*VA.P-YD7:$K*VA*PM M(7NM)63+9F/=EF!VQFP^F7[\DL1^D-V<4L NR_NM^J9C=LV!S>^N%U"Q(T %U/GH)I6SG:5?T9SUR\;,A^IE MW/5-WU9<7[:,@2,; \V7O;ZERH[;&QA]U>_W^MYW[;M)C8RW6/AC$++VQTT# M3W\$/+;JQV [?"?J+<$S'@%OH=\T&TC1(0K>[3ZS9?0\W])47[:5KB(;BN'* M765@R9YCJ_T^>$^&8SVE:SWS'7;=6EYJ#4@)N( Z._"P[L^JBD%<"N1N M[@; I!9S$L0T&3.B(]:ZB?Y/;1=6)#E>MD,!H^CI8SNTD%98M4,ET=>ZG/"] M70!0J#>CW\6L+?6"G@;CL!9AQ_*L\BQK=A-.L [Y.L(V4]PF+ITD#.9C2^AM M474AZ_6#P%374L3=KR(T+LH,U47E0."^EV>F_3)*S4K2_C:?B T'36(^BT5P MLS)>.GE ?34)D 4K\&@"=L)W,1EO2>\'L*!M0:OU;M-U7=94S32LA;YC4G%K MQH17YLWX ?TYN%K(/1*=<]Z67?!T*H_;HY($7^6AJG:F(ZG@W&2%!TCEC5@W MQ/B,?#\6=V"UCN.BZ05[Q0S/7%,A-BV:G=#':6G[Z<_K$ /X7[Z+G_8_TQR09P@1,;F&=$3I,]YCKIUJ'>7Z3 MI*RJ\4%$28R1*Q?)&P2Y@UXX$!L(G96YF;0_POC<=%(/J">#/#PE%VUS$17+2O!4<,& MXU"A5IY2[TJA"1<6R#<=_/(Y05"?1Z5J:@=3=4A0Q2.,'"ZHU#'<.6 LK,\I 2T2;=4P9:,'+I>C^IIL MZ)KK.TJ_YQEN(TKQC!.)8T@J(TVX+80DB6-)8FCZL15ZQ3)#(2!&NG-<")BK M! .#P X?G[\^$AT+9>!;7*.0"?*0WQ^SO;^N4=*-WH.O[]W8B>+?"R\,3F9SDDG.H*1O@OJA)0 M)'662Y1Z>K>$?"!+H,68+O"M$]NB4/$$RWU9.0JUG2!!%X3*TR ]6G98AC&+*N8T!ML!S9%E.V27U+;BV9^W$H/\8XJQ6':;DZ9L]2!SCG]_ MMUS#N@]NVAU\FF+L [Y]L\-1$K]?'%*_3"-PY _. D][8@4O6,?!"B^%T]#4 M8^2)5Z(BR#\Z/MY0M3?"'*V^V# V!P&P[BOA\Q0.7XW3/'[SFAH:-9V.$INA%@-W9A/UH;-) MNV,*5+?[\18MM3:1>@Q:JDVDMFF[-I':[L@R]SV62'U)$O2QGD6#)+T*HSWU M?'U)SR+KD9Y%Y<+K+5V].(_&V.LUN@VK[A;]>^J@-QZDR12/;\]S.A)_=M4/ MTA@-I2BV8:NVW-6ZIM]N2^J?1EP_5Z,J"X*_N^;O:ZNJ^Y/8\A6R5:W"-.C@_I MMFIJFK$GI&N*) M=2=]/@Y-0]7N->USK2=%7=T"Q?MK%AI#&P=<"C8?5(=PZ8&DML#NT"1] LUQ:AU-\]8-\+3^+)JIK-_-&U) M:MNC"(2JJNF:96D"P3T!9,&R>1RS+^7''TE+.B#*58RJ&>F6X(I]6K'KS]<@ MAP%5:Z^S6$#W_G$SFZ>AB!3M)3A!Y7"BZ$5WUD?!JW,6MF0]+;L>#]C=F:,' ML*])4$4C+LM>A!3+!"0XMF&:B!3-ME00X)KM6O8RX+KENZ9A^[)O]!39\$U= M]MR> 7A0>ZZJ#A37'## 3;#[%)DU+2KZ*I, R+B34#'3ME!NPLVA$/(<#MH> M:>!+:(99$\8;P=R($3;D,DRG+Q,H^Z$/4#P+=[#_GLDDX-9\/LIOB MWB!V=>9PGD4Q]L@>!]07C6Y1(\+K2,/P.HK1>_2B9>1\RO'%U9&L\-DY<*V7%!1\4H+NA+N>US1U1_94 M5Y>-KNW*C@>+Z@_ *^_U>VK?=BN-K9[8^CJ4;0)^2Z1=WL"";Y+)F%_^TPL> M]B>.2KSU'K?_MD822"I["P2M G03CGK8FS&:L1"'2(Y$IPV4V#J3V""TIB'K MQAADU448PP=JY?F/8#*1+O(T#'/I;\D\Q?O;IE$\SR3]1#-_D683^//]\%?) M.3&57T[6X74SOD8IM>]H MM+F6A?%42S7WH^2T(L '[H1F/E?)U2^)^#,,\-@3/OB/*+_Y%B?#+$QO\9G3 M>#;/,[P= DR4241FQU>,U:;\LK*LN$[BP:=>S*=Q.>T+T&S;KDJ14OCKF==F MV'JO9^J:K+EJ5S8\ T/3GB8;?4L?& K\HX)W4L60#H*1%2&\X>/AJN%BN$H< MCJ5:+R!H0]$-)%C=U37]>9A6;=6U7*4O ^VZLJ$[INSBP3/5TOMFWS-=P[;+ M$(IIUOV:W>&@N;@U;%/5]HC;(ORLH<@\ &XW^J+GI3/S?+PQH6H8CF&ZSXQ6 M*7T?_O1E=: !SSM=3>[V-%^V^SW#]$S+5+0NXWXTZU1W>U^[A$\0I)[@DYU= M#8K;.ZF*$A75YR1X0<3SH.@0;I;9!JI&)3/7F2B[3&9J7&,XIF:JS4QELI!J M1< 9Y=PO01?Q-(=PW>C"K:1?PVD0Q;3)<9ZR6^9>&#DR')=20Z;B:"O.*F^5 M70>YIB'2S[5_:G^J6F\'&9]](*E9S,#P;BLV6*M[8@:=*W5=[N[N3+!R=7">W M'_S3OX-9MJ'I8'57CU539>$U!6-_NQ^FDW'T,;S'ZS&B_$\Z&BJ-P5^. M,=#_^[N2>HM+4Q@U(DZ2&(G1NX^R=Y]("O,JDNPR.>>WEPO-Y]G4OWU8^<9/ MOWTHEL2!_U"#_C=VB8 0!ZD>0^6] D1*2LJ_ -SE-^6 \-X+ S395W%J2_?>";N)L=Y:+D&'>TO R:;>H;V[Z:>F[D]GU.XNL<1#E:@)9-[QFW/(]JSDB%1^X1C_/&-[5S-^6SDSIW&HV0:EB+S[I7^$,5X1!COJC?$>+':-W&WX)C>U M'NILY*:6XPFT?7GR>C75'+Q7R81>,H2!^$$D_A=5Y^>1.R^TZ+FT/? M&/5L/#_02.JA*/*RO]F?SB;)0\CJI%@H>5=4=(G7I)Y=G<;CZ#8:S\& KBC( M3V*\41,#A2WE5,=]6LIYE'**U[9T(YS-:^EF$]V45EB4AJ,\2=\:Y8A'9IM) M*2]+OW4?5D^P$%G=FMY>$P'L?<./$SMVFW;=#;W;V^VH?<@=;7X\X,>ZXTW< MLS;[\UJWM,W^O*)-;6.OQQ9[;2(1<5_6L'7+%&(@NFK9#37!UOBR(.[S-!KE MX9CLK&]QE&=?+[X=(@Y"]9^'"(8TF("*8(BI.(R@7,4QCXJ ]A@,^=^0#FPO M.,&KZX]I<7CQQ$UX>9>\;6)J([(-C,@>#]VT$=EF162/@7)LU27UI>M*2SF% M:84G8NIO^Q.\K^E\VA(+$8OF6 T]5- ,8@GNWSBQO'+B>'5;UZ;I#I>F:QH! M-"M-UP#L4&0(7J%J1XP>5=LS>LPFHL?<#CWF/M&C$G84IXTX'F'$$0C(V8J M8-B^"(C74!CPAU*5!]N*:]LN?78(Y*,RE<9)N*CI\=1:// MCF)K]%G7F"FOFPVU!ZL#5%5^[6N4_6O1LA^&XS$>:2U&\]8LP41H9[$KZA/. M?I5__C? B4GYA\^8DJ^OKAS$VF31"'T/BQ$:=)6=@M>L1!B:E8VZ]LL;S(S[ M<4597%U;ZC-XXS@":"VO-(97FAV"!*O&DM5MC!\VK,'>6EI]$R[Q?K&Z8MM;2]FY.QU;=<[8] M#MMRU5%S%7 /<8EAZZ;[.@R@E1>T"YM^ 4@,L^YV79I;LZMEJATQU5&;8V,6U:JIEJH,RU1M04X=FJE9-O5:.4H2R^_9"C0T;%\5X MWU9>J_0OOMO??K3M]QNZ+TSS6(YKT#'-(RC#>$RSH.$4IBD_:5 TF'OU-0Y- MH9^C*^MI##VU!3Q-(NX??CCMD#!;S8/9VC?,[86'3]^4\C#% 3;%U'3C7E<, MPU(:NBGGDR!>N-'BS)\WO7WGP]I$_="?:0$-#]J,--#1U7]KS'^WYCQ_O/AZ2Y!^Y ML/(HCO\>?1/JQAV;;2 QML3WEDW8]D[)YQW5.X>YO=;H6(UZ^T"DT21VV#O,;8^9 M-L;8+%.D;!US ))O-(],6VYY(YN.SG*@DS* M;:OV/A6'"6*_4?E\X#Q35MRGP#P'J4L 9W@N-BNAF;*L["?V]6\?BL]L"GQJ MX?DH2PP-V/+;16]I$O[;1_CM:3-]AX5_7U@972,J-#'"Y[[,IV$:Y$G%B=N\ MG>%F]?,T;2^,DVD4KYMX%6ZJ.9'-D[1W;C^-+C&2?RL96V"A..T<'AQW"A!?Z7$Q..Y_ONOV[LZNKSF^__OC# M^W]UN^3\\H[\Y;& 2:H9&=+'4(2S!;GSIFQ&29=,M9Z?]'H/#P\'_EAYX8$7 MSGIC+JCP. VZBLE[[C'5(]UN2O*/F/D)>7/P\OC@C=5R&T;"/R$OK4=GDE$- MT,0'_M!T>/1+]_!U]_"7X='QR?';DU>O_V=#A_.%Y).I)B^\GQ#X+3D/A6!! MP!;D,I7J9W)]?79 ^D% ;A%8D5N&@C+_(*&E8O6@JX0Z[5@Z/AP?A'+2>WEX M>-3[Z^-UW V='W\@,>S)XT@&? 4#GZ0XQSTNE 8AF(42LHG3!BG0-,='J\ "[!--"M7WM>RAWQZ -0%*":Y9Z-NQBO@((RO M,S2[GU_WXD8+V@-GU'*Q"JZ8=S )[WM)8WD?>)&4,*;6H2:MY;@^X^5HT( 8 MKPH8[-&;EJ-@2SD7+NZ9TN58<1OB'1?P!.6>*D7<%/?*<: !,8Z*&'HN MUZ! 2QY'4SEA^A.=,36G'JO@?C"?S9C0EZ&>A'*2(5_(337BRN@*V>&6X=P_[3CA,@D2&7P&*;O\$4B2F12QB[WMY"GGBD6+^0/QJ?GLT\*+ (%[#WPER N%"G$N8A87> M G,IV7J\Y&EJBCU8Z Y$-6XT&&=+RTVHC!QG 54J\2:TU2T@_%T1P6VZ8[!7 M1HC@DB=\)D!7_*7"@.-"Z9,/-,!UAMQ-&=.JM> .%KRA,%_K*=,<.J:V.0WV M!IN^VL:FY,6*8#^U-MYDXRN(LW())F]M.KZO9*0-1)!R3P1QC9R#0CL*- M%CJC:GH9A _J2OA<,D^7&ZL(YK;;FVWLADR(X=+:K=1NGT+-U##,YKYE]PWD MA K^C]%DV[[2"M\6H:[XY/ M!,0Z'A5Z:8H;&'\>!XQ:@[@B*;>9W^7-?!?-9E0NT- 6 [+D0%(6K>UKVG[9 MSX,Q#*(YY?[%XQP75P7S[@"B4WEF$AZZKQ1$K?7<87OJ3@\Y.LQ[2$*'VA=>%$!Z=K&MH M$9M=ZQLU?>.2&1VO6FF:]H%+ M1E;=,&E&73V3KL=VF[.0!/O$(*8*E2) B1A2K26W"*NXCN-D ?.H25 PX>T0 M;]2=VN2/*VM]Y[MJ6'G333<-BXD\HJ9 MG]:\WR8%5,/F6Q%V.T(A!6CQ:#U@PS<>RY77*A[L^[Z1A ;%3SYJ(+C-5LCB MV00QS,MHVE^"D!?G3%/>%IMO-&B27AF,G5F<2J;>A93;"78HE&M=9&<7J9*K MP0],_2BHF-G)>\X3<' ZU/'V=77H?(DD23UNU213ZV[5W VS.-\)>Z#H]I!=,Y:K"U$!N76=BJYC57E66DLV MPKO-7L@PVA6B[=R_LSG38LQ*MG0#NPU9R!ZFQ%HC[KXKQ<%@DNYVSKW:+K0& MJMO A=3AVGX4)K/\"5?]M)'#<87LWD0+ABS3*M^QQDX/8Q'5/*NJ:$5>L* M55TA&]WV.]WEKLW:4R4 ?E]G. /1O\7$C82-NOD*/^\E>Z;N=*!7A;SENC?6 MJYM#>]N82D&HMK'!L2C)9$D.'&A=;!<7JQ2NUL!TNT8A_[C>-=I@]4DG%/OU MEU+1S"SAGT&\*_$Q]%EPI6YD.(I'9"&,W2MMM\<44I35)I.5%VZ9# 2%(%P0 M(P:!R<,2I'6M/;G6C61C)F'V-M%!DG!(9_=%7_CG3/)[T/N>94_/(,RLWL6'-=TN_WQ=;MD(2=:S24S\9*H.7VGDLEB4JE+&:T&2TKR &(2 M(RV%OV*N ;<'6[9R$/;1>VK?IE+!I)9".& M(TFE(Q&*1_24$1"PNY209"(F&! RDEA*,Z^"G,0(VKIK]:JKU0\B*]9754%R M.TLQIYW_HK+='\!C_ !A]MWTX/"_ >/@<1:D()IK MY'*VI$.0D/J9T"#H])JK^:H9*R@.""6*GV=DGHG>,.FRH*+* %NB\C52>";: MYH=Y!:4!I41I^VC,,MW?]^Q#[^&OU4/QWX/JH=1$%([G=]R.0>(+.*Y#SQ!R MH.!?W12OBX^Z1R^[QT<'C\I/1*PCP;*GZTF0XM65P'FKQCH9#/_2:SQZ+- J MH]5=TJK?':7W;U3J%1OS4XR(W?(.N^7HS2Z2;"?%=B*4W@Y2U2M2!&3ZNK8C MY&]EV<$/\$E=-]ATT8E3G#*\](_=!"FY-J6:)#9B]M=.LN3N8JDD1HJ#/[I+ MY/K,\[>Z5.*>(9E?.RE?O!^FD@066O*[NR117XK"=3.5A%ABQ3]WZHC<[365 M!$AQ\$=WB;P%\]P].-6XITCFUQK^R=TX1H#33E+_> 8+'-XR$7\UIJ( MZU) M]62\G\)0XN]*T'%(9&[*.IF% C8_C >,WSI_)'- M1DS:VJZ'B56,[V4[\<,9Y:),PU@\EX)[4.6#YI/KP"N(GWO>))'-M3^# M9"#-]8)QQB](JZ>,#IL ;5=3)IN]I:,]E5(7CTQZ7&U6R@)LO%*7H1PSKCU\B>J&M2:+C5V%7$&9(8V9'(R%.U)+G8KP3Q;Z["\ 6-5D30#K M GH.4G]G?V2FT#[B2RVYI7 5U8"C4'B=QO-:?%V<1HJ MM#1I$LJ*?V('LJI%_QM1['A3-&-U_C47#*55EH:[$&F0"6NK84Z.V:4?$@+? MN ]\?3(%3.E%(V.%#;UA%5]A,==G$8[P)G)D="7FD5:WS MA+QIP(\9J4?.R M)&Q*Q000,K)E_?9DK)YNP=AC0F!9&IX&OL72.CQ%Q03"R!U[0_K,[ZLU( M*#Z'!?>2/S+_ENJX*FS&E<+H2-Q14SRK5U?6*L#)/ V3- X68/3]5L__X&@- MF%IWD$5AT:F*T*2U"'-YWL(4QMV =Q1T6M/>)!4^TD-2O [N:!62"_#\7BNK%JBFV&;8YBIB!/3:^$9I(IO7HDA%%G+<1SF!1! M> ^$O\4ME/VI6ZI9H?%9*!7AR!^,+[Y&-/@#;((1$_I$$)AR1EO%C:"VPAQL M/&'R^\WSJ;A)S;),SQ6X$EX0^?BI!V9B2O3;A-"DG-G*N8#"3V[(O5DM!BIL M,FIA-6A7L5GN_#:B,D8C]PTF*[%^-US>W*0UO/2#EZ(B;K"F*80%WGYYAK>\ MN6$*8.HK?64_E!SFJ54-RMJ?02;T1H8>8[ZZE.$LW8,-9+P+B>\I!$)J5=>* M&,]A(;\%NYFH$+;L+]?[]1*,Z67Y8!W(].T-/ =$ ;1 MD^FR,!>5-S=I+HHE_.!6(-_<* 6R:Q)6#DE">2<&[L.B<)-"_X%*/YY=EJ]D ME/&^X92*Y*02ZUNVW"=XZ0OV&\D].])I@"PK.U'#[+MM1>^FH<07'M>AF."K M+G-R:4DDO &N0;%OF:3Y:-P##V?2^NTH:?_P=0 M2P,$% @ TTJK3)1>4AGE#0 HK !4 !P=6QM+3(P,3@P,S,Q7V-A M;"YX;6SM7=USXK86?^],_P:OOWS[S<=_M5J-WOVD\8>%'18OH,\&*0Q(/2O*1*XT6HL/&]YTVX_/S]?V#-AL0N+N>T9H8A:!#DM@?F* M6%BT&ZU6.,'O&U)N&C]=O+N^^"GVRYCYU+YIO(M]U>5X,Z<-U,!/EU<_MRY_ M;%W^_'1U?7/]_N:''_\7;\V6:T[F"Z_Q;^M[V?A]H\?O=Y>5U.VS8_/:; MQJ;QS8L@.QV>K\/F5^T_'@83:X%=U")4>$#-3D"[!<>SV^;2=]R67*++ZTW_[WK,\EU, :I]1SWBK?MTQKBKJ&XV MY+B?Q_TM^=SW%F2.J1(B+Y"\MFS5SARH?2Z98^CYY\0#$9-S#&=;41DQ0>04 M70<)068$VT=177#(UZ1_A#@^CO5'C.LML$-Y>)3Z0YZ:Z>JB\3B MWF'/HD]MPK'EG4K@X4!GT]HCPG*8\#D>\CFBY*MZ5CJVK18..2<_B4>,JQ'$ MQ'==Q-?#V83,*4BLP,I0.+K*#\>;A4I%@>68&6TXHO MD>SCK$<<'+?X%R^0C/.$KS-$N,C4!K4@9)IX(]D)G2,P3_C% M^\T!Y7$4,UZ1K++YJ'P(%:L&.2U-C#@M<<+)J8 Z_>%7LVTG+ MYD$L%UTHX:A;%$Z?O[*<>9(62Y>XG$M%Z5S"4Z\\@Y VNB%4>E+0I?L E>SUX64KN7DSI^@,R*:J%E M*?0.0FB+J2TWB#??RKG.+G#=3-O>F[<\8@K6K2H"@ 3@SMRZN@$/F[X.L_]^*+('L0SN2@ M*79NFSF-VP;I'F,+DY6DYA%[Q:A/[&((PUXDEPL@I;T1ZK=[%2-$[#[MHB7Q MD!.+V])@Y'HY4RF.5Y?:8*N',G8:6."2EEP+2T:_)&![ HYRL9Y836C M\EM3J"_6UPBJ2"8S >PW,T'KX?Y\KD+)[&("PR?&[&?B."GT;G\V05N,1;(P M^2!SDT)S;C?#6+(EI")R,6!T_H2Y*[/D.00GM#1!\6XY39;R2&IIB.+8?E*X MG53$^A3I:0816V+NK4<.4@<'Y .WE%XX^'VI4#*ZF, PQL+CQ)()O40K^7 MS<:SJG)3G^'3DA,FS^O<-M\U&[X XMARX^M7%5VVDHC _O@6P!ZC32+H/[T% MZ)%K&0%[7S=@>W8XCJ]@ !:!OWI#X+.S01'F=V\(2 M(IHM^*L:K?LIX)-:1>!KI.72X]*=M4Z*!B-)__FMX4W+T4>0/[Q!R&FI\4BP M+]\:ZNP47@2\1J:[F )+S)9$>&MDNXKA/.K->U74()Q-U*L6^/?"=O<.3T M,I'1ZE,/5=J7,H29JKFIUQ?"EY>+J"-3_O3 MO7QZ:D2;UZ]::**]SZ,!Q;I6!M->^O\83/M=JX$IV*_M!9GNQ'W;PB@+#68H M!R.5_8BS%0$3^-MZ<_-:D"RD\^ &2KFOH0X_^?!=8+09S4C:G#-HA?BP]4]T M\J'HH&\Q)W=XV$U^\Z>Z+TPL]H+9?0(RF^JB0]KU<6KF)JV5H7I9"V-;W(/G M'?HNZFQYSH&>_'ZFT8Q!6V[.OP]GTC,K .2@BVD,\7MK[UXPMXB(0HP,(,G] MC-3&;F\CB-]7D%8?F]S8:!!Z2D 4CT[/-0JUK HB6F%/8I:;BWK<:/VZISS ME'LMZ^7*Y52*TJUE:4JYG#HTL;4L:='CM^_IK^1=HQKIA'YF MI3E.M=ROT,>>U BKED>4]/,E.0*NZ[:U=@5T=N*_EB>D]'.R6$HZ93^]^F4$ MI7.K6&(XY7S#/_P[W,ZIY;F(5^+4P;;*><O^)@_.3N&^2W/"? MFTLT(NI3>#C56\TSR8^:&;5@1RQ#PCGF&-9:IDB.1)_UK-4RZW'BZF?IOUJF M-T[D0[+M.B^18<25T/+R9K/D%WP5LSDB-;Q 68>K$(P9JJ_-A<;"=Z2GFVQW M"W?3XLJ$F($],WE?P#U.K+Y(:J9S_@&>*Y0C!.N>Y"R(M;ZUJZW$?S(,4BUW+;\&CPN^Y0+7<#CWK< MD\Q2+7?NCD*=9]S..]YJ).J)U:I5+6H,HMK*Y?45LPX*1^I!9;23$M7@!9M@ MZ\H1>R<\XLHK?;;OZ!+#V9V[=-@:XW@1X2[%,_ M,!L[?3'B;+I9$9//: Z,W=OF MT=2M):78NP?P_?N@L/]QR,XE=L?R'>8B O M3K@V"/$1>[*>-'R-7 1./KZ^IZ8=SGK$\4';?%'6'1Z-%>9HCE4/,?0](=^. M)?.;U".J*2 VB"GV/#&0BLS,,/T'2R1):1V\!VJ1([F$(XO=0W1!3M;?1^J&S:^O0) M9L7_Q8CGWA]UQ$C51OS,]. -QZDJVC%V$9$/H[P44(".D.2>@3IYO&IK5HF[5Z%13%]>UY6SU =W>X[0ZOA*:>_XS1>DRCS MJLPA]D:HJ W^IH V@4^6^2KOZ-6HU8&F(B>U@QQ4,5:(MLPJRRHRLQC!X1<5 M(CS^NODB!:!59/[)&((7,5<("9YZU=8:*116CI-[IP?D$<2#K'FU.7TB@LJM M1"R_7T4V'][V+MM66S3B"B^>UQUC=?^\*C:,#I>&_N,;1%(Y8=^F*"-@E>1[ M)IV5XVKXCH4P+5I%CJ;26#ENQO*QFVH1Z:MB:E7>(AY'>.7XOA_[%F#QQ[:< M>PJZ#S[\'U!+ P04 " #32JM,YLKB4!L@ ";'0( %0 '!U;&TM,C Q M.# S,S%?9&5F+GAM;.U=6W/;.)9^GZKY#UK/RV[5.LZEKZG)3"F^]+C*L;RV MTIG=ERZ(A"164Z0:(!VK?_T"$,6+!( @!>J BO9AMB,#Q/D.#H!S!?[^SY=% M.'C&A 9Q].'LS:O79P,<>;$?1+,/9Y^?SH=/E[>W9__\QU__\O?_.#\?7-T\ M#?[MX1 3E.#!&+W$4;Q8#:[P-(B"A'UC@,)SBLESX&%Z,3@_WWS_US4E[P<_O'K[[M4/I;\\QFGD MOQ^\+?UT23 28_J,&/:GUV]^.G_]_?GKG\9OWKU_]^/[[[[_OW+K>+DBP6R> M#/[3^R_>^,?!51Q%. SQ:G"SH>J_!W=WEZ\&PS S$LJ7"0E?Q61V\?;UZW<7FX9G?_W+8-WX_0L-*AV^OMLT?W/Q[T]W M3]X<+]!Y$-&$45/IR#\FZ_KFYY]_OA!_+;=F=/A)WKQ,UO<7ZS^N6]/@/15C MWL6>8*4!G(&R!?_7^:;9.?_I_,W;\W=O7KU0_^P??,"_DSC$CW@Z$!2_3U9+ M_.&,!HMEB,^RW^8$3S^<+=-P<NL 18XQ_'25!LKJ-IC%9 M"*K/!OR[GQ]O<_))FLR#&8Z$R"69F%[P5A?:#UWL2^8CZ_G;4$$DH\QFN:" M]1!3L4 N0T1I, VPWXAJPT\>DOX'1' SUC?X;C+'2>"AT#ZB6[:]+7!;NK/> MUJFZ1'1^$\9?Z6WD!P1[25L"=S^T-ZU7 ?7"F*8$C\@,1<&?8JT,?5],' I; MK\0&W[4(XBE=+!!9C:9/P2QB$N>A*!EZ'CM?$G;J/<1AX 68VH2WSX@6@3\0 MO$2!?_VRQ!%EXT7^B"TSR3%*HFZ"] D"!EC<4D(M[JTA&MA8(ML8/Q= MQ-%3$GN_VQ3BVL]:A)"M"*N[M?Z;-@\BSJ*/3%?VN:2SZ;5^KC89H7-@Q2G( M_SQ:"E*$'AFNYQ5?-J!.H=Y39. L13[-R@@OZ(PQ70TO69?CE<8ERBBOW I M:V@&6!^\^UF7T[G>SNQ.NW8DBT!SWG["B/^;'\6E';NTC6<-_&&2]QE%PT=^ MM!-VT#%B@[9'B64BNF:/S5VMP0"'F_6R:D]INA#+[#,3QMOH4^SC\)8^D'BR MGI2VVYU5$@['&J; 3S'3<'RQ0K/C=2.@*Z8$76$2/+,)>\;YKY=L$YO%)/@3 M^U^"9'Z'GW'XKANVV2//(DOO,3,$*'W Y&F.V(Z74\OWMC01TCV:7@5ARG;Q M+YB[*MD*?\8$S;#H04=IPMV(W),[9':F:,H@M.1A=_185FB#9&MZ;]*$_>E3 M$ 6+=''') _H)5H\SGR,1G/\7T<77)_:X@FK,.2^[89D:+I34Q&4[:D,!.# M.S1Y6B*O+06T;+?Z9)I M17$8^&L5.?+9MD"YFW@MV9+.!9@Q?DD^AFSS:,2, Y+5-1^%#B%LU#8L\'[9H')5^TDY8E4N M]J.A:PZ5G-RVA4+ZZUJZYECN=2K(M2XU^C% $5J=<9.1 MND9[C4C$3)3*! MU>EO-73G6L^6%]*ZEJ/\?H8,$<\4G"+M=I/0R_-MOQ>841B>#;(/EQ'DO8(H MN?"#Q476YH)WZ) >-A0[H=GY?.[C*4K#I!EUN]T/0VN\0$'4FM1U[RXI%2.< M+_!B@DE#,BM=.Z1QSCY!O'2"SW/.-*-4]H&,7C\O.> 5!Q6:V2+#D<\S*]:_ M\D_MG1F^'O6B.FQGI!BF>[M(5#5]&XS"+%$;;/S=/.S#DM(DN5H0PM>X=H@L-U=TWC"QNT?$R" MV5WHJ<>O-F@V9GG/FB(Z$1M72L]G""TO>%G1!0X3NOF%4_?C^>LW61G,W[*? M?^/BP?4@]O^X^^,9A4(S2C8YL,+:V2*]65\05-QCA\D2D61UCQ9X^,+SF^0@ M9$VMS'Y%WB,_BR&6XZ9LD>%;ME"W:6O<_4#T"FVX':WKKA"R\$!B#V.?WI!X M<4MIRI,81N0)\;2'M<=/(1D&'2'P/.)E2KPYHCC/O]^6X:M,9Y3",N\/@RYA M0V-_8Z4//:8+I<*?QHL[O2!1PJKM"(%G+2["R\PY.YJ."8HH\OB:T$Z304=H M/"D_M=@_1%H57R$\PZ]$I@&RVD^ 8*Q:R]+C6]_6 :K';#S-L:=J[0CE^J6A M;-]KZG]["T9_X >(K$H+LT9RY.VM:"$BW_ K"1)F;CRDDS#PZM7XVCY6*/L2 MD]_9)R_1,DA0*#^-- US&@HC:TBJU"#B;;Z7>1Y:^'JR#TR9UE*CY6[&CMLH M!X.8,*:+JQK8_YT-EB2(>9W@A[.W9X.4,LKCY=K"ZPJY\"^6P;;5NCD#FFG M&^RO7V?HUQZG]]S2Q?Z'LX0(HRG[,6;\>TFN0\'.#V<4S_A_0+!LRUEGBWE- ME+=";-[ B$W'/# TJ LVO#TJ-NAVR@+SNZ/"W$XW+KCQW5%RP\3N+GCP/0P/ MI)&!%IRH>$8JVX'TX 4_.SO'K=$J,_!OCQN\U!3+H+\#@ZY9\ZW]2_FVO^7N M+H3\!V?!FKMG524%"L M7 =E);B?74+$N#,=8[*XP=)PI*P9A&N5\^TVH@D1Z3P:GZJD(3R]0N-]6A*, M_%'T*R(!5W=XH XXAY(X.$Q"68S9;RNP0>I\0.<'YUQ15:F6TF M==^ 1WF%J4>"Y?HB@?)&D5U+9 "RYA-6PC_5$>N.($UK>([?( \WV/E*S1V@ MG0C5W6/*X .S06,_\++**C,LZN[PV&ZYEP73A$NN2.'T&8T>=S?-5#EX#3X MCV_'7ZP%<]TP[4$)"E9QL=?+-TTQL*ATSB3+ M_-2UM'+B%M<$3C,3<_<&-&[V)YOPTB/VN#/#'^:7.4C..*N?MH+S7SP:$6*J M,K'5B2^&/2'D9W,491X-SC6%_,A:0E*<7?20N5YJB-YJ#$'W71S-&#$+SKB: MK#]I4Q=HUIY/BL8]I;OQJ:K8-3ZA%WY97Z'@"2=B=F0P.T-:5%#?"8*KV;V# MVD3;:AL['%Q_LB$':SO!%#D$"V'P:GFXW0HDP1]%,]T65?P=C#HM#\LMK$@A M5U3Y^:T^Y;=:0/"E[%/13-Y.,VA:M?NSI&'/Z"V?)2 !=76$HQR%5-NC\+%E MHYCK?C"="*+O9$L;NFC4 (\W%WIOUI0=K"XG/.\-=#N.YG):\]Y@]>Y9E[.; M]X:NBP6[G,B\-_"ZX!1X!G.7X*N^US[D<[;?L35AI3ZD=;:?8S5:J#0X*VC5 M^4+PR:KV .J"TCG.-^[F;9KB-'#5%'![K6>9^O8*N$>H:35,;2IX<82JES[) MJ8!^A,I7;?Y3@;[7VI?=:&?!E*/0TZ2!Q +C4:ADJM!C ;,ONIBF/,PTS%V M!M+/:NL##7(DU)M:7RI &X*41Z'=K_5L"',W$ )>TVD;8BE"EV'[S@7WO"X, MH4N!T EIS\(0^\%T(@QA<*#H^OT'.[$OW>6WFX]HKMS)8F7 ME_%L)7844P1EHIMM)ZIHM^H@Z-DVT@Y>7[8/=3B]>CO)5L),(9MF_A2@,LR\ M$G;;+\+=(2A:4?$(0+-B2SMI#(P09JK_N7F!MV22/A"\"-*%(JNAOA]$4D:5 MJNR:\6@FWO0Q K+5Q34,_#GIC,UM\%2Z6TF#THVV.>IER5%&_3HH ..A!;PK MLS(2S3K")_D?0U'L5CB+;?-,')8H-$*C[ R/ZW.$UH*.?86HF?=S(7'ZE*3> MX8VNW+/&KUR5R1J&-:=YV&[B<2&AC M!U-G@[N7:==B\S)S4;B3TFP(N-J[ )Z"9G:I<:T=9!S2=_FZ MR$W:K_PRQ5(R57'_XE87L*L6^?/$<;2^T_/T1J(C;R06<[*^SY]?P;JI"E&_ M*ZCM!(/#@5<1;X(7[// FPA9+0+*=ZI15+JH5B8$!KU +BY8YVGK+RZHM(&Y M',"5%Q 5,E$_SB\DIE+?H6G7TU4'A[SJ (!"H,O*COTUS@.A@WK[[HA?Y[2, MQX$9.MKW1CDUHJQ'A:!H $(?T N1=J@?X\4R)HR8M3KP<749(DHSJG3W&AIT M= #/CO="C^)N-ZX*DF)YC ]2 CW%Z49BIMFT]RG[V6HZMQN3M']"=]7@==G! MWUJ'K7_/S+WH37,%L-E[9O O(M4]ZP7Z)!+0YF,9MQ-[E'$UF[E>U^Q=RJ.% MKGV*M <5FNU0[U8SPE5J*N_@J]/IRX!,V'"$&59M6%47N %/M+.$USBPXG(V M69L);OOBMGM99:W0E_Q&+B>/-19EXWA0'V[?:S*CS=Y,-TN: TABR.ZOT3W( MN6?$,#OSLH%&Y#&8S9-+SJXP+"@O!PIK>EB)8TK'N'YAZDU &U!5].B.JIN8 M3'&0-*"JZ-$=5>MMVYBDK#E(+H6,GCI?;$TG9W#HO.*:#A#T;]T%IPURR=M: MJB]B1_%'Q-8L_SRS8M#ZA"'<^A 7Z*Z*)EGVX/ K(OZ:IB+#D(I,M?$<1:.U MECI*$YJ@B-]Y]@5S7F-_^(P)FN'--B&+'#E"%%@T[<"H'S$7)9$3&R6$Z9LI M"G4OEKE%8Z]FZ3[.H.ZRHH"^-@9L,[_)T" \Y7>2BWM@JQL=U<5JM7T@4&0G MBS;OI]KFT-X:L[._XHC0G+)'[*MISJC#; M]\/N8\\Z1L[X7SJ4#2F0WZD0? M?%@-15=K"?;!KV4#;\E+T >GE@W()7>-RX6@-B&7O"[@V03&<;=Z%T%EO]0K MH>!!5H.9UOH4REBW5%67TB5T60,F9D(9IH(?/2@$%)&AW<-[?[>TI0O:0O%Q M[,N5#/T5+X:=02Z>X_I/S2U/U39V7,I,J4K#A$<>U.6$NXU +O<*"/;8M[56 M[E8C$/?J8AG&*XR?,'EF2KYJ/RVAR7BJ/@L=L"1ME+U,&-;6>$;4C7K>[L)Z&P6 M#- N='5[*UR[PS/DK:W4AU#WT+"\H14:-ND93)= X:],DIAURVUC%(;".):1 M4]O'"F7"+#<0+&D[D')>-C4UY=N5)I T:N-Q6XUZ0B=8H2E-2. EV;;ZF9U6 M]/'IL[X\5ML')$217[A1ZU>C*L>:+CIM[_N]"HJ)_\EVR+52H]*EK [16QX) M%X;UX*QD!# .3>KIG]337W[?6,TKZV/U2JYJ_?R_B%RXVVB]:@Z>$; U_''Q M-C=+NHGX-QZ_5^O]^F49$-&X7C2M?+]7LK?CVK@"7_M(^R5!/MAFLQC MPJU\ZUDVJG'ZS*UG%(1G7N92A^%0?W9M;SYW>UEE,7PSDI:4KKN(C;1+Z1]Z23H4X\:SP4U 5.F\%R8\+J4R?EVFWQ9G?M:5:\H^!N)G -2$6Z!?C[Y,8)O]:# MM#*Y=B0=V VF;!T"_;F3J5.N* PK\&N/*=>U=;V8N_5)0B>YP] MXOK+CGAO/X+4AX),MYFY&V#J0SFF8SQ5AU'Z4';I)C.E4;P^5'4ZQDYIBE\? M2D4[Y*/])+<^%*+:9:AA=CYXN6J_5^PFX12^1+1W"W8W2ZT/M\X[QL3:E(?" M[^:N<[$;GAZH],[E9X%[RF!%#:G+CQ [>E0USF$'?^X8C,>F-?L%ATXFCBTI MW,GV+YC<8_MGC[0QZ3:[6W1-OX1 MWJ'6[YN.[%"_]9JIE.)J&Q JV?*HI;+2!N1^FNV'<+?OHLG_#D:=_JZ<4HO3 MS3BZ[SM415;O4\IW^"&EZ6*]JW,?'7< 7'&UDATP_-$\%=#N^N*T.B)I?Q;%DB?4B6JT-4 MM0#!L]S<*"V1ER-]ZT5:I:4.7J!U*K=Q<*]Q+.?/P%@[U=UT:'"<"G ZM8]/ M)3D=.L..HD#G@(E5AO4WSD3 %'&Q+'D1P$3_!4>8H)!-R-!?,&[0A.?\/^., M)*WKWJPOA./A-F)3@_,'M^[X2%Q&U6$270^'$&A](/H^1X$"[A$(S';(.1/U M*_R,PWC)23-9(R8]3V$O)\->;73_[=()ZX&9W0&<=.RZX.@&R1XS.'G*.D[- M!@GN 3)SQMH$W9?L,Z.C;2L!OOX,Z8/MVABYH8X);EBZX>[4+B;PE7%R@#JX M(AUS@$J4H*8.3P"#/7?2?,*(_UO(5"%_=P&:<"]8P#/:10-_F.1]1M'P$7LI M(4$T8UQF2Q5 *Y,^&*ZQ>=7M(71**35:2U'7H_<(@"S=LJL2)Y2=V1+!'T6Y ML+,&]W%$*K)?I^3;':.O7-)9S_:^#\J=CZO\/_\5,!60:;^K.Z[[:C8EP\[ MN$IGQ W!?Z0X\E9FH)0]01'=1LLTH8*][[3^+%T/4 0ROFKW7I.>KB"BNTNA M,3;U-YQ!F>]G9B*HZPJ!J;1'YS06^J4"34TG*X]9/+ _8D*RTOM,V] \N:UM M#^M?J]5QRQ:,5B$#-Z7-?&NV /?%KV:@1.>%QGJY!D^R4?I*.E&RRW)@43\] M8K=)Y]-0=R#TQ^-IW>"12FN-O0"^?3G'+K49 IXIZP:O-*"FT7"$/>,@8@ M5WY!4G&U(\^8U_@IM5U@[CF98)^MEH*PFR!"D1=P.<_OJZRY^J3!)ZRX6[8T MFI(Z\S\IXA=G91S.UZDJ8++OUV#0R (;^WSI%,(XA3!.(8R^AS"L(8(.C'][ M89DN4;HTFV#AI[J3-W=@%#I,Z? <)K>4L@/4P_P^?F:_^$-ZA2<)MQCB-$JT M1_&>GSZZ,-O!S5D36Z-:%==$(P;W,!N&]4QLEK06=2=J^9R]X14=M(,:"E=\V/.5P**\[ MKIC$.!V.VUEFC/X0="E(I]-?3E$Z$'XXH?4T%Y$C#%P"QV[=$ 1GHK?NOLIU MJ.BM6?S:E>AMJ*1]G$"1:Z7C:9754NP#HNDIRM1T>/+1/A&HO8]+Z8\O1%V M>B-,UL)*9L7CYO"XG",RXZ\0\J"-+%%"T?+X\P7@G^$^4.3< <=AIX6B)@:P M[=I1M:%XA)%X)R9+IX/VJJH'DGE5,Z17[O0#L$U[(Z*LWS;?;GKN_YD*)SR>(X^:<69? UW7U(Z5+X& M5$;QZ;'1;3S*QT9_ZBTBU6.C/_T*]^QS%$XK),U?IQ([- MZQHBC_422M\V)K/ 66?CGKAI<5SH4MS]<>UX8KICX9T;R5S[ S%*X+(UC-VR MZ-+AR(^T'0IHE80JO<4*F'/MX3;*/RL+ W8^IBMI R:@J *5C'O=CN5,18=: M.Y#:0MT='? &2%._@B.LZUT%2=?JA]P!ZHSE7A\S[T"?Z$@BOZ'8^*$FQ>Z1 M!I\6 \_B ^E>X$[1YM$4RTJX(G8G.R>;'E@ KJQ[G-S%E#Y@(AZ+*YQ8_)6X M-!'P1].K($P3['_!_'YF[ ^?,4$S+'K0$9.F!$6^"$@E@6C*3B((WQ4?W\_& M?^(3+";]^L4+4\:D&R8>%537B$2,ZAS\<"&YC\GNMR'LB#TI_[B2?T#C8^MR MQ!YRL,[O8>WS[O#F'BWT1:>UW8X("Y#G[OJ/E!]'3'3BB.D!6@CRMKVD&HC; M=W$T2S!9\'P[GKVLV1ZE35V@6D&ZY4]@#9:MM#JCW1XKZ*12]8QOCGACU4Z&6TK[/(W[^TVCVP4NJU?YS-Z?1X0CNJ33;UW5V0^7V5X6N M#KX)&\RJWL[(IW5;TP(OC#/V-7=CD%C<[O3'/[@,.<3H&INI/U4XW;-*OG6! MU]L8&B)&QG&E5%]^-H$O'K-SQ@[<-FH_0%2+JP-!LI66?9,F[$]9_OP=9EK# MP[I6EGYFHY'Q'-_'T26_+#SD$C]BZXRMB&@FFM[$9#2=!A[F55EH\K1$7A;B M H#WE$ZH*'))KI^=>EUPR/6R6?;DH:A.0\4O8_9?%'DBGJ]UY#3]"DBH (I MD&L[>Z57:-=:%[&D8<_HA>6P[!UD'>&2]LY0;\)X:0]G$-RG?,TQ\UIQYJ\' M^LST ?EQH&C4R_"K'8[E:V2=8D0V'I_;:&VTW I&R=AHV!."MZ-G3(9A& O% MU""@I6YOA<>\3#'EBFB-8$K;0?#O@<0>QC[E%NOF71^1J+99Q0H^UO<#"6LB M<:$\'Y^[AP-*<\DWG M@3 S435W10/0A("RYFN2#+#3_I3.L#>*G?"6BO0[T 2_G QMLDRU$5B:"-_> ML7^5\LQNIL,%L;_6 ^[Q5_$G-:^-.H/@JCI[]"DPTK8.4%V3$:=J[0CE^N-8 MV1Z*^L /$%F5U(0:SLO;0U#/F3>:EKQB&LKE;:WH'<(?_)7;YM%L."-8?%ZM M?NB: V8-M/-0YM%8+1.:7M("P0"U&S#'*#',P>]YM(-,;MSEX-Y 735K%*NJ M=8>6XU1:[R-\<,YX-G7NTWQ:Y399,:WN)C$U1[EM]Q4HW;V/K39_2>-C+?"Y M*ZOF3HLR6(WCJP -?Z.]4;: RG*6;$F5_1E^)VJ6)M .IQ-IP8=,B' KC(+ M6NUID"8\'7\^LBE#S!P)?4@=UB-N%&KI0_JPV00;10SATX>MP=T_N V>B6MO M<9<\]'UX0<(,E4%D#/P%"//$5:G#N3*)*N50X*\&S MB&W"5.O4X/?N=P%3FSG__3% U3BH,I@_N&[]Z.,S-;NM,[:/R0E:%\_18'7G MEG7C2=4&?RI0#5PY\/-KYIW1QHTJ951-@R(N<4 S\UTQP.EZC_LXP70#_,"L7-8F*W:2="[J+,:,LH\A5Y]= 29N MJV,3[7F\?#F(9LY0]A3,HF :>.P\+*A[8(SWF&WI'B/-R-W\X S9A6R*9R:6 M*/"O7Y9L@\!\-8^2.2:7*2%\ Q!O2+G'^-8(A#+FT$S@2>+R3J&@SS$N9FN/ M/J 5)XQ) /N%I+C\\IG+7&Y)OV.S4'(4N<=B0=8\#ID20M>6)6_KLE"4MSAN M!;/-+;ME-^2.YLN8,E2B*A]1[&^*4(\.AV-"GM_56\!RD.=:*AWCZ,Y% +Y=1%_/WK]?\*$G;+-C__A_4$L# M!!0 ( --*JTS("%QD<%4 &3W! 5 <'5L;2TR,#$X,#,S,5]L86(N M>&ULY7UM<^0XDMYW1]Q_@,<.WTR$-%W%>I^[/8=:ZMY36-.2U9K9.W#[NCELA$/LE\$F^)Q+_^SV\'%[WB('1\ M[T\_3'^>_("PM_5WCO?TIQ]^^WQ^\?GR^OJ'__EO__1?_O6_GI^CJX^?T7]L ML8L#.\+HP?[F>_[A#=W8C]@-T8WC_?71#C$Z1\]1]/++NW=?OW[]>;KM?D%7X MU66 [8@\C79$$?*GR71]/EF<3]8/T]DOL]4O\\7_*3[MO[P%SM-SA'[<_D0? M7J$KW_.PZ^(W]#'5Z@S=W%S^C"Y<%]W3AT-TCZFB>/=S(LM- 1*K>>&??BB@ M_/88N#_[P=,[:S*9O4L?_.&?_@N*'_[E6^B47O@Z2Q^?OON/7V\^;Y_QP3YW MO# BVI1>I,)XKTXWF\T[]M?XZ=#Y)612;OPM,XZ$@DCX!/W7>?K8.?W5^=0Z MGTU__A;N?O@WVN"_!KZ+[_$>,1U^B=Y>\)]^")W#BXM_2'[W'. ]7PLW"-[1 M]]]Y^(E\PAUM84-;F"YI"_\M^37SK!\0??*W^VLAH$U)5OS2.V-*WN' \7;;3"@5 MZV]+ EWJY7[ -0>3M;?#1R;P&)X_V?;+.TK\=]B-PO0WY_0WYY-IXM;_+?GU M'Q?;+0DY$0F"=[[K;!T<7CR&46!OH[0UAO%//TB\\"[3G[Y20A#@T#\&6ZQD MDOA+*6KQA_M(7SJXY!4:V;%W_MOG'Y"S^],/SNZ/Z6PV62RGJS^L^T?5_:*N_@&!3>V6_VHXLOO!WY37 DL=FQ'QW7 MB8B25TZX=?WP&. '$AS>$VW^VOS9E:69YYZJBBIN:ZU*Q Q1TA:RO1U*6D.% MYE#>'OI"6T2L25CJ#FR@E-?,%A^^O6 O)(:@!KJ-GG& +H]!@+VH:*81\+PK M33A!H)-]1Q AD@\CYSSIPW#\3C10\,[-PN+3]RQURE'PLALPJP3L)18U(F)5 MO*N!-T7\D+2XQUOLO%*-/N%(CAS<5P HPM-#P9]6\RI1=K>V2WNW2]\*C2P>] M?'9(OZ:9(3M_>SP0N6P%IJ-.LFZT6"_7D_4?L^*@9YO(98.>;289;6/1/P]" M&EY8& CLM @VE8N(8)1+A@D0 P&VN%_W?]B'EW\I?%^(D*'*3!HVE(RD,W1\ M\':W^P<<'#YBW/#A2H\!A8:B#M(]RF:]F%GE4( )*?P](@Y[0'N,8:C? TR) MZA_H'&Z/J"1$1,%1NP<@J^'K0!.8QX\J86O0=1+T!C^Q4'!G1X0C[9TZ_WD@ MRG*5D?6.Y60VGRW+W'6I0-:'OS"1L/VW#G@E-C.!K->.1<+WV#H@6O4O&/?3 M\3>$IG@CPZI<%]L#:%I<68KH;*HN9Q7F)-+@Y\(:X%7[A63 M-=MA(/F1[9J M*20'FAKR)8 9G!NW\RBRL2^P1: 0>"S[=J!; 2H/FR>_A4- M5%96UZLR]U-1XR!^/V EUG^UGY)M&HV<[NVOOTGYQ2-]\Z1\.OOTXP;V/!H/R2=M,2U^0L!,.[_W<,([I^$C[X]YB: MP&'[0]?>UC_@&S\DO[^TP^>[P']U=GCW_NVW$!,,MR\TP]CQGBZV9"S !I]M M&7A#-&64V_KUEV?&;#*;IM$@TP-%/LHTH1NO*-8%_4BU^8G^F2J$4HW0XQOZ MD2I%0LA/*-,+Y8K!YP_"6]GB6#G(K.P1*[M$"_I;^O.6&O@8VQ3YF4GM3(M? M8 /6+8#_-XFBI)831<'V%@I25H3.;#^7M MU)V/(=[^_.2_OMMAAU)Q3G^@#)P7&$A^]<<%B2([&DD^NO93YJ'3.P8V-8+:#O1RO\>#]/XKBDF&<=,8^/7A;=+PT 7 MKI5>'PGOBCHI] 'KQ5J:@VQ?+6MD?(SL88(V=HZ5C3Q'EF5FS5QZDO :6J09 M?S>^S<]_DWG/>%*>A%+26=C+^=R:)LEY%;)EDF.BG<79J52ZX2P]_7BYP<4P MWI:\/?V@QQA.E-F9)_+)&@BDF_X1YKJ\1EOCP%;G/WP;>L>=WCWD4"G M:T3'*-'^@QUX1/?P#@=L%8E@.XH3&[3(-CE T*&PRD+C*ITS%QI&>FCU#L0I 8PL Z[%(<>?3U%C'=E%FPS"W(2[9<%NV(7N! M_"W;[WDAMMS&N^TAU0ITY**3FZ5AC;8O=8(AZ_T;7\#%-TOH[P8:"@E8L_ MG0B5Z:RRBC_7.P9#7Z@6B*EQFD&LJQ4;(Y9N*YY(G*N15&-0*W^G\42P3_8! M7_D'VZFN"4F_!AYQNU-8R0Y0U0L^A(+'E5LZ(RWB?,2>&%97'?4=G96 M+ 7"NB @GP:S-+P+;_?)]^S\-P_DIY"F)?I>^"L^/.) Y B*4DQR4DTUE;V* M59K35FB"[-_VB2 MG:Q%A7YB.DW[1?8FT(GB+EH7CP\+=3?F\24W*#ERC@W./]O.A90?,NZO'>H3 M+S>+HM_"'YKH \1J)J!9)VX\8U!'">?4+0=W2\\8=VGUTZS+S:KHT0,?SI4+ MR=U0%")S4I!G-!&ZZ3AN#3&X:TN%[>JS4*[>X:C7U+*X+C^2:-X/& OJER7_ MASV'UN190B+TB/6B)*KHX1G_:@=_Q='M?H\#QWOBSH5;'C:>+B721+K\U6:Z MGJ5U2",4/6,4BT.I/--ERS0AFHH1H2^Q1,,TU@K/Z@C/3,Y3&YGR1*=&\W>=7S@@^3OTY@QY>:US!.[*E6B:$[A(6K@F"OT:E+S2K!.V. MZ)B.#""=7^A510+PH6L9N+V/G*<;=RL>K)4?,#U *[4NW\=O%M.D(O3[A^L_ ML]L-S0[#^N@]+>H-.=CJ \*2!F%D2,5U\VP850<*T<'0,AZT(#SYSX>_'9U7 MVV7[)-&E'01OA/2_V^Y15!U#[EV#'9&40O(1?#Z9)46[6.$=NF'&?BC(/D-V MA%+QB,D?A#,OE3LOC<&?E^"S^C@XEXW.T[KJL8(#8B]>G&D,_:(-_2-^/OGFD4P;U-X^H' 7.EAX5V*K@-C5P4XK6Q<&< MO-'&TPG%%]Y>>]L VR&^PO%_E;Q"( *\2^+KI>"T\_1 "TE;0CVD[ M Q7E:-L(&M 4;)^(ELS[<9=BI*6-8]RLVN3)D+G9Z]LYW6!/$&J[=DAFD:S$ M5F.V*.=!DS2MM:[@@;-%LE+'I-"1 ),#G$_6&Y*E",D8;X0N56(''SX@!_[" M\LZBV^#>>7J.&I:JQ<^;9T1="04O6EB3"C$2<<@/$!,(NJ*M"Z+5%:)AQH@= MD$,<@56TK/]QF[BD!_]=%^]XJT(M;YA>(6Q61_X:H\5D.8^7##/W^9J[3\#< M9YN*-;R:J!5C(0KZI%?XF&'^$<$6(^4XEZU. M2EAE-%VIS+B2^P9T=ZH\+)M:U9%FO;<9PZ!3 \RV3G4\ ]$F9VSM6#L/356Z MU@_?<+!U0H6N-7]C%%UKIHY\.-[,5Y.VKA6G8L?0M7;%V-*U9F+'TK5VQ2GJ M6G$30+BNM<:YYJZU;)7A0L%'/]AC)U((!?D;HP@%F3J2[C.;+"?SV:(M%.Q3 ML6,(!5TQMH2"3.Q80D%7G*)0L&\""!<*:IQK#@5EJPP7"FC94H4XD#P^BB 0 MZZ(P-UNU1P"'R1P#_3NA:^%^+',LQ.^$4,1Z1P@-CO)E;C7SO6",T4RI;UJJ M#K6\!#VQOE&O;3-?I&58&R:=-] U?[2B;9MBMZ %G6;7'+1UIGT#7D>'JU8< MT&[W>>V12YLNL;U_^V!OG\O/JCB%DEQHOJHHJ[2.M&RA]!G*.Y1"&:NX=7K# M'FV_]M:(N#^@Y2K]+:N32E>R4]-@:IJD%QY=?.A"J]80HFSLT429!_O1%:9. MB5^ C@M,"Z5>K7U]G,D<4_?=!61;URT&"CK-KQADDEB-51Z@&5R**0@+DXT+ H$HI$VA%85X8^?_ BCZ8R; M(VF,.^VN5R)/BSE&QAYZG8KKA\< MU2E4),Q#H;5%5.)[,N)!.=0W@9X>8LA M+5'C9@]+C("Y8K>7Y++ H*-E-SV\R\[N]O&=7,C8^)UIII)6NYFI$AS\"/2@ MQJAR?/3EL\-O:;GU]L\G?!.&'2)U%/QKG>T? M%OSK#!')=$DAEAT?;LY+]X.S2!/N(J_"&/<+P?TJ.LH-P*PV5Q5PK=% P.QC MBH07Q^C9#YR_U[(09-Z 85M5#97U!EZO=!:S*42Y2'!F]<3(852R=V W8@1@ MEL@-!8SB&F843.+F\K0]#2WZ 4GI@U<@HNDOS72!3J] MI:K/[3$*(S+G%A=3:WP%DC0%/91B\JR).06A(Z%/=YAB#OG-*,&(Q/'&1C95 M;3,*2GT^/H;;P'EAUVC(?N7R2Y"T*FFBY'%S'K'88)OPJRAU),SJ@S2NX?GT M%. G,J5 ?EJYEE+-=NDOLAMU:8.C8AG701MY5K>4GD3LO!W1\KCX.>.IUQPE M9)UFM9S,%ND!K();F,ZO[@^!LY (MB:O"U-M,1$N>[J!$'G:M @Q<._76!RQ M^AA,#Z=:#6T]YWA\UJ>-9);5!11G:/C?)S]/)I-IOMYW/IU,SB;Q_^IK%O^" M+.O,6D_.ILL)V[2SIF>3^>ILOEF79VKLCX4!)ZT1^2LAQ#.:3<\0[138$U=X MRU;#T]^NSA"1\8*W]"I"]XT;*0%Z4'%-.=X'T=A+_N8Y$?]R0\%#,/UC00/I M*#Q9+>?34N=XI%) .L?N^A?C!),"63>X+QA+"8S!OI%#@TK'6 6MB8->>'0C M>L*JB8/5A\QSL**!]&>?3S;S99AAAJ5'CWP?,I:)WNCMQ4WUY7B/&AV>UMN7'\TMYM-L'RV7DUQ"#5E-KC\J M2Q65N>&@V+G*0T*!#;HS(L3;GY_\UW<[[% RS.D/E /S @?(K_Y(;AG[Z(1; MV_U/; --J+5, MZFD#UQYA&IM47VRW :83Z]M]VC(=O_'F=G(OFI[\2VDE[3.;V7*95 EBA' R MR0C():-,-*TFE,4'*AU@96$(U/%VMO"[FK[= M9KBOVP&HD<45I5B4+;C(FPAJ$%'03KP$PWG0\-"AW+K*0H4H9$ NOO1&9*DA M,CEXX#M4==S 00_/ ':'Z.>7 -N[6^]W.W!H18=[,A&>2GW'AM?!V"+62 YFEX! M=W'@#/ZE7@'C8ED/I3NG1F3L4L[WV<6;0X)3C(V]8+%X^$!=T?5M#[T$CK=U7FQW M+*GK,E%#' 8YIAE!Z/,],B6+'!*1R_K=[A^>,;U4+WJ[] \OOH=E(Z.21+C MJ:*F@A]/YC/!N*;0XEE^87+<*)V3QFVBK-%1T'E *S&V_VI_CK]R4(D.<9(]:P,EC8PL&O0U F_J7(C;?D*/B\0-I)7SVW=U#8-,AV)7])K>HUR9C#&SF*:;D MRZ)EC!*ALU90T@RB[8R,TQI,(4'K*#-%E)AB)S %.+.;'%^*W$*+PO/["F>' M^V[WQ449MEHCY3HM(L#8W:R7DD>O!>0N-$&'[J4ERG@!+F8RQ(6'" KX8.W(R-\'!P^XFKR9MO3L/D'155D MW6NQFBZM52'IH+#[1),=;_>(+0D1D9")!CV@<;<*34!322GH@<]*UEEI7& + MR5LR+7\"B0*29!+LI==L -]-?[2W6&%;HO X6/>;ZZ#4PVP$72T5EZR2C:%/ M[8Q.N+AM"['!])EUEQ/WCQ5KC( O ?[;$7O;M]O]'=N6<;9W]MM!=O&ZX74X M/@EU4EIPY?=#A%^I>!J^TP90TL(H&*<+/W>[_25%_!++1/NTN1$QLM6I&QC: M;#UXQEXG,PFSPWXW99E?>C9WRO_8#O599/6Q\'8 MDNN@,K59BSJH^.!V+' 4A.F,C\<8"7PPG*D[GI@T%8O LR89FM)ILEPG4WH! MC#E%+92BL8@[B4"V/#B*K80>"/G3K@1@) ((0QZ>_XGI4S/*" C48=%C-"L= M/:;W"]$V_!A7-/KA9'RZQRF#XL7V,7%(=8EBG.L2%:WNTO7:+E\X?WDLW,HT M4CFRLA9MAU=)=H8R^7KYMHEA>ZP L\(Y EWHV9&"[.VT%QLO^6I>*\W"LHG@ MZ=AT?3?O23"B*=YE389(":L^;Y_Q[AB7$2\?RBEP+82]O;L_5$L/5!AV"2_O M%MD%GC>_>?;!#R):O5=0W4+^/3!.<911F<)O1-.L@MR!BCN4.ZP[]1-P&J O MASX'QP.I>!Q. \R5]*$XF.#1P$1Q*!'9!2RPA.&1FO72#Z/PVMO2*F^[JR.] M!N,3,8@=/M\&=^3+.[:;_/LAL+W0WG(2R/3)-1V8^BBKTE].Y\7 E;2*6+,H M;1?%#:.D)7I=9=)V]JM"ZX##!H-&8X,,(N6@0T@"7%/E+@D_W7:Z%!X$( ,>>LJ87II5:A Q:!8 M#BP/.N.Q:GC&X/IU+^(Y?@4TC-N_!'CKL+,&Y&>7E36[\'87\0B8=P9!Z56C MU&C71]ZYEK-95LLWETM/(262V64Z1=E0!-*.VJJB9E#M%JCF*";OL67221H* MAH:!\VK3&Y@N?8]5)'X@3;;DLC2\8I1V8CT48ODFK^&1RD.I0/",%FT(K2X( MS3&KW0G+C&JQ"RR3\@6=>R?\:V-5S(970)A4UT/>SU;68EUC4C'K$+1>IC:$ M529)(33/)+$3\IDDL LLDVX<^]%QGEEA4<96VEZP*)!&B?[P/$D@9B MS,>Y;E/R\#I@&/].;TRYW=."@-@+V1K"/7;ICCQ;U/Y,:R4^VB'>)1E>8=L= M6/V$&N5/'TT5!OMDXISR+;LIR-^C8ILH:33=V6'MGK.&T^S($/X*+I,&LP8W MF+EXH(-FY?C1^T.,.MZ\+ZK=>J-83ZECC#A\5148E,_[>C((_D(SHS:+\TQI M<'2$JL1FRD!6?7JG8 MQ!;8!*Y^6]\HDI=WZV58/2$Q"1ZDO0]>Y$1OU][>#PXLE@@F8/+O&0]T$DI) M]].+Q7R:QK1$+O-%S"0C)Q=M.F#I1SDMH:11*):,"J+!9H5#@;;Z@S83;Q0H MFH<667MUGY^%>/OSD__Z;H<=.C6;TQ]HA)D79F3TJO54E?BN]?CXQ4?RN^H> M<_.S!F9/C0JHC.\W5H51L;3D'"IB\LQR2"V6,,V(_\1V M(,>'_$D0-F3-*SG,C,\%*FP<3.@*B\N#9ECF65!S+CX'RC8PQX#LQ.&5'56/ M3XN?,^S]I<85G&0^6U=\/XF2M!CUE?';0G5!LE0AF?1ZKD-5?;Z.WIS'T[R_ MA@_#_FS8OVF;2K%O57%K*@#.ESNH;TFI;])OBVY1==<,(,1>R@<[H.>50\(9 MMD;;LBLK?-S@[H=(!Y4XMTR.MJ:R:)R+=R[ =T]:?0N00155%#)G-FEA][JGQ5>I;]FB6B)X'(3J MAS8^W(TCY/IA2.NWQ]> GK&;TV.T.S%:*'X)7+2)9CPSC8%M;?OXXNS'4 (Y?FO'QW/]K:. M[1;2>!N3495$F*25@EX*XZ5%FN62RD>%U.>L!>DD: /D&\X.5LD.['[GHU(FUJ@:$(?*+Z[]A_!D'K\X6YSDTQ2R;3_2^SY!TT!=?[6 7/OB1 M[1;_3M-O/OG1?^+H'F_])X_6E1-\DR$WDA/FVN:UDYEM]P7M(6*:B/^("PN M_N8%F=#XAO#D8VR+QDZRH;F78H4>\["\D]+*\>B4%K@!F-!$8B M;>W;:4E53-7ESTRYCYA.0*RT+YW_.EU8UCS.-1'$"![V?I?CRTH*.:/ *TK".)GH<8/5254.EWUM-JCU_HG,%7@_0 MM+H!--Z1BIR/V_EQ;3)\/DB"Z(W>4+ MY>.]\%AJ>,QY.=^1RF[.00XRI_[;D2C3EG=;?LCD[+G4LDHR05I\-98 GU?; M!X@E#<38;)CK-J4I&2"8\=%V@M]M]XCC\@\7WJY0L/57;-/*$;M;[Q[3 M6BIDJD$>^.33?:_XGS1!-[QQ/'P=8>%]]7K;,,A$K8HKC-TG5I)U2Q5 3(.S MM$P+3>XN:(%2-1"K@I6TS)XJJL+RX$/TA6J#F#I 00#2I!:$24W%GT&(7(Q; M^K_!,R(>2R&N-2XK&\U[,FZH'> UE+6L :YU2=!)> M/:WW@YQJ5*+OLZR1![Q]]IR_';&1@5ECLR<6PYJP*)%UU3FTG:%,"91K\9T, MW#3:MVLP[&C?4XJ3,H% =_AL_;+?450=>O@G;/+THZGBL&>UM#;:(^FI#QTU MF55W /T^QIAM=#<0-[N.1 4IS14M"RK^[Z--]Z"2B\ZRTHVB06-?::83I;NK M*LVDU7(V7\4YU04F):M*Q16E8HOEVI]#C^MX0=ZL>:KQ>U3F:4[P-F:C:C#6 M:2,CR>/]HTR69][3Z#!!DSOP @QBC5GFE[Q$&XDJB%V= ^#XUG!/![BE=1D%;&1_G M$K?5F*#4S6^";+OVOO$5"*)R]%!RSGEMT:4@$?Q0F$:8U753>9C&6=;@CEQR MB8PS%DY)=X/<=X!9U>6*\?7$:J;5>'HY#4B;TF7&QB>YWDIH%%!&77LOQRAD M*S6SQK)>36] L*FNADKL7M6X=(9BB6>(R40SX )?^H#&RR,2H(QS2.Q\7 8) M+#$"_K";OM]H<)+9<^.^ \>ALB(J<7I6/U*4DB@7.H8--0U \YOL8U0OV+-= MNCT\(B;QW;"!2QR+C()-V03U=G^%]_;1;9TZ-;P)R:RZ.BIIP\O:'EF!7YEH M.O=/A(^$9KU1)V0K0;0]1"(_81[Y>2>&"T8]L<\V$E!@*U :-N=5Q^?W9*=? M2K(@J*JBH+P;;R;USO%,XM1[% V^-@#QF^>_QCBX)4Z-HM]M+:\MR5OL>7;ZI9G8\F@X=L=:2#J!$:) MC_7S X]OJ+:W#EK7:&P&JRY5*1ILC#&J%UF[QK/NW^K$8]^-;-D G4V=9H2[ MZ7!\?;;@+/9)CL3.4%&A>/:%RBJ-J58 G(%K^8TR"$;1&^8&"YLUXB@+T M!R-5"$!7,Z<9'U7K',T6LV%CXRA._\/8=="0.*+C_YJ)/5 D',EQ+0U -*Z\ M23=UHM&P2VK=AG,P13MS3VMI;R SUU;^[@CC<$!M&U]$]1<[8+7E\^FT7;Z6 MO##/CJ\N8%=#?G6BYW07_WN)D+H6#94^)6BDY"5ERZT*-KP)$5,_*HTNM6%5K["YE]U$;987F871Z3 MY_M:S^0[DA)HDZK%F>.'U4E^-9^G M,$]EVM'S>'D30+6VQF'NAG*SIV1NR2)>X[ YZPD2TS@>VMMIB3CX(EX#!])Z MN:\AO\A81G\RP$(!,EX_-&Q;P./+W@!4YDS3VE'9\O+&5[D(6!J^)4O1>1 < M+NJ]X,#Q=Q^\G>I0UK21Y_&EI?3R9O1HDU>V0QKD8^?',]K ML0KDF%];Z&J;).@QO]Y9Q>T^V0')MSP*2_P7T748'NE'HUH&.[R["*_P8T0/ MFOI'KWID1JMHL#E"/[VERZ).)M9L62N@Z^_1UV1+:I=O0A7KZ=H1_H>)]ME_R& M;6QSO:S]+>-!MU4E69]>;:;335J0G$IEQ6>I3V\SP32?(K3C1("0"C<=)G6C MG>9HJ5@: 7/!Z-9#5#3]+1,.$=AT([9RQ(7ORCXUIB6T7?*'R$Z%H"M_VEL') M>(LJ"ED#JU4R_DA$LK2ALE"42(79W=$+U:I"M4M"(:=TDDY9G)S)V&:$_&K< M5Y5[=SQ<4]U?W,RLF2SC@#=6AT!>(V %^1@V5)7<5X&/P(5X_NS[NZ^.*_S: MZ9]-GUXL9V 3E5O_%!T/%OP, +RQHH1?%UF7)G M*)>%J#!8'O4"QDA3@./OT=.(*,3W,1Y?.%;0LF#Y[SC8'ET-MC["E20[J7FD]4LJ5 2BT*9+/!:^7JP61VPF>J&6]RMV \W M&6,$3+FA+9$>L>%&IJ8WX!A35$/!LV;SI8 UJ4#06YCT@>331P(D$(=XCMC MHYIE1L2EQF.-S>_ \TGQ"!]UME4KHT#/+NH$VL:J$1Q8E')*"68!'T@D6@78 M#O$5CO][[5UL6&>_-=1T:G_/+,>:E5$9$RVG&<^8,/1C*O8G>B CE8P2 MT6!DTXJ8$2Z#]B*&9I!>?2&1N/"PQ!/)YB7C-&.&Y5W=6.?I5[#,:!@9'\L7S/%25 M[UY]%9J!%7V4_-!J8R 57LP''U&GUP]WVN\Q@#C.F@"M5J_BIJW,@ M3AJ0]ADI8:#DEM%0P4.8E+%B,Q1QIN+Y39D,=\@C6W,L;TB]OWSX_VP&^ M([85IUKR'S2=6" FC,C=:"RU%$9R7IL9$R6Y"BV $3O5JQ#X>W8.?%GW]V1;_CA;TZ"-EFNTT(SQ M@NQ_1EB(V51G*.NXG$>A*&<\@S(FB_JW=O LSJ%SJT;GD)WEJZ*N\U;]0!T M:9C&"0PP#@K(]TG5%T IH1Z$R4Z3T WC]O]KIDP8^H[ MLII_M'J?Z],:KNW?E/<2#($XFBC%X_0^:\>SO:V3U)SYY'O[[!-)X@%3P,R W5HY2S MZ7K9Q [0XZ):P#4P9 1'1)O=K8DEP(="?[6_.8?CH;%L:OD9@ZPH-:P04=?+ M9#I[HC7&GD(-=J_]-)7O MR.:3M(XK:1'1)E':)GI\0S_29I'C_82REE'>]!G*&T=YZS#9*T8MMDPM1L\H M$/KG%MMG=K*S!B''!'IX5!Q$:##TZ064ENP;3<)/)L"HI[S,EO.I[D #G@L$ M8L0X;X@:<._Z7T-$^#2 MH3]>3.:Z@\Q8!S7#&I$[J.&%G3$.:CK235_\&<.@)JXJW7 #5OD9LU$A;UAE MHK\LS%B2&N _4AD_H8LH"IS'8\1*%40^NK/ABC'T@6>E\-S!;N^2&-YT5G_9 MIK[!P%#W_PJ_*RAA:/HU*81+P@>)-1[Y,;YD/8SOTHO_G]Z,R"Y&%'XR13%& MR:ZFFX+'33=9//B*\D90N97QW3,YL$E8#*%UE;U(;!58D04FXDZE3I!IK=,]4":)I#B MJ4*UOAG$YJ@>7%:"ZYS[K<#V0UNHD^V"-AE!%X>I9>X):?@U*D5/ 3"WHH*T M)\QGR\VF3%IV6BAQ O-\[0=D6@1"Q0Q3>%.6I/W E/E9_"R0W!10HDA+'FP] MC#S2%*C;_8>_'6WW=T)ZTJU?>R&9J[BL4^=^AK9WC+.U12'I2TVMY<*:)MQE M,FE2"Z92T6LLE@3U7*YI+NN%.2W#9%)1(A85Y4(P72]42_:+PH4!21[F04'& M0EI#!"L/%]X&?[&#P"8MD'F\>]S1U;G?/*>Z=J[R)E2X:%9+VL4F,UH?O1(T M6*G&$/D!^II()WX6BZ<;24?2 %#TT(JZ&$-N]W'EPQ#=!BB5CE+QY =$&P , M)EJ16[SO#1X^Y#A:"R(2EH%8ILM6_063??%S!A?::HTK[/ALE@F%\GVQ8>? M;8O0?<$4*E_EFU9CN,5)Z$K%Q2T^^E%X?LL6M?AY2":H[X$2-YJ(& &^(:P+ MGU7&-TIZ-.W1-ML!E"ZMFZ^\)R$HTFFK;YI>@I([3VD[%KC/Z(QI&1<-",OI M#H)$,^.4:-[0%*$'I<$-O:PH_'B,C@%.C[;$9UG"JZ.H^)OLVQ!T:59)P=V6 MZ<)'3J%8]AF*I:/L_%8B'Y$&@(FE%7T^1!L%N^1X@U"#Q2',PR; QI3:S)"9"8 MY^D="%VSUKC)_=770^U4SBB)G2BGU 5UI_57_S1(WT])?.[I.^M$)M[9+5>[A(WQY(Z,W5TD%AU[/:U/55IIG;=(%];A5 MQO?QTEV'E5+:K\=.^T8>J-)?;#DM>Y:WP9/M.7]GJP@7WNZ]'3HA*^D0IAN# M-XZ'KR-\X&8XJ+QN>O=203=I3UQM9NLD[Z$H'A'YB#60E##)FD!?:".(M6+X M#KKA\$_'A+]Y2W,X(U@:C6!DZ[,#U;/]3U4S&HI-#_0X3;?/'K\ZOIC$])+> M8I]O%NN%6CQB#8PN%'6!K12&!H3=-P)UP:X4?<381Q)X2CQ6"#JYY4#F1 7] M+GTO]%UGERI;U)*.W)(;5#Z3W\2'0-KVJ;7(-CE7TJ&PRMK>+80,9#UC4S.=="Q-T[1]G).+4ODE.FU'/+4W M3C8V-9!06Y@2V1LD8D7/.+C8;H,C MWDG?[-KRDLEHTJB)@A?/IND)1)/Q).6.) MA^U6T;,\0MOY<'AQ_3>,0V[1=_%SQA<^.$I(EU&>39>KI#IV3 6<"C)\-$0# MB@*A,T% )>UU0;)4(9E9=6B@1[[$($(/UN]]\CV_G"G)/P N^9+I?D^HB7QO ML)@L2S0IBLS2>!.I V7R2G5\NJ 6Z.,DZ)*.[R=VRR1X[]?JDK7>K]DT8-RZ MHU7WG5VBB\1XDO^":4YQM5 87:U6RR*?$G'I<9$QC"%U((QO64BP,:G@Q> MMQIIQ$8 ()%U$2BB$9"L[:DB$G6?24"P. M^/8A70"M;@"-L:?-^4KD:;0)!'?NXCNBPPMOQ^:!MMNVW=/TAD'^-*BAXF"; M9$TS%<<6,%.!X'LM^D!:74&:XI&$(Q:9U&89$"Z1+_')/C1=!%YZQ"1;"NVJ M>,XLZ6#H^X@* +WMNP<*2Q:%,7_G.$O)P:M8(3VZ\0KORD, 7JUZJ_5BL9K6 M_!KTGNY>2*J^/8)+N?F.P_-OX$NXR4QFC\GT9?*J,/8_0O!/TKE0K*,B7G+;%/WE+PK(PK&5T-A5">$C6QRA @AF51VP#86%:PR%@;='J,PLKV=XSTI M?-[B6\!<*JBBX&Z;;)E 0*B"V/&PJCO61FKYS5@A^<5QSS:258T$SS0V0I7Z MS/&38(QBS2L-@43=$I-T-J)NJ0LT/FG^^^3GR60RS>=3YXO)Y(S\JC#@8\O5 MDZ3/8O\H< S9$?J5\.(9S:9GB*:>L2>N\)9MK*2_78V'BR4'%O,OM[&6%+RR M\+0HK#@5K_%YTREY3@*P_+*QH-NF?)"AVYXO !B"%YS\IY& MC%9GC$:R^628EF7UM9I%&_F/W@[O:.GG%M+7GH,@>U4)20^939:3^7*=DYS) M89793>??:D Q+:-@@J IW!-22MUS:4S&*"OB1XFJ7/BZ*$I3JB[)D\[6=A\" MQW:Y=4SX#P*0M*Z%](AP8TT6LXRE+ UNFTA"$1-EGJV]X4R+<%))*!8%P];> MD"Q%2*;(*F9*D:T"^$!3V$+"Y(6WBT_>A"&.6@Z+R;QI=HK;IH[*O' U+=,F MDQE*1S=J J56L'W7A*HF7!+L*9(/S M=5FV5N;O4O8::0!JR_M4D#"N@-0A97*]W"@&)OADTQ(@XW)A?JFA- M0$Y?>^$QL+UMPZ)X^3'S[,S:5MEH62S*%,R$@/*K*Q1+&HIAAM3 M!PWCZ?X6XUWXD0"@.WZ4=K?[2_]P\#VV2"S\:&WO&65#BS(*/C699ONBL=#X M1J%4+*TP% N.=P*@**,7L%4'[!0 ;V/ R2:JAR/ZR^R!K1\.-&=\Q<&C;]82 M4XXI0MNMF0$VO$ARMAQP9 PUFA 4?"9&9W<3.]&;RKJ6TK2YT];6GX/Z_89*KYK? )+22];; M%M/%9&VE6T*)MWTL,>PV8=AMRC#$6C"]430$[.E(8+?M* V!G048]B)ZX889 MX&NX%;E;V("2MQ9T)W]/9OGQ'1ZW^RO\*%X";G@%J&.OZJ'2O:T6O"[]QUPD M<;^?$)4*WYGWQ,E8]H"# W)]VR-,<[RM\T+W81*I8^G 1:XHZKJY=H'F$QN^ MQ_4]P@_?<+!UPH:#-6WO 3&+JXR"V\TM[KP]3M=+Y*),,#S#=.#EC):C9XQP M(HYU9PR__P)^&;*TPXJH)S88$/]>7?-,8JN7$8( MYK>-FX3%)TS[KO*&VGJR+'DO:)6:[A L.0A&?5B\%5C%J64-,)NH7#[;P1/F MS[2;GC2]PL=70WIU9S6W9LE];YDDM(U%T7'PC@@SG.6M!=&TC.@R1V1^H4 ? M*D;0#S07I/?!+^3C/MLAOG@*,+NOY-(_>L2B M+S89X;764I-_WV3/):N40J>PF2?GFXJ2QE");2BPECI88[VAJM.6^DHE>\%P M,L3T@#B965WA5^SZ;&[5?%5!\SM&N=>@B,(T8C&=ICU7+# Y)9^)3!-[H5BG M#Z95@[G+1<+R3,(1R]QJL\KH^-0\\Y)XSY!@&G-RI'W6=<$74 M8TC_5'!9:?X!IXD2W:+ V49X=VF'5$/Z'[IR^&J[=#?L$[%*X\%"!0%F.2FI ME8*3+M.=J%PZHG*9K[(?"BVSIG4[P@M\:6M !,4$5O MKO!4Q6"P=&6[9JR$P/WGW]JZRX9W0$C)443!!V?+18V'\79P7 ?B1R(T_ F^ M?]0&UFH .Y)^L=TK^4P3&0>&7!&98.+=!SOP'.\IO-ANCX>C2^L97^&]LW7$ M?6#KBT9IUJ:-O/NM)\MLPA=+1:E8]&-!,$HD ]U.IQUR>C5KAF\7BX%EF:Q[ MEJDF91H8OKUB[XCO\=9_(A' \;T[WW6V;VT7K[>_9Y1M+I.2C0E% M!:EG*):+OB3_!;_M7#=R2X /PJY#.MIO@@9 MOPOJ_ZJ:6VV:&_9M?@)&$1N$I\8)[FQT2-?^;_V%]I:RJ7'K2^)%@][= MKHU"D%RMDA2D](18/ ^ W>C2CM!20VB*+?(.6>21I'6@&7:D\R[RCT)!_&NO MH*K$MV\5 <2Z-KV4O'/!X=\9BMM@ORA>_( <#Q4:@J>G9E.4B)H>(<],D92Q M#WV7&2)J-@0$BV6=7L1G*7.",'O[C'='JBB9[-%-]#"YYC*]Y1+O;AS[T7') MV!2'#_0O;5.N7B)-,K^'G@KNOYDEI[C3]JC'IRVBI,G\>E02"PJMHB^L7?@) MG$%C61QC,;LDNV"@ V$=?"D%B;YV!0X:7N3L'/<8.:_X,]X> Z;FAV];][C# M.WIBY](_O!SCC,_;?;JPE-[VQO"T>YR.1F "BP;-%::,L_F$$VH*.J!<"91J M$1\9*^C!ZDFD"[?9]8I))((//^9-6@](PYL4()YII+(@PNGZ=*<=\^2'3[H: M.LG8UV5E>,(;:FDEZZA&8C 6KH7#BNVNJ$K$KG_!SM,S^>'\XA4']A/FW,S& M/L[Y58+A^XB#DJ,]G=\.-A[2TP^*$T/.*R QJJZ'REQEL:E'&RIQA*&B-]"8 M],?#P0[>&.?M('AC##[064L:!FSO[9]#],F/QC)+$SLGGY<"0\$R[,/AQ?7? M, D4P:NSQ2P"O+=#O*,F)U-B%B0N7*8+"Q?)=N+?\8X$#,V! M<%LS"!6^K#C3L%0=E.@3]X;GCU0C5%3I#.5*T1=SM5"L%V**C3#(P%H\CE!T MM?7\?E@?C,CVA#?!78)W;ODH),'_W@ M]H6,-B/2-=U@@E)UR;J/;) PUT-AA66015KGI1C2XJ91TC:*&T=IZVCO!RAK M'\4*C#!JF3-@;>)4,2!K(K^24MYN="MU& M(+#1YQ<;MM*_5K;R UO?#Z>EQ$*N3OGZCC"]OR.]N8-=X]$8C/K+,UVNH8^R MLMQ9K:S9FK30=O96: MZTH8-%4M&-=,90M,!5:?0D>LR:I8]#8U[!A0,(RE=QD_L8H X?NW_)FD7[CX M:@<[N3W'OO)!QH(]E589SJ2U-(H,$LUH45$#]/A6>C#1 C$UQK+):-:0M5 T MK"'-#P$UD94_#-3QK<88RXJE3B^VD?/J1&^*D]G.@D<4O=JU56#;/$N0$"Z^ ME6H%GZ&TR1%.7 W9J[KR7S109IXQQQEY(JD$&$D[CR6R%.->4?7?;?<8!\PP M/![BWW6.,CT: 8XXW3578A-G$4W8A=="4:8+*B@SZKADS*IQI3/;W=+#JLF^ MR4?;"9C-<,E>OX5TX>R]:Q/3$IT)MC -9K_Z.^R.+9+U)VY;5.OYE4 B',V8 MH(>2'Z/&SF5R MT 7Z&DLR7)I7 XQI"48B"8BFNC!9/$RPM6-:*9*O:HKP:V3I>TF6OA\#2]]W M)A&@U+^12IL)2#'V0LR9W>B\9 _(=- MCBJY&B@,Q99IE2;1&AC0Z%('KD(.6(QKVX++V/BRTH<9/H+-DK2E1)TDO' M1'\CQHSKMS%+O":6>!%: C9@].-=>YCI8>^3#4[W])22J,J5SA9.+33%:BOU MP/.!(E.LR@E'IDZVY 0F6D3YY,-2F7':HU+!UF!!Z;$=PV,[!A)?MW2*_R3, M5QJD+=.!2C< A?Y_NFF9#/4,66HTJHH&5*V^63?5\A]Y/OT>D"WL7E4XUSHMK^=Q%T*Z"4F&Z9 MCKJ9LFGAY.\M[/;[&BSNYA6EDX#KY_6UOL^@*X@+9J(N[XOI22X:3.5"P;6T M)EM2DNW#-QQLG1#?D8Z[NL8X$J6,ITU!(Y8_QSQ;S>=)CA;5B#=GM^;.]+W24>:/%<^YBGL1Q\*_6BIXF** :55&5,4B,& R(8[L4_'>MVLN"7? M^VEWG.1+ M8+@#9L/?$/6J/O<)8D1GZ/Z:4QY/>7OA<%]C8ZVBX]=J$]V6$0 M';^+V58'X IKUJN-OH0+R1E9 =!9O2_)0*$"*G;4Y]22-T;P9?G]3)"9>%LP M,;M<&[C/&:7-S4X.NSK%26WB?OCVX@3LX?:]$"WR3V$+MZJTTL[C1E\4S]2 MWZ< ,&,AT03GEAA)-J].KFG9MN4:^Z0&Q_2,/SOB7SBB3NN8T5VH*^?5V6%O M=V]'C>ES@[9["H-863!*PY>UMI#&K^/ 0AU3$:4Z(JKDB0TS![(]BX.9@7:I M@=X<[,+'01-$US+<4_HX)S6$:T)&1Z7:\_+:&SR%05XK"I7ARDI?#DMKB'P0 M'!L8\4A0MZW+(3'>T$"NL\?HQS=L!^%/X'%Q4")K&3#*?9/O9@3YNT^K2;ED MRF]Z#%EI^=1'D64X*DD.RY9ZC3J#9*[E]S:2[&7_^=\*\? XRO/>+P.(Q,Q4]NNZ<:/7E@% 8]Z\GP TRJ(J(ZHE3)[R5T M:C!^G!5-Y)SOJ86.AZ\CK'\[/A=\"J$O MTU9A7&)IBVWH"VT?,06@ZFJ:MIQEQG*CCVUA#F.H-'T*44T!CQ)[]27\T$OEDL+7]=R?2J+/21Z^&.X35,Y=I$DW)W_R MH@/_M81,U2]U6D&5Z9T47 \OCM&S']#+5;6[NZB=DPB7 N65%OGU%4+(N1TK MA'*-3BT(ZC%LG%CS]!3@)S+7BL^1A,FE[P=BVKAH0O1L1^A@OZ%'C';8=5XQ M+5T?WV/*.4)RFC&RAZVY$XR%50Q* MJU#+ 4-BJAB[?YBI=MJQL:>A\UEUB.R2;?;Q-<]/(A.=6LP3D7B(T,?]*">5 M:W.;;O>P8T@4R[47!8X7.ENVKJD]UZ:]P5/(M6E%H32"T1<';_-]XTRS,Y3I M%N^2G%BNC6Y;5T:+3F:<5RJM9#KP>#@HI;5DW+M!!G^:K#LO+P7Z'".!A[@A&*IEK-?X#4X\H"E4 M6C'=^FD&/QT5'!AI]5V?P0^)HZJP,>X/43KB+"@D\SW&4MFB&1!?[\0GUY+G MK@W,NJ4U.$3 M'D_CK,KM@Q_9;GGY8]@!3W/3IS>2;L2C-'K3=\*[&JIQH<[VF)96QV5]R476 M$ZV\W2$ ##!@;O]>IQA5/_K!'CMT3S*\\ I50 :[W4"ZW1.*IZU@E/9,!@BF M!061[>T*I8$&N\9@$YO=8Q%IT&5;[=87K>,F#=$CXT%<4^BT ZHT]W5&4[FO M]5V&4H!EX'XZ?4\A6--*Y41CJ0ZU\/R=+B:;_'!R2\S_<&'>] IT_T_^C] ] M&%G9Z*G4=]Q!=)^/3_75*>G=0WP7"R9&/UW;4LH_>N\P_'J+AL]]BOU#^0JW M/P=^J+T80$-+)Q3).>HK<7R 7SU1DCZ&Z+6:8;;_O:UN LH*/+1"T'[3-JE M-Q/1LV+L=LC$?@.=IR-!XM$?N\6F?),U6N94>IB&P*:SVQ!]A%/L"PI'G8U, M \3MG5"_( 2AM$J@K_X^_YZ4[V)$KLO4;8/MV^8#PJ?0-VCSRIZV.I7>HC7T MZ>PSFC_.B?<<@QZC.:0OW _62)WXFJ]OM MUZ9;/\V>5-=1H*F^TDV2-U4:V$8WW?%J_!ASJ4WS[[YSUFC1A;)%I3KP$^RS M3&<>G,3-T#W.@ZC?.6H-=/:HBR8G=/:M SR5+-3U *4:NM[6?)IGWX;_0.IG MW]3ZR%,Y"M)IVEA\=5/DLU]7>H5\=^&[V*4R]<7:=F8*'P 7/L K M^35XX(>,0CI']OV^]??9"0RZ 23=_'<5XE77G4E\&&"[2#ZBG^1E#<-^#5&F MU3]LE!YNXT#I"WZ?,1A@FZ&G4M]5O-:S:KM>;@9(&I:/XM_EP3^C'T_NY-\_ M;!=@>AU>P[<_Q>5Y9=BF*]9I5/"$%O/UH5;)Z5R/JTOYWC8 P#ZJ^K[ F+N= M47R!(?8+-/O'Z79'Z8F9['+E83L73G,GUU74,2C%B.'6^ L'$/-KVD\Y?O>V M=&5M_FLU+ML'_TCLZ>_1GAJ,K=@7EH5./_Z*Z:T_F@J^UBA7=D+1%(7]WP/1 MC_0-=\3'/MD'?.73V-]U(MREJ3&MPG307VEZGA2\2VX>9D+1EUC.6*]A']XD MEI))1K,4T8-62@L,73_ :<4B4072(5:5]2IQ$O&K"S(E&BL<)@Y[%48^S15B MR ^C=-W(R LP#!(_](3CSE_R) -UN08%1)16T."40K0\+*5L@"'B<[T6T/<9 MG ?[)'*1^10*X^@/%UJ#LN(7'%%$9F-\HOWV&3]\]7_%ZGEN7 GP$9&GEM** M5^OAR3A:)6T@T@CZ$C\:8M>EG&"=*UW_ M+M;G RV]U.G+,&SL3?2" W3T'/B=U.9^O&LW^W)T#Y1PZ\DLH1O]#9'I!]&% MM[OQO2>Z27F%'Z,;Q\/7$3Y4RXI*O*"9CCM_>Z2#$1:DE+61=H;U9#U9_C&+ M:4H$(B(149$LK0%1H>@+%8N8W&$Z0%[HT8YQ"HM1&*2T [5Z 1V:[_+4H_R7 M-,Y@\>"!7ALH^\'BA\<0!Y@FLFZS)!W"9-X6 YC($="_"[06Z@\(39WU7?"U M,%Z,#XSL)5XU$CVW!\AXW'GRG+VSM;WH8KNE:1!D!'CGN\[6P>$#_A:])XW_ M530VDWO9Y#A>2B.%D>0\JT242T:Y:)3*)DY(I",F'FH2/03VF'G'P\$.WNB4 MH,4,H -L)5(DK>-2_E4N6"QD$<#? L57C&^=/D@%P.":T"RB/1<%=Q&D!3TH V[WEW;X_-'UOX87CR$[\]'V[7BO M0+""HX?*Z'\QJ_*##%2H1,1$DFB;"(7F2G^<5G>UO'=N_\T&'[E-+L$K\*PS*A/@I>.)OPV)9)1JGH,;%.%^XZ^Y1Q ["PU8$% M;&RV&B@K>9L!@H<@F*:T M?7='/E \S1)^H-J#1OV\VKI*'+72"X<+4OX9I6>'HBAP'H\1_0ST5/F='9"O M,@P+_,AVFUG0$^:2I7319N+,E PL9M)@*2'RM#(MN!88!S5:AV'"%T"ITF7H M84V5*3."X9A^$1[ZZ. M =W?C6^/H7F7X2?\E?U)O,PM];)I2K9JI#+'6*P+?$2Q:!3+S@XQQ>+/$&D@ M?@+J=O,AT%=JPH9,&')B0]"Z3"'Q;W"&2KMPC9YR]AH=-]D?*R=(=UW\@B]H M+)SE:J?2E\P&N+2:<\Q<+^$WL=4\5IBG^5ZTP8TGNG)T',>_.U-$.@Z(C0@6 M$V)MFH_VU9XSS>ABXPH^MTA/#R5#WE@,]$&\GH!8'YJ>L:.S9J+A,PDQ-!+1 MHT1)GM,8SMJ)_*O&EYHY0.AP? S)_)PFBKR2_VNF!/=9D[3@*:#@2LA>5TPJ?("/(R]*#C M$F4TV1@M3M= EQ%D8504:EV3%#X/R)DNZVWK]4I(&O@%1DT ^;P9$UF:5Q(; MS3 "NK"R@@WIY(*GX:B2JJ#D1VO! (P*@TTCUP*./PIK 0?$EZK#-;"E9(V1 M<*6Y;*[P>5B^J%9K)2.6:2-C8"O9:@+8Q)HQU*5M<[X6YD!7B"4:.3O'#MX^ MVRZ6..8G?-XP=[A*J+A6EKM$1(SDE)\F6)8*+),\:72T*D_$EH#@R0,^O/@! M42A>.'W_5CQ^V)3"*O&B0>:T:Z/B:ZMDQ2R3FF12G-&MGNHQ4\@D6.VP+0VP M33%/WG6+%)0TV0BXF"=\M*S"M;\'Q\2Z,M(>N9A,5DL^$4O93, K=+H!-P3+M1/^2Z6:QF H+!G][5!(]/I[$$Z>IEY>9E/6%EK-L? MP=0@@N9:9+U@6/(PC)0,@Q6FATK6[EM'@]7GC/9)E<85HO5FD8WV MTMVC$0SN^N&QE/"8ZW4$KE3N;GC003S?B>ABR;6W@/LW'J&?._]5_>/:/H>W1J]L? MGIT@PMBC]WPVK *TO6-\7:!%(>D)ZGRU6F^2E8*O/DJ%LD+9J5A$Y4(M'^@% M.H4&VK+*H!R)@09.!*&KC=%X[1-4WJN,^:'(3R%%#H9[*",BR] MATQ]BL<'J>=]\KUSN_ [>L542.;<[.@/Z*Q/ W)K .3&!J)-;EH:;@H-!<&N MWSS[X >1\W>\H]U MP#05+>1H5PP;$A;1,LS_S=OAX&O@T,L8+IX"S$*4>(3?]+CIP7V#+O(;3YNI ME>P %L4A.Y7WL]EQO#Y,TQJF3![DT%T?0*LC0"/C<0E:94/Q-I/HY7E$1OG' M1]?9WN[WF%8GD""[Z!TPQ@L4DO:@R6:UVE1H']&)+1.*4JE DWG-,*>P,"7C M@1ZL5B^L9D-#"Q/K\:')1""3B9#,;#Z$D7,@0SW1'+WRD,G)0JEEA4%D=B,2 MD4"GIIF,L_@*KC?T)?DO^'G67A@M'D;083+7H4K#XCI>",__W0X>,.GS>;,* MKK%.+[!+7H<-[YTA6'(0C'EUW4E*[ES!">C'S4&\](QY7U8.=.OT!N',%6"# M=@\8EBP,PS[=$*1K:"'\.BGOW5BTK_R,0;\N-:SB$.D&<2( N#9?'QB6+ Q3 M?LUUF*)?U]$"^G5XX>WNG:?G*"P7?6\Y]2'[MGDNM*FD,LQ=+4HL"5D&02R\ M?LL!\-&18>!;>N ;YIZL4W-8*64_+5LG:8,/?EIH-ZZSRRH#B'=/9%XSO8$B MH9/\@OO*6J[C/93,[QZZ%",>;B-%/]SI". V;ZCHQVSUQVQD8T6!I]G>BJRU M0#I^3,,;WEV\XL!^PG'1_-L]JR-_>XS"R&9I/._MT-F28'CEN,=(>&E#1V$F MAP6=-%3H)A?+9%LG;0DE3:'\/H*X2#\JM'>&6(NL2TW:!!HWF+"/5;*/G=@G MN:7E2&^QB'RT]0\O1#9ZS RSBQM#'HX0Z89#]$+,R=X"'63T(E!IS-'=]GJ& M('[P5R+_TGYQ(MN]PGMGZU1'_ T/&A]F\+20]<3%9CU9I .+6!#:QI+0+A9E M."E+!YQI$4XB"26B($8)&B!9#5\(;A#0Q)2\VQ?"CZF2J']#7B+_)O\B/]!+ M?,@__C]02P,$% @ TTJK3%!^R04*, 4J4# !4 !P=6QM+3(P,3@P M,S,Q7W!R92YX;6SM?5MSXSB6YOM$S'_PYKSL1*S3>:GNND373"A]J5<_+: MRLKI?E#!#G? .#LX-__C/UYU[ M\0)0 'WOUS?OW[Y[@M_GUS9?GR]GS]7S^YC__XU__Y1__X_+RXN;N M^>*_;> "9(7@8FF]^IZ_.UP\(A +[1"_)6+>^C]L;("<'%YL0W#_2]75]^_ M?W_KK /;?VO[NZLU]"S/AI9[&0#T FT07%U<7F8C_)[0\LO%W]]^^/CV[Z6_ M//F1Y_QR\:'TTS4"R9@.)@?_Z=W[GR[?_>WRW4_+]Q]_^?CC+S_\[?^66_O[ M X*;;7CQ/^U_)XU_O+CQ/0^X+CAO[GW_^^2K^:](Z@+\$\5?N?3L&1X+ M"V8+\J_+K-DE^>GR_8?+C^_?O@;.F_\@ _X#^2YX NN+F(9?PL,>_/HF@+N] M"]ZDOVT16/_Z9A^YNTLR1>\^)OW_[<:WHQU9-YYSZX4P/,R]M8]V,=5O+LAW MOSS-<_)1%&[A!GCQ(@K3I7=%6EUQ/W35EE_M!!H!GV#[X9;$$+;S#W'(B ';8E\/A#G6F]@8'M^D&$P )M+ _^%>^5F>/$$V>YK7=B@^\J M9.(YVNTL=%BLG^'&PRO.MKQP9MOXQ CQ2?;HN]"&(%#)7I<1%3*.3]Z]!9W; MUSWP CR>YRSP-D/7$2(;;A8$( S(H>)$+EBL95JWQ*,'0A3"= -6X;UO>7B@ M9V!'"!\1LPT"\?["OWVU$"+SE_^D<*$H&5HQ%/GBO<:C'_!ZG>W(PL7_]G=[ MRSL$#WX(VJZ$!@,H9 OO/10!UHJZA]8*NAA84%J$M2XMV54PL$(8,+X[WWL. M??L/E8M8^%F%+*0[0JFTYG]3Y4%$(/J$=66'K'0\O@WMF\#4*((07.G071[Y8;@6"QOL5?]@\ E"@*?B.KK.$U M0/G@_<\ZG)M]@4OQKGWV7> .P\>D;]*)J6M MN%-*PG#08 5^#;"&X\0[-#U>LP5ZP$K0#4#P!4_8"\A_O<9";.,C^!=POL)P M>P]>@/NQ']C4D:<0T@> +P)!\ C0\];"$B^GELBV*+&>+M8WT(VP%/\*B/$1 M[_ 7@*P-B'L$BR@DAD%BG9WA>V;<%+/0$L/^Z%<,*P-KUW48C_]!EZ!G<6ZOG MO66W17 @XI0:2E8!^#/"U-R^J);A]" M)U&1/:?LIRC9*XO.!3-+\!I^\H@578 MWX' ^KHFKM3.+'>,OCE,94^ U2XR(%Y+J<&U=('N;U[;CCY25)2NBVXT](U0 MRE%0/]V[#D"&V_HNOG0$MW]&^(I+VO:W\N7'&_)\*QL.G_"5*R2VQ !3 M2VZPL6DQNY[U>?ZWH6+D*/6F"[2GI6_$O*+D)3/5U7P&@XZ+@R43G^K MH7O7>FI62.5:#O/[*6?[DC6/Q$)76,2-@><0#W'R*QFL&5-1&,C 0=+,6A[]SAWP(*D.RV0]-)9E&.RJ+E M<#0FR+ 7)+W=@KKNU' M#D\VL;Q.0U%^!UV 4H\V&]=JJZ%H>P(;2$2<%SY8.]I:I#;KG[HELL@TY/^;R?H2IM%K*S#^'_K!SVQ[DV:8NK?9PL<6EOH9OK"6OD[YJ< M'1D5/F5W7_C( 2C.]GK_[MV;BWT6+'&?\,HD,*8N!"@ <4O2$_HDH/G7-Q_> M7$0!9L[?)Q[?TX*GIM\4^'R8\.&<;05.'R>0"A'/;6+)AYJ01]"!ACMM5"?AS4_ M6M"9>]?6'H:66]K?+#;$';7PDZ9]TVDNIV+KH(MA16G8 57VFBG4@K4 M>EL=5)/*%\2UB/^/1!2]6&[L; RSM/(X@(#!A5Q?+5RQ_:8L7C@]='&0RBSN M%-2;Z:#U.-5+>.!PN^C@X3??=[Y#MVZ5/OJS#MI*$)$:%T=!@ R:A=W&R(M M<$IWU\P;?_6/9,T?DR&/_AC.KGO?VRP!VI%@> '@E)8Z**YFS?($.ZVE)HI+ M:2-9UHB,1B;34P]'_AZ@\/#H6HF5 0N./3GX\9V-R0JGBPX>G@#>=M F<;M4 M'>S!]VSNY#3X@![^0@MZP,G"'_']--I%<:#R#5A#&[+Y$G;4P0_/2B.0N5)= M]? DJ8>,1/-HK&O(:!<#6D?YMW9B"A7<1$TU&\L#PQ?]PUF(QXI/DV.E0,NL M$ YYM(HK8X&%66$:345.&8DV81A^:+FG@ 3CME0&1-*N9FJ@6&.\^%X74^/% M&L,D=1TS-6JL^:)BX6*F<&IJ6RM#Q;,%%4+=K'@Q%;CQ;=\%.$].R0#'93BP@LYI.XM!.9D_-D:E)FLT,3U)2U5_, MR5&/47 P#X)(GOJT]2@H9Y?+D.JB/P:NX::0[*R?+\FM(>@T%CZX&X3382ST MB[>)J)?146,G=(&5E1ZF.];5X'Q84@,<3;V8Z&I2!=BS;)H<#%S"&8.O;_:#+YC+W\)^!#HM*O20V>>[* M)@\.)L_H,11B42\M.:? \ARR2,=S@YZ<7$E$DF4O_-*Y4342PD#"!/@R).2##JK;710F3^V6#SZ3J7TN-THJ!6L M7'9[K=0+UP6MI1:*2;3R SY1JO3P-Y^@DZ;\2X!UC&W\SNT+@!A!> M ZAJRGNWX#JCMICP.F]ZVGH#K-HJ1:9GM@NO<;4D=Y[N;KKCL!%60@N5Z>[" M1FA1;!_=7(.G$'Q',MSO7/][,,>R!P&,C):*L?\O"I+(&?YT^!( 9^[E4S:S\;I.XN(%I3O[&&JJ_'DR7'W[,"*^DF<] M\,I#P K #4C^OQ%[C$_HJ2.Z"HG?T?)L$+]'/$_*S3@W$<+PD^HSF/8%>K10 M""TW_?<265Z -Q&6;PS&NW]7#QI8=-LP%MSXOUT0'WOX)-[YF,R_+"[#$ETU M^8DJRVSNU3("V1XC0;]Q<5-4,6G,4*GK:'BJ92,VX:G>=1P\Y6=QFH0C=EC* M?F <_*5E8FY2;9-:+D::5ZF/:?*(TA2M-(ZCK&@EU1(B_%LZ<;['<:%V^>CI MX2!8^XH^/B)<*(IX]_4A^]'3PZ'=^FCZ<1,C*AA/6F/]DB!6\RW4"> V544' MT7.?F)YK5BM-59MM )S@#OF[3)=?K,5/PHC[Z>;F"9^NA]B>L%B3FXH$(T== M=/,0([F(#5+![2M -@PXZ4*B?EIR;5+? W#PVB#+G'>_8C36G".46^+DC%:]:LTWF9FVZ(V HM%D[RW370=_X,L]PT].1A@*6KJ29'F,UG!#N M;.P]@T"NAG:K:NR2C'6R7;#7B04T*451SK9V%H%BO:S.W!-P!N%CJ@$\,M2; M7L5-K>FS]E:(R.!@>F3:,. R; >FQZP- ^ZQ<F&/H^G@M,&0K/$+QO'SK6 M2D_@N_6D+8:#)HOT>'A MP=J!V2MDA7A1FRJ9_;;1"( :[O[!M_9T%64)=\?SW+K'MGR"[6)<\ M^]QIDNBHFY]R6GY:2'/NB=/4&GU""X_1*@!_1B36Z 7_#U6IX;<= =5+/!Y' M&6"U'@GE_*W!;*^+>NA "QU*"UN /+V]$MWF"[ZZH._X5H0O,8_1RH6V^'(@ M[*.$LJ\^^J,P^-*E.:>ASNLP3\NNUMR0/IN+B 6SG.IM+P2M'\0R+&Q9!7Y- M35EM(I-? %KY)H+(DU6FAARK6'3--$-3PXM5("ES8S4U)KB-?:9:KYYV4F=H MO3O3TY8)%T=YS3 [5PV%BQGUHI4A]F%"K'24-A*&^48U;J?V8J1M /*R'FQN M)KR-K:,YA#47EO$OZ$@;)G.$. Y'XY_/:8Z6V!!C>M*"P"(I.%---Y1(6S\Y M.!VO)$,CS$0V5M9%E+57AUM4FD)0GJ/=#L.%<8 ;#ZZA;7EAFGF&)= CUCIL M$MO_V%D3DU.;4JF$TGESN7)>[";JN:+D,9Q36M*W3 MI-R\2G.:C7M-,LKQ!H^3=*H" MRJ>/)(=/+'G5<8[SCQ%0OHR+H MZ-J#J0Y%M3*-?_1V[D=0PN<7SL%X"M+L#U&AS6C-=+Q84* HT&D9C;2\M>)B *)Y.=E >I:%^ M>F,OSC/>$I:S\'ZW\,&Z+-N01*I06I!^A[O?MO^BZ-"(+:W/B)H ZP!;C;,@.D&'Q@5?TL\ M2K#U76>)+/+XW(UUD!,FHF_HY_(&!#:"^\025Q84L0218E+P"24&C^J(HJ.3 MTUH_XG>6#1I(OE+S$=".8@>4?5BLD]1R:#\FM9?D>&%WU\];5@:5K-S8$NU@ M&FVBD&Y8AH\&']#/WSTC#5/46C_EPK0V9G/]M*?KFX@?.> K'49 ?XMM/KZ] M34OIY;54>]Z8J1;$YCU;06NJD.*TMR_>I,!KKH/O> M]S:8F!T!3I"X2&TZ!IJYIQ.CL9*]]]EZA;MH5R@:L>,W%;Q8WZ4Z!<6==&#Z M&7J$*F[&;;6-&@233S9$4-A)C[L.[N*+%Q?#>BLMF?Z6M^%M].+OVJCC8EAN MH605$G6/G(+LL[+60@IQ#:Z#XMC338QQ:P\9S^ID>X] : M-)$'P]1LZ<[ 54V3IN>\M3\9.3X/TU/?VJ\M-E)F9BE)(,4._C$]&5 6')Z7 MU_2'B&0QDK!7F?ZLD#148N.HZ2\%M;_J-(MOZO;NSWG@2(F2,OV5'Q6PT8.O M3'^/1U;&*7,RF_[T3H.E2/7]=GL@QTA\ZIYFT]^Z$44EY9M2-B+"]$=L.$$X M;-%O>-6VAMC0HR.,K<_6$)UCCZ2Q==@:(E/RL&>0?#QS2)@GG/F%YW@Q5CQI M4L:C%KG5Z)^X$T& % M K&.YG,1(^R@HVHZ=BU,K].[>*=0N8B(U;PH6=V<2*R(EG<('OP0:*E(A E! M85JI*GE!/K.*/"*P@]&.$3DF[JQ\8#OTQG,;?BI M=%<2NLD;+5,8: &=4OW.(^%?*NF3>$[!\5ZC02O7\01H_/9A!,E31J3K=^5A M%#-1BZK B@06&7M\NLOPP^RLGZ\OGI4(0^ PMHQ\/Z.XT;3JII2L 9^0(\X! M\K;52O#8X%$[)>?7\Q8O.:P4$426*2)'SI_RN<7OT!M-S$=YV8UUS&9Y#Y/- MG3I=4T\B8VH%G0SAHRS+1IE8(UI[IELO)B-Q5R,Q1Z:;FE,C?XBP73%4A:E= M;LW/"6 >V*1))UCE?0XM%)J 7I,+IZDY-NW6FX2)S]3\FIXV*#[-6V;6T+;H MK>>8A)Y(>VJ7:V.T;),S7YN:;]/',JONT"81>6>P0V7S>EO$Y>W-VIB-C-7= MLG3&_ZQT,]3D/$.F9NNHE_]5UY^IJ3LJ!!K;4= N4:=Z(IB+VY'/IUN&SOY$ MC\Z6T]WPB9I_(JL7_#T4/#I8::GMNL.D2 M%W324H\RR0\DQT!,F.6*GCWE]=#Z ).8D\HEAK%13'4"=8/I2 Z:7E9-$B9Y M5<949T\'P!BZC:E>G@Y(L4H1F5E7H:&(HJD.IE=*:PB12%LQU6?3[=#C(]6F M?L()/,%X[>]VOA?7P>GQ><5PN06?+?0'"!=K#" ^*-E5M=F-E5RT/X5P<^_: M[/&K#70HZ:4Y>=[BQ1X\1ZN\H"8KZE?020\?$2E+@O=K>""E.3@QR]2F:IY\ M@:_XK, J1YS6MH-!0-P8'M9P\2\Q7+1%(-%+RX,,2?DT_H,,E39Z'CWP;0"< MX X+Y%0;Z_EJR&0G812O % UE>@%4B+-FX;$ETU,U/1-8,_D=\\)%M M"9RY5R)3@C/A)[3P2*B)ZQ.R."@::*$/ZQC0@18ZE*#D2"!V>QW4+\%N[R-, M3"*X/QVN72L(4JIX[]-)=!P!/]()P^)^(^#FGI$!)6RN\R+*TX KA5OD3Q[3 M4SJF C<45WVEA>J"-#%;2#@G3PVV:+*QF=C[3XVX:(5>R'IH>92.] M_:1]/Z:'W31923(>O>%B<#2%2J2/N03]Q4FD*D8ZT (]P=D= M*>BAQ%M*'>/V%2 ;!@VH*GKT1]6=C]8 A@VH*GKT1U5R4$F3E#;7$K%!HT=D M>1=T&@T?/(\.IX,.^FN/N7'=L_2VBJJ^X5/DDX7W+/D\P%I6 +(V(!,3 M-*_G2(C2Y@D>F.LG0)92G.KMQ??DR'+3IXG9SNC1T'A2L_3@IZP>0U&PGEQ_ M5(/?9&@MF)+'ZN/'9ZN"+N#%&7#[Z. B/5FX\4_5-AJI)('3\0D8OP @'4<@ MVUNK1UY*PSFZ1?>^ITTWC\GC/I)#WG@;W( [H1\=Q'137\,MP[UZFF[^4X%5 MR:1ANNU/!5PENY3IZ7?:QLK M0U6[8;/!9$D_LK]L ?:__=G6&**B&Y\<>! M0[^E\)_)D.RLI<(3N4 )7ORIME'CR$I*FI"-PDZ5/FZDI9841,#&W^;:UFJ- M]-"9;:7DA_"]%Q 0.P!9V\&2E%(H_YTPA@7W/T'X!&Q_XY&*VTF)5:QHIS^1=N]97K-A MB3 *Y_@D6'"K$0PSMA))EY'*D7/U)EIGLP" *_#8[96@1HHYV8FY[]&UZ*1P M&BJA(0L'Q(JLY?Z.5Q+T-L3(:+EN+.5HY C[**$LMF]*+"QJ.RTE&_#4"$IT M5)KHI)$;#5%KI*>, #Y\3HG0$;0BMQ/2OQ/3CB;;)Y7_# MK12A?*R36E="-^1OL6%H[B6[9O HI]KP9F&;*_O]1#$U'O^D]OOMZQZBN+%X M:2KY_DFMO2-/G*I%=:\UB+E]X%$E36H6A5L?D;NS\LA!UCBGC-:+!5VB5M[Y M*);'/8-V--Q)84<]N&BU\_H_QP=W-NMW%D2_6VX$ MN#>G/H8;Y4ICWHX+KY#G2-E.>AEJ1)C%1&)F["U8?O>Y]I@F7]!2' V&Q'0R MQSO[!3J1Y7(,=_2VHZ#Z*PRWL:>*;+LMW"_]6R\D)1IXR[3I5Y18=/%T+[=^ M%&!9BM?X<@M1"(#'-WT+^^B8@_0FSUDOY18:*>2N@6H;G>$D5/]\HZCI5@+< M]"@=-<[RRCRH,VB;#C[-&U0I!W!FBY&N/>7QON*SH7BRU,P :0% #&=QCLH' M,Y>-291TKUC6SG#CB^SU"B;C:F)\7;Y>0:UH[1F4'R,FEQJIDO#],3I<4_$L;?$]+3IDGKT.">"Z@HS/?MZ9%-! MC;$S/:6[QSE0'Z%F>L*XVLF0#'8W/:U\Q%(FBU(U/L=X7$+F."S.]%=P1C8! MPOB,PO ]79/EYV.@S+UBX%AOG"10S,]TSY:?']ER M#06ZT]5Y#*O_*(VCF* SO5=WB+^D'BO'^=T%Q&=ZJU $L2 QMPA',/.@Y<:, M5KJN,4K!I@(R M,S73KI#1JW04J)FI<5("P"F1)N=-0"G"JMJ;'KIA6Q28#'W,.JLQ= N]?,.\Z (\HCDPX& M*+'3:Y;G\3@GCE:#-Z&&'OW$]['D\PH#;'!I2DYX+8/<3AQ[ *HRK=^%S!_Z M%#%-*^A').[0*_E^>RO8(SVND6AJD,'=:#J'61A$@G0DZA3G8:I@TB'B>)!% MR1YO0J_#>-\^G#I^YU(_YQ31.OW5I4$+,O(9XE-"5N>J[7"W;OZ(XH>>;OEM M*#G%U9S$O28Z,B!Q!4N?_%1B?[;9(+"QPF$4]_;TF(E^KX>=]/!F8JM!?'F.6AS;H*B1PE/N$&7K&LK;VL2_4$G&2.%?-)CI ;D"!%H2)ZSUY[ODF M0GGF:\Q24,[[*#US3 >J^8<,*Q2G_K;=J4C%/L$_M% X[EB:\4V%(!N_19PO MWNXK?^Q!33U,1 OITJX Q<\)SEY\2W'.#N?^?:3MBE%,TZ+:,-JM(D5R*-QZ MTU1TC\GJ5(UBFHC>S3>F%[88W]Q(VWDZ%;R8%-MA[L.F%\48X?0T- N97B9C M?!*N8_B;Z:4SQC=A\K[;;A4S)GVN[_!]TPMFC&]JNGKS3"_"T=.,#1W+87HI MCO%-4ZO$&M,? QG?-*GTHIM>NF%\IQ5&32&3Z M6TSCFS%>2D:W:C?GZJ-6I\P=53LPO3;8^+9'A]CJX>H>C:H*RVT0PAV9K;P M<[!84\H*)KX#/+Z&*#7J:ZFU +1J&QVQ=%/]F(1D3DU**HOL]CJH_VR]PEVT MXU)<;:.%2GS/%%)9::.#RBFJ.B%%>MR3RCGA<=5+#HEX0&-6X^\^ M*4OI8F5RZ/58&_GD$7V"P1]W"!"M'V U.QP*3^JX)X7F?;UDO"JXB@^/$H\. MY<.5)1%QAM)Y[Z?>Q]1$0O' -;VJ; _F%'4*I.G@']U5*F\ E*\*9X%$]5Y4 MQJ)V]33]4481&E5S@>E!Y[V^L5X[5O+GTDW=:+V"69)G&9#&2JQ>@52A..=+ MV=RUK.QZH<0Y)V&4Z)1=?=XSTN^EO%.F]30Q?=J?VB5G3U/3NZ&Z77JV01,S MX'MZ;1*O3S<^@!$UD+ZT.;G9M;G9?P,>0):+E_7,V>$[.2$EA"\@G1JN8U.N MKPZNYAY>HG@I8M0)Q/=D)++3V4YD7H\1<<"U$//[:'&.8U&#Q?,6+Y$;\ )< M?T\(DUE;,CTG9_HHG>EM;EKEYD1,*G?W'@\P2G?1&-QGD\_BO'P6$H=E&5G! MR72F:'%??A:?@:9;*QJC)JF7&F]*Z-,FS=WXD]]D,O=KM\<,:^ZG**'#F?+,G8$>(%.7$#QTJJP;T?5&[1BGBA+/;J#N^UK1^73(__._(%8 L=Y\N"=:,V=#2W;6 MS%=)OMXA\&<$//L@QQ2SIU:.BB-$9!7G=M'*P]S;1V$0+Y&/7&LDKX=6#FAK M@WMZR/0<"T?!\79NS!O[&Z/A,I?)/ A+BYM_;1+AY<2S T0/ E#J_(:@Z3 M4'>NK8W;14O=M)R@N8?%9400)IE!'!L[MXN>FF1,8G.\!4$/W9F04W8!627>Y'7ET: M*/VT<6Y&'2D/$CIW-:>TB6YH>ERTC+9?1H^/MJF6#T7Z>3NWGEE^4X50JI7R MIF:.*+B-M?;D&>?BZ ],*>?S)%CY>/)/,V/=H(I0["R:)]?FY-J<7)NC<6UV M$@MG V*_3DPS'W$=RHG9MPMX3$[,4AHMW'AP#6V\/8M*8U\"X,R]S[X#W'GP MB/Q5LH\/DYMS#8..EZU=FDN^@$OJJ6GXUQ?@#(N:>0Z6_1:5W;#=[M,?/M MNR&,F5/@TXA0/\\(*5W GVDHE2ZX*>]#?IRP52Q#>CNGI\"W*?!M"GP;3>#; M,(+F;-#N-T+.S+RJH2+DS$H.8AKZCU2E8R3,W(2B]^ZK?IL"C9_.$HVJKZU MX^>SC".E%F;-3L!#_(Q2/5/N<&V%8(.9_0LX7V&X3<2.WAA3KDOMJ)GF^*(" M2%*.42ZRB-)GBBGJR -?T8LUNR^>OPH >B':7'S(DLQ0S\:]XOU:GQ>YV(K> MQCUQ-(^,VOT!>#^.&-ONC$C%U:H:1FW)C=*!1(Z1(PJ"*@E5>HOUOR7G_=S+ M/TN+;.A]S+%$0LDP%3"XHJ'7[U@3:BW&^O9A')=6GAY#O:3V=]R:?L%K;=-2 M=KZ<#<)]ZX1T]]FYV&SZ5!9%]D4%0KY3O. >S[:/K]D6"L][D@;2 L_&>GR* M>PDK,=W"&I/==.LY9S-),N$O-(WL?,*-AL!8Z68;,B1 D_GY 83W?A \ A0_ M UT8GLG[SU$R[&)] ]TH!,Y70-ZC <[L!2!K ^(>P0)+EM#RG-CW&L*X*5:9 M=-B;R?A..OXSF?-X'=R^VFZ$0;K#J[+"U:V%/$QUSOQL1ZD5JO;;.F[4'2G_ M=*!_@&,7[W/$$T109#=5]OGQ8/-@[?BU1(3=M-3BJ&]:ON>$V5P+[7]&1*_ M"\7W\'G!!9_>5DLA8]_;X&-R1Y(-2"X31ZA0FXZ!9B[4C,8ZZ"[.]HX"A^?3 M4#R(%IPP2?$MJK9->"<>OX\>+GS[CT6L8W*=[\?ME'B1EGC-W_L6?6Q:"R6C M9@_7+OW'"-E;*P!X)G:^%S/))D6FF\X;U :7/DR)3[233--]__,CN&P9GQ+[-OZ#"[5;$/*C.73=H-,R!5MO>(.9M[2SPJ^">P$,M8VN9+ MX^;XNZ^&W^P[8^7V"1 QC$4.EDEXOUDN(;<#U_3OZ3RH6DFI\L'5 4;337J# M8%O;D*;;_P;$M"3633=G#85J5PN/'UKNR!7:YV@5Q/4FPMN7&$_'@0E=I?>J MM 2+$;/M!F23C#5HJ_AEB?\KP'-+XF2Y[M.F7]%QLL?!IHMU;)#F!BM0&FJD M-S6L+] 3B3KD.-_9[4=#O0SLU!ZCX> A(NL7+X[=1$WU0VRFDX),D!9^Z4*!H3HG0>4309@:+%@VT!GJ6 M]5Z9(,^C]E.8:FTS2FV,]X %\ MC__$QEJJLQ:^JN8$?F@SM>T(J!:5Y&(V'P'M@BP-5NN14,Y7)9CM=5$/'6BA M0TG%$2!/;Z^#>@+>8EVRCG$HI[=5HC/%_O'OQ*[@;68;!.+/LU4G7G.MP=#M M;)5Y7"$7AN%*;&HRYC/-GSD^%).$Z4^O2*!"OQ+GP+PW,R95:'TN^WFXQE[3 M@YHE+-WY6J)?GXNU9*C'NS%"]>M]@9"9GE9AC@7'#%]@8^;^DK>)55S/;+MJ M 9B9P1!"@PY%=%<.0-,E]NF%X6K&Z<@J=91N*&%C,3VNBX]6(P^6Z>%:<@M+ MRHEK>@R6)%3=8Q6,3[*3$V8E9TVGUW6Q^K'RS+ M#NWX/X,D7($7FHK0F=1Z$7BY!>K.V=A%1!YU#D[G\KZAT&]?P4C"Q&OZHN*& M"E0*+C3U@AM:+>#!#T&P].^@AR^DT')S61TLT,;RX%_Q<-<8"-^%3C*5GO-8 M(H7DG1YU+G*VEIBR3RZYW^J("^_"@R"P2LVWM43+JY[9'@"B#:-3L"A=2147 MF_+)&,Y%,!))%;_$@*6^;9-REM#;Z! UQT30=\5QNY,3 <,*1I,V.V61G-UN M?88;#ZZA;6'E+,?A$4-,,N*U:@O'Y A6.J>#EBA?.63IO$AVUAJY*IR?RG5( M$HUI U*!R7Z8-F)S^G_S?><[=%U\7,SQO'H;N'+!+ A &&1_BND\,-B1[Z^# MNP?PO80WPFLN\NQD:254)?\K$CB-/Z.#UR?P KP(D%>]\*8A&U2..7$_'=Q\ M"C!5,_SJJ\/T^*EFZ$A( M.CJ)H!UN 0 M'"YJ:B0J6&&W6:SQA7)O0>?V=0^\ !!C]"+< G0=(3(?"6 MKT6,1+;VHU=/ MC(X?TY)*F(TN4"B/VVGU:K"HSF-B.TSIV=U_6F,5NZ\;7HA8]3?R>LQ2%)"! MN;NPT_>FC:AN(W:;V//;BV 5CL176"5%L"P9C77L)!:$,H2/PZ['1[ZL4S)Y MG39.^R/JO+=/(;#C1TUX)ZU4E]/82'RNSVXWI3?;X-$Z$"CP68U_01'F&%HK MZ,9I/R,YIMJ2RC6<-_Z:EB*%"8U!1J3EBMP"O!XZ]ZD$)Y58M;93/NUC.:3T MG9H]K6DMYZ<,^ W/UQ:?/*%]W0VZL]OT'>#/&3_=: 7"RMW;T6BEE25Z521:98[I]5(O5 ML^/4=02"\56MQA\E*Z-B;>V*\210FB&FT7H[B97:E>QVMW?] P#/ +U &Q2S M5N:$U,:STU2 -#+H+\Q)7+HK9D_^JJMZ/+WHT8C%->N^ -(($JABWBXZCD0^J/!/C.+AD9J2\ M/07(%%&.\ZVE9ZK1M\;.]1?/7P7XS">;9^[MHY"B"I!D1[J)$5T MLQ5F^F6A-8Q\$6JZAM_GZI/?Z6>GNM]:R,,P!5FE<[V>TQHQ(A\JJ[F6QZN9 M0,H1/XXS0#0#E=>C YC@V>JM9K3]ZTP2P:6=S =)WS)_'_BX.J[LHQ,1\AA[<1;LG MLB#YQU?!QL'T7;Y]TM) $;QG)R3J-?ZUGO0&/7LOC@IB MMM==C%[ZR0&UL4$L! M A0#% @ TTJK3%<(=BI<#P B)D !$ ( !?HL '!U M;&TM,C Q.# S,S$N>'-D4$L! A0#% @ TTJK3)1>4AGE#0 HK !4 M ( !"9L '!U;&TM,C Q.# S,S%?8V%L+GAM;%!+ 0(4 Q0 M ( --*JTSFRN)0&R )L= @ 5 " 2&I !P=6QM+3(P M,3@P,S,Q7V1E9BYX;6Q02P$"% ,4 " #32JM,R A<9'!5 !D]P0 %0 M @ %OR0 <'5L;2TR,#$X,#,S,5]L86(N>&UL4$L! A0#% M @ TTJK3%!^R04*, 4J4# !4 ( !$A\! '!U;&TM,C Q C.# S,S%?<')E+GAM;%!+!08 !@ & (H! !/3P$ ! end

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company